Board of Directors & Volunteer Leaders

30th ICPE
INTERNATIONAL CONFERENCE ON PHARMACOEPIEDEMIOLGY & THERAPEUTIC RISK MANAGEMENT

ISPE BOARD OF DIRECTORS

Officers
Til Stürmer, FISPE, President
John D Seeger, FISPE, President-Elect
Stella Blackburn, FISPE, Immediate Past President
Kate Lapane, FISPE, Vice President Finance
Alison Bourke, FISPE, Vice President Finance-Elect
Mark H Epstein, Executive Secretary

Directors
Morten Andersen
Ariel E Arias
Rhonda L Bohn, FISPE
Jennifer B Christian, FISPE
Edeltraut Garbe
Tobias Gerhard, FISPE
Wan-Ting Huang
Yea-Huei Kao Yang, FISPE

Marie Lindquist
June Raine
Sabine Straus
Suzanne L West, FISPE
Wei Zhou
Stanley A Edlavitch,
Lifet ime Emeritus

2014 ICPE SCIENTIFIC PROGRAM COMMITTEE

Soko Setoguchi, FISPE, Chair

Core Program Committee
Hisham Aljadhey
Morten Andersen
Frank Andersohn
Stella Blackburn, FISPE
Gillian Caughey
K Arnold Chan, FISPE
Natasha Chen
Nam-Kyong Choi
Jennifer B Christian, FISPE
Corinne de Vries, FISPE
Mark H Epstein
Tobias Gerhard, FISPE
Andrew Gilbert
Partha Gurumurthy
Jason Hsu
Krista Huybrechts
Andrew Jerdonek
Yea-Huei Kao Yang, FISPE

Kiyoshi Kubota, FISPE
Kate Lapane, FISPE
Frank May, FISPE
Yola Moride, FISPE
BJ Park, FISPE
Susana Perez-Gurthann, FISPE
Lisa Pont
Mary E Ritchey
Patricia Saddier
Nancy C Santanello, FISPE
John D Seeger, FISPE
Paul Stang, FISPE
Michael Steinbach
Til Stürmer, FISPE
Veronika Wirtz
Wei Zhou

CHAIRS/CO-CHAIRS & LIAISONS

Committees
Archivist...........................................Hugh Tilson, FISPE
Bylaws & Policies...............................Stella Blackburn, FISPE
Development....................................Susan Oliveria, FISPE
Education........................................Frank Andersohn
Fellowship & Awards...........................Stella Blackburn, FISPE
Finance...........................................Kate Lapane, FISPE
Global Development............................Kiyoshi Kubota, FISPE
Management Oversight.........................Stella Blackburn, FISPE
Membership......................................Vincent Lo Re III, FISPE
Nominating.......................................Jasmine Wu
Public Policy & Ethics.........................Jesper Hallas, FISPE
Publications & Communications................Ann Louise Assaf, FISPE
Scholarship.......................................Frank May, FISPE
Scientific Program (2014).......................Soko Setoguchi, FISPE
Strategic Planning.............................John D Seeger, FISPE

Councils
Academic...........................................Irene Petersen
Government/Regulatory.........................Gunnilla Sjolins-Forsberg
Industry/Service Providers....................Susan Oliveria, FISPE
Student...........................................Linda Wijlaars

Special Interest Groups
Adherence.........................................Robert Gross
Asian Pharmacoepidemiology.................Kiyoshi Kubota, FISPE
Network (AsPEN).................................Yea-Huei Kao Yang, FISPE
Benefit Risk Assessment, Communication & Evaluation (BRACE).........Ken Hornbuckle
Biologics..........................................Veronique Kugener
Comparative Effectiveness.....................Aisling Caffrey
Research (CER)..................................Mary Panaccio

Databases...........................................Helga Gardarsson

30th ICPE | TAIPEI, TAIWAN
Volunteer Leaders & Committees

Drug Utilization Research .......... Lisa Pont
                                  Katja Taxis
Medical Device ....................... Michael Steinbuch
                                  Michael Matheny
Medicines In Pregnancy ............. Jennifer Reehuis
                                  Carol Louik
Molecular Epi/Biomarkers/
Pharmacogenetics .................... Bruce Carleton
                                  Wei Zhou
                                  Geoff Liu
Pediatrics ............................ Rachel Sobel
                                  Tamar Lasky
Vaccines .............................. Robert Chen, FISPE

Liaisons
CIOMS ................................. Sabine Straus
ENCePP .................................. Yola Moride, FISPE
US FDA ................................. Judy Staffa

Regional Chapters
FarmacoEpiEnRed-
Spanish Chapter ...................... Ana Afonso
                                  Sandra Lopez Leon
                                  Elisa Martin-Merino
Gulf Region ............................ Hisham Aljadhey
Latin America ......................... Carlos E Duran
                                  Marcela Jirón
                                  Veronika Wirtz

Student Chapters
• Bloomberg School of Public Health, Center for Drug Safety and Effectiveness (CDSE), Johns Hopkins University
• College of Pharmacy, University of Cincinnati
• Gillings School of Global Public Health, University of North Carolina at Chapel Hill
• Harvard School of Public Health
• Health Outcomes and Pharmacy Practice, The University of Texas at Austin
• JSS University, Mysore
• Leslie Dan Faculty of Pharmacy, University of Toronto
• Pharmaceutical Health Services Research, University of Maryland Baltimore
• PhD Program for Clinical Pharmacy & Pharmaceutical Sciences, National Cheng Kung University
• Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
• Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island

2014 LOCAL HOST COMMITTEE

Yea-Huei Kao Yang, FISPE, Chair
Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University

K Arnold Chan, FISPE
Department of Medical Research, National Taiwan University Hospital

I-Shou Chang
National Health Research Institutes, Taiwan

Jing-ding Huang
Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University

Wan-Ting Huang
Centers for Disease Control, Taiwan

Weng-Foung Huang
Institute of Hospital and Health Care Administration, National Yang-Ming University

Jaw Jou Kang
Institute of Toxicology, College of Medicine, National Taiwan University

Fang-Chen Lee
The Pharmaceutical Society of Taiwan

Kueiyu Lee
National Health Research Institutes, Taiwan

Li-Ling Liu
Food and Drug Administration, Ministry of Health and Welfare, Taiwan

Tsuimin Tsai
Taiwan Drug Relief Foundation

Chun-Yu Wang
Taiwan Society of Health-System Pharmacists

Ming-Kung Yeh
Food and Drug Administration, Ministry of Health and Welfare, Taiwan

DEVELOPMENT COMMITTEE

Susan Oliveria, FISPE, Chair
Janet Hardy
Syd Phillips, Co-Chair
Andrew Jerdonek
Dimitri Bennett
Susan Jick
Rhonda L Bohn, FISPE
Kirk Midkiff
Andrzej Czarnecki, FISPE
Jeanene J Nelson
Mark Cziraky
Cynthia O’Malley
Mark H Epstein
Nancy Santanello, FISPE
Nick Everage
Marianne Ulcickas Yood, FISPE
Melissa Fowler
Jasmanda Wu
Joshua Gagne

30th ICPE | TAIPEI, TAIWAN
ISPE Supporters

ORGANIZATIONAL & INSTITUTIONAL MEMBERS

Pharmaceuticals
- F. Hoffmann-LaRoche AG
- GlaxoSmithKline
- Sanofi-Aventis

Service Providers
- RTI Health Solutions

Government/Regulatory Agency
- Department of Epidemiology, Lazio Regional Health Service, Italy

Academic Programs
- Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA
- Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA
- Center for Pharmacoepidemiology Research and Training (CPeRT), Pereleman School of Medicine at the University of Pennsylvania, USA
- Charles University in Prague, Faculty of Pharmacy, Czech Republic
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, USA
- Division of Pharmacoepidemiology & Pharmacoepidemiology, Brigham and Women’s Hospital & Harvard Medical School, USA
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- Harvard School of Public Health, USA
- London School of Hygiene and Tropical Medicine, UK
- McGill Pharmacoepidemiology Research Unit, McGill University, Canada
- Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- Russian National Society of Evidence-Based Pharmacotherapy, Russia
- Rutgers Pharmacoepidemiology
- Slone Epidemiology Center, Boston University, USA
- University of Cincinnati, College of Pharmacy, USA
- University of Rhode Island, USA

ANNUAL CAMPAIGN as of September 22, 2014

The Society expresses its sincere appreciation to the following supporters listed below for their contributions in honor of the 30th Annual Meeting (ICPE).

Jerome Avorn, FISPE
Hsu-Chih Chien
Joshua J Gagne
Jessica Jalbert
Xinyue Liu
Kazeem Ad Oshikoya
Mary E Ritchey
Daniel Weibel
Almut Winterstein, FISPE
Ian Chi K Wong
Fe-Lin Wu
Huifeng Yun
Wei Zhou

In this Program

30th ICPE Agenda
Thursday, October 23 .................................................................10
Friday, October 24 ...................................................................16
Saturday, October 25 ...............................................................24
Sunday, October 26 .................................................................34
Monday, October 27 ...............................................................44

30th ICPE Posters
Poster Guidelines ........................................................................52
Poster Session A ........................................................................53
Poster Session B .......................................................................62
Poster Session C .......................................................................70

Indexes
Abstract Index ...........................................................................79
Advertisers Index ....................................................................89
Abstract Reviewers
Abstract Reviewers (Cont.)

Niklas Schmedt
Fred Schneeweiss
Martijn Schuemie
Renate Schulze-Rath
Glen Schumock
Harry Seifert
Soko Setoguchi, FISPE
Natalia Shcherbakova
Meredith Smith
Henrik Toft Sorensen
Montserrat Soriano Gabarro
Patrick Souverein
J Michael Sprafka
Gayathri Sridhar
Judy Staffa
Paul Stang, FISPE

Kristina Star
Kathryn Starzynk
Michael Steinman
Monika Stender
Til Stürmer, FISPE
Martina Teichert
Veena Thyagarajan
Jennifer Tija
Darren Toh
Sylvie Tomczyk
Marie Tournier
Thierry Trenque
Gianluca Trifirò
Ilce Truter
Florence Tubach

Jamal Uddin
Carla Van Bennekom
Patricia van den Bemt
Stephen Van Den Eeden
Lionel Van Holle
Cristina Varas-Lorenzo
Zdravko Vassilev
Helle Wallach Kildemoes
Shirley Wang
Meng-Ting Wang
Liu Wei
Winifred Werther
Suzanne West, FISPE
Bjorn Wettermark
James Wilson

Amanda Wilson
Lesley Wise
Jasmanda Hsiao-Hui Wu
Chuntao Wu
Wanning Xu
Fei Xue
Wei Ping Yau
Xiaofei Ye
Melissa Yong
Zhong Yuan
Emre Yucel
Jie Zhang
Wei Zhou

Save the Dates

ISPE 2015 Mid-Year Meeting
April 12-14, 2015
in conjunction with the
5th Bordeaux Pharmacoepi Festival
April 14-16, 2015
Bordeaux, France

Student abstracts for oral presentation at the ISPE Mid-Year Meeting will be solicited and scholarships will be provided to individuals whose abstracts are accepted. Deadline: November 14, 2014.

Visit pharmacoepi.org for updated symposium details. You may also contact ISPE at +1.301.718.6500 or ISPE@paimgmt.com.

2016 Meetings

ISPE Mid-Year Meeting
April 10-12, 2016
Royal Sonesta Harbor Court Baltimore
Baltimore, Maryland

32nd ICPE
August 25-28, 2016
The Convention Center Dublin
Dublin, Ireland
ICPE Exhibitors & Supporters

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped the Society enhance the scientific program content and increase attendance at the 30th ICPE.

Thank you  
DANKE  
 감사합니다  
 ありがとう  
MERCI  
 謝謝  

EXHIBITORS

- Analysis Group
- Anolinx LLC
- Boehringer Ingelheim GmbH
- Clinical Practice Research Datalink
- Degge Group and DGI, LLC
- Eu2P Programme
- IMS Health GmbH & Co OHG
- IPSOS Healthcare
- Japan Medical Data Center
- Kantar Health
- Medical Data Vision Co., Ltd.
- Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.
- National Taiwan University Health Data Research Center
- Optum
- Quintiles
- RTI Health Solutions
- Springer-Verlag GmbH
- Truven Health Analytics
- Uppsala Monitoring Centre

ANNUAL MEETING SPONSORS

Titanium
- Ministry of Science and Technology, Taiwan
- Bureau of Foreign Trade, Taiwan Ministry of Economic Affairs

Platinum
- National Health Research Institutes, Taiwan
- Taiwan Food and Drug Administration
- The Pharmaceutical Society of Taiwan
- Wiley Publications

Gold
- Amgen
- Merck & Co., Inc., Whitehouse Station, NJ, USA
- Optum
- Pfizer
- Quintiles
- RTI Health Solutions
- Takeda
- Truven Health Analytics

Silver
- Biogen Idec
- Celgene
- Eli Lilly and Company
- Procter & Gamble

Bronze
- Biogen Idec
- Celgene
- Department of Information and Tourism, Taipei City Government
- UBC
- Uppsala Monitoring Centre

ACADEMIC SUPPORTERS

- Department of Pharmaceutical Outcomes and Policy, University of Florida
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Rutgers Pharmacoepidemiology
- University of Illinois at Chicago

BADGES

All attendees at the 2014 ICPE must wear their badges to all events. A badge will be needed for admission to a conference-related function, such as the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and Gala Dinner. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., guests.

Badge Legend

- Student
- New Member
- One-Day Admission
# Meeting At-A-Glance

## THURSDAY, OCTOBER 23, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
<td>Main Entrance Lobby</td>
</tr>
<tr>
<td>7:00am</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>8:30am</td>
<td>Intro. to Pharmacoepidemiology (Chinese)</td>
<td>101A</td>
</tr>
<tr>
<td>8:30am</td>
<td>Intro to Drug Utilization (Chinese)</td>
<td>101C</td>
</tr>
<tr>
<td>8:30am</td>
<td>Pharmacogenetics (1) - Introduction</td>
<td>101D</td>
</tr>
<tr>
<td>8:30am</td>
<td>Practical Skills in Protocol Writing &amp; Computer Programming</td>
<td>101B</td>
</tr>
<tr>
<td>9:00am</td>
<td>Intro. to Pharmacoepidemiology</td>
<td>201ABC</td>
</tr>
<tr>
<td>10:00am</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>10:00am</td>
<td>General/Asian Databases</td>
<td>201D</td>
</tr>
<tr>
<td>10:00am</td>
<td>Registry/Prospective Cohort</td>
<td>201E</td>
</tr>
<tr>
<td>10:00am</td>
<td>Comparative Effectiveness Research</td>
<td>201ABC</td>
</tr>
<tr>
<td>10:00am</td>
<td>Device Epidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch on Your Own</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201ABC</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Advanced Topics in Drug Utilization Research</td>
<td>201D</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Non-Database Pharmacoepidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201F</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Advanced Topics in Drug Utilization Research</td>
<td>201D</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Non-Database Pharmacoepidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201F</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
</tbody>
</table>

## FRIDAY, OCTOBER 24, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
<td>Main Entrance Lobby</td>
</tr>
<tr>
<td>7:00am</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>8:30am</td>
<td>General/Asian Databases</td>
<td>201D</td>
</tr>
<tr>
<td>8:30am</td>
<td>Registry/Prospective Cohort</td>
<td>201E</td>
</tr>
<tr>
<td>8:30am</td>
<td>Comparative Effectiveness Research</td>
<td>201ABC</td>
</tr>
<tr>
<td>8:30am</td>
<td>Device Epidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch on Your Own</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201ABC</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Advanced Topics in Drug Utilization Research</td>
<td>201D</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Non-Database Pharmacoepidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201F</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Advanced Topics in Drug Utilization Research</td>
<td>201D</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Non-Database Pharmacoepidemiology</td>
<td>201E</td>
</tr>
<tr>
<td>3:00pm</td>
<td>Advanced Topics in Pharmacoepidemiology</td>
<td>201F</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>6:00pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
</tbody>
</table>

## SATURDAY, OCTOBER 25, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
<td>Main Entrance Lobby</td>
</tr>
<tr>
<td>7:00am</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Concurrent Sessions</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Noon - Concurrent Sessions All About Statistics 201BC</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Biologics/Immunohassas 201AF</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Continuing the Discussion on Antipsychiatric Safety 201DE</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Improving Strength and Balance 4th Floor VIP</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>The Good, the Bad, and the Ugly of Anti-infectives 102</td>
<td>105</td>
</tr>
<tr>
<td>8:00am</td>
<td>Women’s Health 102</td>
<td>105</td>
</tr>
<tr>
<td>9:00am</td>
<td>Noon - 1:30pm Lunch/Poster Session A/ Roundtable Discussions</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>9:00am</td>
<td>ISPE Committee/ Council Meetings</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>Development South Lounge, 3rd Fl</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>Fellowship &amp; Awards</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>CER and Safety in CV</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>TX/Care 201BC</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>Pseudorandom Exposures</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>4th Floor VIP</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>Understanding Antidepressant Use and Safety 103</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>9:00am</td>
<td>Watch Closely 201AF</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>10:00am</td>
<td>Concurrent Sessions</td>
<td>105</td>
</tr>
<tr>
<td>10:00am</td>
<td>Antibiotics and Other Exposures in Pregnancy 102</td>
<td>105</td>
</tr>
<tr>
<td>10:00am</td>
<td>Cancer Care Continuum 201DE</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>10:00am</td>
<td>CER and Safety in CV</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>10:00am</td>
<td>TX/Care 201BC</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>10:00am</td>
<td>Pseudorandom Exposures</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>10:00am</td>
<td>4th Floor VIP</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Noon - 1:30pm Lunch/Poster Session A/ Roundtable Discussions</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>11:00am</td>
<td>ISPE Committee/ Council Meetings</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Development South Lounge, 3rd Fl</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Fellowship &amp; Awards</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>CER and Safety in CV</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>TX/Care 201BC</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Pseudorandom Exposures</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>4th Floor VIP</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Understanding Antidepressant Use and Safety 103</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>11:00am</td>
<td>Watch Closely 201AF</td>
<td>South Lounge, 3rd Fl</td>
</tr>
<tr>
<td>3:30pm</td>
<td>3:00 - 6:00pm Plenary Session</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Symposium &amp; Workshops</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>A Guide to Guidelines</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>From Pharm. Studies Plenary Hall, 3rd Floor</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Impact of Methodological Choices on Findings from Pharm. Studies Plenary Hall, 3rd Fl</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>The New ISPE Vaccine Special Interest Group 201AF</td>
<td>Banquet Hall*</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Educational Sessions</td>
<td>105</td>
</tr>
</tbody>
</table>

* Banquet Hall, Plenary Hall, South Lounge, and North Lounge are on the 3rd Floor.
### Meeting At-A-Glance

**SUNDAY, OCTOBER 26, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
<td>Main Entrance Lobby</td>
</tr>
<tr>
<td>8:00am</td>
<td>7:00am - 9:00am</td>
<td>Poster Session B Set-Up</td>
</tr>
<tr>
<td>8:00am</td>
<td>9:00am - 10:00am</td>
<td>Sessions开设/Poster Session B/ Exhibits/Posters/Lunch/Poster Session C/Exhibits/Lunch</td>
</tr>
<tr>
<td>10:00am</td>
<td>10:15am - 11:30am</td>
<td>ISPE Committee Meetings</td>
</tr>
<tr>
<td>10:00am</td>
<td>10:30am - 11:30am</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>10:30am</td>
<td>11:00am - 11:30am</td>
<td>Diverse Topics in Pediatric Populations</td>
</tr>
<tr>
<td>11:00am</td>
<td>11:30am - 12:00pm</td>
<td>ISPE Members &amp; Awards Ceremony</td>
</tr>
<tr>
<td>12:00pm</td>
<td>1:00pm - 2:00pm</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>1:00pm</td>
<td>1:15pm - 2:30pm</td>
<td>Concurrent Sessions</td>
</tr>
<tr>
<td>1:15pm</td>
<td>1:30pm - 2:30pm</td>
<td>From Epilepsy to Dementia 201BC</td>
</tr>
<tr>
<td>2:30pm</td>
<td>2:45pm - 4:00pm</td>
<td>Symposia &amp; Workshops</td>
</tr>
<tr>
<td>2:45pm</td>
<td>4:00pm - 6:00pm</td>
<td>Gala Dinner at the Grand Hotel*</td>
</tr>
</tbody>
</table>

**MONDAY, OCTOBER 27, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Registration Open</td>
<td>Main Entrance Lobby</td>
</tr>
<tr>
<td>8:00am</td>
<td>7:30am - 9:30am</td>
<td>Poster Session C Set-Up/Exhibits/Posters/Lunch/Poster Session C/Exhibits/Lunch</td>
</tr>
<tr>
<td>8:30am</td>
<td>9:00am - 10:00am</td>
<td>2015 ICPE Scientific Program Committee/Exhibits/Posters/Lunch/Poster Session C/Exhibits/Lunch</td>
</tr>
<tr>
<td>9:30am</td>
<td>10:00am - 11:00am</td>
<td>Comparative and Clinical Effectiveness Studies 201BC</td>
</tr>
<tr>
<td>10:00am</td>
<td>10:15am - 11:30am</td>
<td>Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepi. 201BC</td>
</tr>
<tr>
<td>10:15am</td>
<td>10:30am - 11:30am</td>
<td>Drugs and Devices 201E</td>
</tr>
<tr>
<td>10:30am</td>
<td>11:00am - 12:00pm</td>
<td>How Do We Overcome Challenges of Multi-Disciplinary Collaboration on CER? 4th Floor VIP</td>
</tr>
<tr>
<td>11:00am</td>
<td>11:15am - 12:00pm</td>
<td>Improving the Science of Regulatory Decision-Making 201AF</td>
</tr>
<tr>
<td>11:15am</td>
<td>11:30am - 12:00pm</td>
<td>International Collaboration on Pharmacogenomics in Epidemiology Research 103</td>
</tr>
<tr>
<td>12:00pm</td>
<td>1:00pm - 1:15pm</td>
<td>Lunch/Poster Session C/Exhibits/Lunch/Poster Session C/Exhibits/Lunch</td>
</tr>
<tr>
<td>1:15pm</td>
<td>2:30pm - 3:00pm</td>
<td>Symposia &amp; Workshops The Common Data Model. 201DE</td>
</tr>
<tr>
<td>2:30pm</td>
<td>3:30pm - 4:00pm</td>
<td>ISPE Board of Directors Luncheon 801</td>
</tr>
<tr>
<td>3:30pm</td>
<td>4:45pm - 6:00pm</td>
<td>The Final Word: *Poster Walk Awards • 2015 Meetings Adjustment</td>
</tr>
</tbody>
</table>

* Banquet Hall, Plenary Hall, South Lounge, and North Lounge are on the 3rd Floor.
7:30am–6:00pm
Registration
(Main Entrance Lobby)

7:45am–5:00pm
Speakers’ Ready Room
(105)

9:00–5:00pm
ISPE Board of Directors Meeting
(401)
(Open to ISPE members; notify ISPE staff if you would like to attend.)

**Thursday, October 23**

**PRE-CONFERENCE EDUCATIONAL SESSIONS** *(Registration required)*

8:30am–12:30pm
**Introduction to Pharmacoepidemiology (Chinese) (101A)**

**Content**
- To introduce the basic concepts of cohort study in the field of pharmacoepidemiology, including study design, structure and statistical analysis. A brief introduction of time-dependent variables and propensity score is also included.
- To introduce the basic concepts of case-control studies in the field of pharmacoepidemiology, including study design, structure and statistical analysis. Some empirical studies will be included.
- Introduction of confounding and bias and how to address them in cohort studies.
- To introduce the type of confounding and bias in case-control studies such as selection bias, information bias and measurement bias. Additionally, give some examples to introduce how to deal with confounding and bias in case-control studies.

**Educational Objectives**
- To understand the concepts and design of two frequently adopted study designs in the field of pharmacoepidemiology: cohort and case-control study.
- To understand the concept of confounding and bias and the methods to avoid confounding and bias in cohort studies.
- To understand what kind of confounding and bias need to be dealt with in case-control studies.

**Course Faculty/Presentations**
- Tsu-Chieh (Jay) Lin, Institute of Pharmacy and Pharmaceutical Science, National Cheng Kung University, **Cohort Studies**
- Fei-Yuan (Sharon) Hsiao, Graduate Institute of Clinical Pharmacy, National Taiwan University, **Case-Control Studies**
- Chi-Chuan (Emma) Wang, School of Pharmacy, National Taiwan University, **Con founding and Bias in Cohort Studies**
- Ching-Lan (Rebecca) Cheng, Institute of Pharmacy and Pharmaceutical Science, National Cheng Kung University, **Con founding and Bias in Case-control Studies**

---

**Introduction to Drug Utilization Research (Chinese) (101C)**

**Content**
- The educational session consists of presentations providing an overview of drug utilization research and presenting essential methods.
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples.
- Interpretation of study results taking into account limitations of data sources and methods will be addressed.
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions.
- Interaction with participants will be encouraged; e.g., by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations.

**Educational Objectives**
- To provide an overview of drug utilization research within the context of pharmacoepidemiology, health services research and public health.
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges.
- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms of volume, expenditures and quality of drug use, facilitating international cross-national comparisons.
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research.

**Course Faculty/Presentations**
- Wei Zhou, Merck Research Laboratories & Guest Professor, Xiamen University, **Introduction and Overview of Drug Utilization Research**
- Yong Chen, Merck Research Laboratories, Merck & Co., Inc., **Data Analytics and Observational Methods**
- Chung-Hsuan Wu, Department of Pharmacy, Taipei Medical University, **Quantitative Research Methods for Individual Based Drug Use Pattern and Medication Adherence Research**
- Jason C Hsu, Department of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, **Using Pharmaceutical Policy and Regulatory Science Methods for Drug Utilization Research**
PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30am–12:30pm
Pharmacogenetics (1) - Introduction (101D)

Content
This highly interactive course is intended to involve participants in:

- A dynamic didactic experience of the foundational principles of pharmacogenomics.
- An appreciation for the different methods used in pharmacogenomics research.
- Examination of real world examples of pharmacogenomic epidemiology.
- Application of methodology to designing pharmacogenomic epidemiology studies.
- Interpretation of the data found in the pharmacogenomic epidemiology literature, and understanding wider implications of the results.

Educational Objectives

- To understand the genetic and pharmacogenomic terminology and how cellular and molecular biology informs pharmacogenomic studies at the level of analysis.
- To better understand the study design and methodologic approaches, their strengths and weaknesses used in pharmacogenomic epidemiology.
- To understand the latest statistical approaches used in pharmacogenomics studies.
- To understand the role that pharmacogenomics can play in pharmacovigilance.
- To understand how pharmacogenomics relates to the current focus of personalized medicine.
- To have an overview of clinical utility of pharmacogenomics and associated regulatory issues as well as policy-relevant research, including policy and ethics relevant to the Asia-Pacific region.

Course Faculty/Presentations

Geoffrey Liu, University of Toronto, The Convergence of Pharmacoepidemiology and Pharmacogenomics and Analytical Issues involving genetics using the GWAS study design

David Pulford, GSK, Overview of Pharmacogenomics and Methods

Bruce Carleton, University of British Columbia and Canadian Pharmacogenomics Network for Drug Safety, Challenges and Opportunities of Pharmacogenetics in Drug Risk Assessment

Kantar Health provides a broad range of epidemiology information and custom analysis.

Our multi-client epidemiology offers span multiple geographies for a wide variety of indications.

CancerMPact® Patient Metrics: 30+ tumors across 7 countries, plus coverage of 10 tumors in expanded markets

Epi Database®: up to 190 indications across 13 countries

National Health and Wellness Survey: 165 indications across 10 countries, including new data for 2013

ZEG Berlin (Center for Epidemiology and Health Research), a Kantar Health company, provides expertise in pharmacoepidemiology with a focus on drug safety and risk management and minimization. ZEG specializes in large multinational observational/active surveillance studies.

If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/contactus.
Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when executing the studies. This highly interactive course will engage participants in the following topics:

1. Pre-specifying study components in a protocol, including design, analysis, conduct, and reporting of the study, along with a science-based rationale for the choices pertaining to these components.
2. Translating elements of the study protocol into SAS programming.

Educational Objectives

- To introduce a framework for translating study questions into a clear and detailed protocol supported by a rational thought process that is tailored to available data for pharmacoepidemiologic studies using electronic healthcare data.
- To execute the protocols of pharmacoepidemiologic studies into SAS programming.
- To develop the skills to document and report pharmacoepidemiologic studies using electronic healthcare data in a transparent and reproducible way.

Introduction to Pharmacoepidemiology (201ABC)

This half-day course will provide participants with a short introduction to the basic principles and concepts of pharmacoepidemiology. The course includes lectures on cohort studies, case-control studies and bias & confounding.

Educational Objectives

- Explain common study designs used in pharmacoepidemiology and appreciate their strengths and weaknesses.
- Describe the key steps in the design and analysis of cohort and case-control studies.
- Understand major types of biases that threaten the validity of pharmacoepidemiologic research (confounding, selection bias, measurement bias).

Course Faculty/Presentations

- Almut Winterstein, FISPE, University of Florida, Cohort Studies
- Sonia Hernández-Díaz, FISPE, Harvard School of Public Health, Case-Control Studies
- Tobias Gerhard, FISPE, Rutgers University, Bias & Confounding

12:30–2:00pm
Lunch on Your Own

2:00–6:00pm
Practical Skills in Protocol Writing and Computer Programming (Chinese) (101A)

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when executing the studies. This highly interactive course will engage participants in the following topics:

- Pre-specifying study components in a protocol, including design, analysis, conduct, and reporting of the study, along with a science-based rationale for the choices pertaining to these components.
- Translating elements of the study protocol into SAS programming.

Educational Objectives

- To introduce a framework for translating study questions into a clear and detailed protocol supported by a rational thought process that is tailored to available data for pharmacoepidemiologic studies using electronic healthcare data.
- To execute the protocols of pharmacoepidemiologic studies into SAS programming.
- To develop the skills to document and report pharmacoepidemiologic studies using electronic healthcare data in a transparent and reproducible way.

Course Faculty/Presentations

- Yaa-Hui Dong, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital
- Chien-Ning Hsu, Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital and School of Pharmacy, Kaohsiung Medical University
- Fang-Ju Lin, Pharmerit International
- Yi-Hsin Yang, School of Pharmacy, Kaohsiung Medical University
- Chih-Ying Chen
Real-world insights are driving healthcare decisions on safety, efficacy, effectiveness and value. To develop the evidence you need to satisfy diverse stakeholders, start by integrating therapeutic expertise, real-world data and powerful analytics technology. Harness post-approval research to maximize value, contain costs and drive better outcomes.

Learn how at www.quintiles.com/RWLPR

Contact us
US Direct: +1 973 850 7571
www.quintiles.com
RWLPR@quintiles.com
Upon completing this course, participants will be able to:

Educational Objectives:
- Recognize when missing covariate data threatens the inferences from an observational study.
- Know study designs and analytic strategies that reduce distortions due to missing covariates.

Pharmacovigilance (101C)

Content
This half-day course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including the EU-ADR project, and the US FDA’s Mini-Sentinel program, aimed at using routinely collected electronic healthcare data to conduct signal detection and active monitoring in prospective medical product safety monitoring. The course will involve lectures with ample opportunities for questions and discussion.

Educational Objectives:
- Upon completing this course, participants will be able to:
  - Explain the need for pharmacovigilance and its component activities with a focus on safety surveillance.
  - Describe the potential data sources (e.g., spontaneous reports, claims, electronic medical records, etc.) for safety surveillance in pharmacovigilance.
  - Understand the array of basic analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases.

Pharmacogenetics (2) – Intermediate (101D)

Content
This highly interactive course is intended to involve participants in:
- A dynamic didactic experience of the foundational principles of pharmacogenomics.
- An appreciation for the different methods used in pharmacogenomics research.
- Examination of real world examples of pharmacogenomic epidemiology.
- Application of methodology to designing pharmacogenomic epidemiology studies.
- Interpretation of the data found in the pharmacogenomic epidemiology literature, and understanding wider implications of the results.

Educational Objectives:
- To understand the genetic and pharmacogenic terminology and how cellular and molecular biology informs pharmacogenomic studies at the level of analysis.
- To better understand the study design and methodologic approaches, their strengths and weakness used in pharmacogenomic epidemiology.
- To understand the latest statistical approaches used in pharmacogenomics studies.
- To understand the role that pharmacogenomics can play in pharmacovigilance.
- To understand how pharmacogenomics relates to the current focus of personalized medicine.

Pharmacovigilance on CE EDUational E-CCE

Content
Covariates that may confound or modify a result are often poorly measured or not measured at all. The result is pharmacoepidemiologic studies that seem to contradict one another. Most critiques of observational research rest on unmeasured covariates. This course will classify the options for dealing with unmeasured covariates in study design and analysis, and present examples of self-controlled case series and matched designs, propensity-balancing and proxy-variable designs, and instrumental variable analyses.

Educational Objectives:
- Develop an intellectual framework for understanding novel problems that involving missing covariates.

Course Faculty/Presentations
Alexander M Walker, FISPE, World Health Information Science Consultants
- Confounding by Indication as a Motivating Example of Missing Covariates
- Self-Controlled Case Series and Matching
- Propensity Scores as a Technique for Controlling for Confounder Through Proxy Measures
- Instrumental Variables

Japan: An Introduction to Pharmacovigilance and Spontaneous Adverse Event Reporting

Content
This highly interactive course is intended to involve participants in:
- Understand the array of basic analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases.

Educational Objectives:
- Recognize the limitations of each data source and approach and how they complement each other.

Course Faculty/Presentations
Ian Wong, The University of Hong Kong, Introduction to Pharmacovigilance and Spontaneous Adverse Event Reporting
Andrew Bate, Pfizer Ltd, UK, Multiple Data Streams for Safety Surveillance: Leveraging Real World Data Sources
Gianluca Trifirò, Erasmus University Medical Center & University of Messina, Italy, Electronic Medical Records and Claims Data for Drug Safety Signal Detection: Lessons Learned from the EU-ADR Project
Joshua Gagne, Department of Medicine, Brigham and Women’s Hospital & Harvard Medical School, Semi-Automated, Distributed, Prospective Medical Product Safety Monitoring
Introduction to Drug Utilization Research (101B)

**Content**
- The educational session consists of presentations providing an overview of drug utilization research and presenting essential methods.
- The theoretical framework will be described and the practical application of different methods will be illustrated using selected examples.
- Interpretation of study results taking into account limitations of data sources and methods will be addressed.
- Additional perspectives covered are the importance of drug utilization research for public health and implications for policy decisions.
- Interaction with participants will be encouraged, e.g. by presenting short questions to be considered by the audience, and by giving time for questions and answers during and at the end of presentations.

**Educational Objectives:**
- To provide an overview of Drug Utilization Research within the context of Pharmacoepidemiology, Health Services Research and Public Health.
- To describe fundamental principles for classifying and quantifying drug use and to provide an understanding of the methodological challenges.
- To motivate researchers to cooperate on the collection of a minimum dataset of consistent and reliable data in their country or region, in terms of volume, expenditures and quality of drug use, facilitating international cross-national comparisons.
- To explain the process of developing and validating prescribing quality indicator.
- To give an applied overview of methods useful for evaluating interventions, in particular in drug policy research (time series analysis).

**Course Faculty/Presentations**
- Lisa Pont, The University of Sydney, Drug Utilization Research
- Hege Salveson, Blix, ATC/DDD: Introductory Methods
- Morton Andersen, Implementation Research
- Andrew Gilbert

6:30pm

Student/Young Professionals Meet and Greet

Students can meet at the Southern Entrance of TICC at 6:20pm to arrange transportation and ride-share.

---

**Value through Innovation**

Even with more than 129 years of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company, today operating with 142 affiliates. Research is our driving force. And we equate success as a pharmaceutical company with the steady introduction of truly innovative medicines. With more that 47,428 employees worldwide and a track record built up in more than 129 years, we are continuously dedicated to improving the outlook for a healthier life.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com
PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

7:30am–6:00pm
Registration
(Main Entrance Lobby)

7:30am–5:00pm
Speakers’ Ready Room
(105)

8:30am–12:30pm
General/Asian Databases (201D)

Content
This highly interactive workshop will involve participants in the following topics:
• Examine the use of database resources in pharmacoepidemiology research.
• Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource, workshop will strengthen the concepts discussed through participant interaction.
• Review the details of data resources available within Asia.
• Develop the skills to validate outcome measures in pharmacoepidemiology resources.
• Discuss privacy and confidentiality concerns within data resources.

Educational Objectives
• To review the Guidelines for Good Database Selection and use in Pharmacoepidemiology Research.

Course Faculty/Presentations
Gillian Hall, FISPE, Overview of Database Use in Pharmacoepidemiology
Kiyoshi Kubota, FISPE, University of Tokyo, Asian Data Resources
Kevin Haynes, FISPE, HealthCore Inc., Selection of Databases for Pharmacoepidemiology Research
Brian Sauer, University of Utah, Privacy and Confidentiality
Vincent Lo Re III, FISPE, Perelman School of Medicine, University of Pennsylvania, Validation of Outcomes

Registry/Prospective Cohort (201E)

Content
Designing studies to meet various stakeholder needs, including multi-purpose registries; practical considerations & challenges including collecting data from clinicians and direct-to-patient, informed consent, adverse event reporting, expectations with regard to missing data; intro to network building.

Educational Objectives
• A pregnancy registry is a non-randomized prospective cohort of women exposed to a biopharmaceutical product who are enrolled early in gestation and followed throughout pregnancy or longer.
• The frequency of maternal and infant outcomes among exposed is compared with that among a reference group.
• A valid reference group needs to have comparable gestational age at enrollment and time of follow up, outcome definition and ascertainment methods, and distribution of baseline risk factors.

Course Faculty/Presentations
Nancy A Dreyer, Quintiles Real-World & Late Phase Research, Registries for Safety, Effectiveness & Value: Designing Practical Studies Fit for Purpose; and Assuring Quality
Sonia Hernandez-Diaz, Pharmacoepidemiology Program, Department of Epidemiology, Harvard School of Public Health, Pregnancy Registries: Methodological Points and Real-World Examples
Saad Shakir and Deborah Layton, Drug Safety Research Unit, Portsmouth University, Interactive Group Session about Risk Management
PRE-CONFERENCE EDUCATIONAL SESSIONS  (Registration required)

8:30am–12:30pm
Comparative Effectiveness Research: Methodologic Challenges of Newly Marketed Medical Products (201ABC)

This course explains the methodologic challenges of conducting comparative effectiveness studies for newly marketed medical products. The faculty will describe potential biases in observational research that are particularly salient when comparing the effectiveness of new medical products — including biases related to exposure misclassification and channeling — and will discuss other limitations to research in the early marketing period, such as sparse data for confounding adjustment. To illustrate these issues, the speakers will present case studies from past and ongoing comparative effectiveness research. The course covers solutions for these challenges — including confounder summary scores (i.e., propensity scores and disease risk scores), time-based instrumental variable analyses, sequential analyses, and distributed data networks — as well as practical limitations to implementing these solutions.

Educational Objectives
Upon completing this course, participants will be able to:

- Recognize the need for comparative effectiveness information for new medical products and the potential sources of such evidence.
- Understand how the patient, provider and healthcare system characteristics can create confounding and other biases in comparative effectiveness studies of newly marketed medications.

- Appreciate the potential solutions for overcoming the challenges of generating comparative effectiveness evidence for newly marketed products and the limitations of these solutions.

Course Faculty/Presentations
Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, USA
Michele Jonsson-Funk, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
Cynthia Girman, Comparative & Outcomes Evidence, Center for Observational & Real-world Evidence, Merck Sharp & Dohme, USA
Jeremy Rassen, Aetion, Inc., USA

Successful Journeys
Start with Great Maps

UBC continues to power global patient access and product safety strategies with real-world evidence gathering and analysis

Value Demonstration | Safety & Risk Management | Database Analytics Automation

Registry: Its Use in Real-World Data Collection  
Pan Yi, Dieck G, Stemhagen A

Post Authorization Safety Studies (PASS): Application of Prospective Observational Study Methodology  
Pan, Yi, Walton A, Dieck G

Post Authorization Safety Studies (PASS): Application of Retrospective Chart Review Methodology  
Stein D, Pan Yi, Payne KA
OUR WORK IS SOMEONE’S HOPE. JOIN US.

Merck, established in 1891, is a global, research-driven pharmaceutical company dedicated to putting patients first. This philosophy was first articulated by George Merck and still guides us today. Join us and experience our culture first-hand – one of strong ethics and integrity, diversified experiences and a resounding passion for improving human health. As part of our global team, you’ll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.

MRL Epidemiology, founded by Dr. Harry Guess in 1985 – Improving research to assess patient outcomes. Our mission is the scientific study of disease, endpoints and patient outcomes to evaluate benefits and the risks of our products. At Merck, we pride ourselves on meeting patient expectations – leveraging the most complete data and a strong cohesive effort to make the products that make life better.

We provide epidemiologic and outcomes research for all Merck drugs and vaccines. Using existing information, database analyses and conducting epidemiology studies across the globe, we characterize disease natural history for new therapeutic areas, assist in clinical trial design based on the epidemiology of the disease, develop and validate patient-reported outcomes, link biomarkers to outcomes and help understand the safety and effectiveness of our products pre- and post-launch. Our team is an active member of clinical development, safety/risk management and outcomes research teams. We are part of a global center of excellence in observational research–CORE (Center for Observational and Real-World Evidence). MRL Epidemiology also includes European Research Units and an Asia Pacific Unit based in China.

Join us and participate in our investigative design and interpretation that enables us to bring life-enhancing products to market.

Visit www.merck.com/careers to find out how.
### PRE-CONFERENCE EDUCATIONAL SESSIONS

**Advanced Topics in Pharmacoepidemiology (201ABC)**

**Course Faculty/Presentations**
- Juhari Juhari, Sanofi, Benefit-Risk Assessment, Communication and Evaluation (BRACE) throughout the Life Cycle of Therapeutic Products
- Robert Reynolds, FISPE, Pfizer, Risk Management/Risk Minimization

**Content**
- Use of drug utilization information from administrative health data to improve medicines use.
- Development of Prescribing Quality Indicators.
- Methods for identifying and managing problems with medicines use in practice.
- Methods for evaluating the effect of clinical or policy interventions.
- Interpretation of the evaluation data and dissemination of results.

**Educational Objectives**
- To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
- To develop a sophisticated understanding of the importance of project planning processes to the effectiveness of interventions.
- To develop an appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

**Course Faculty/Presentations**
- Kenneth J Rothman, FISPE, RTI Health Solutions, The Unimportance of Representativeness
- Saad Shakir, Drug Safety Research Unit

---

**Advanced Topics in Drug Utilization Research (201D)**

**Course Faculty/Presentations**
- Libby Roughead, University of South Australia, Methods for Identifying and Managing Problems with Medicines Use in Practice
- Petra Denig, University Medical Center Groningen, Developing Valid Prescribing Quality Indicators
- Nicole Pratt, University of South Australia, Evaluating Drug Utilization Interventions: Analysis Methods
- Jerry Avorn, FISPE, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Evaluating Practice or Policy

**Content**
- Use of drug utilization information from administrative health data to improve medicines use.
- Development of Prescribing Quality Indicators.
- Methods for identifying and managing problems with medicines use in practice.
- Methods for evaluating the effect of clinical or policy interventions.
- Interpretation of the evaluation data and dissemination of results.

**Educational Objectives**
- To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
- To develop a sophisticated understanding of the importance of project planning processes to the effectiveness of interventions.
- To develop an appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

---

**Non-Database Pharmacoepidemiology (201F)**

**Course Faculty/Presentations**
- Kiyoshi Kubota, FISPE, NPO Drug Safety Research Unit Japan
- Annie Fourrier-Reglat, University Bordeaux, France
- Hisham Aljadhey, College of Pharmacy, King Saud University
- Lisa Pont, The University of Sydney

**Content**
- Basic theory and practical tips in conducting pharmacoepidemiologic studies when large databases are not available.
- Common study design used to collect data through observation, medical records or questionnaires.
- Strengths and limitations of working without large databases.
- Case studies illustrating the use of different study designs to answer relevant questions about safety and utilization of medicines in primary and secondary care settings.

**Educational Objectives**
- To develop the skills to develop pharmacoepidemiologic studies without large databases.
- To discuss strengths and limitations of different study designs and data collection methods.
- To identify strategies to improve quality and reliability of pharmacoepidemiological studies conducted without large databases.
Raising the Standard in Pharmacoepidemiology

For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop compelling results for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Peri-approval safety studies for IND and NDA submissions and post-approval commitment
  - Observational pharmacoepidemiology studies (claims analysis + chart review, EMR data analysis)
  - Prospective drug safety surveillance
  - Drug safety monitoring boards
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analysis and meta-analysis for drug safety endpoints
- PMR/PMS and PASS studies
- Strategic responses to drug safety concerns raised by the U.S. and ex-U.S. regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Advanced methods in causal inference (ex, marginal structural models, mediation analysis, high-dimensional propensity score matching)
- Comparative effectiveness research
- Quality of life instrument development and validation
- Mass tort pharmaceutical liability litigation

For more information, contact Mei Sheng Duh, Sc.D., M.P.H., at 617 425 8131, mei.duh@analysisgroup.com, or visit our website at www.analysisgroup.com/epidemiology
PRE-CONFERENCE EDUCATIONAL SESSIONS (Registration required)

2:00–6:00pm
Advanced Topics in Pharmacoepidemiology (Chinese) (201E)

Content
The educational session covers four advanced topics in pharmacoepidemiology for post-marketing evaluation of medical products, including:
- Safety signal detection and refinement: relevant methods and data sources.
- Comparative safety and effectiveness research: trade-offs between different studies designs and advanced methods for reducing the biases that can distort estimates of non-randomized research.
- Benefit-risk assessment: relevant tools and characterization of uncertainties, case study from recent regulatory history, and the challenge and future development of benefit risk assessment.
- Unmeasured confounders: application of propensity score calibration in pharmacoepidemiologic studies.

Educational Objectives
- To provide an overview of post-marketing safety signal detection and refinement for medical products.
- To understand challenges and proposed methodological solutions in non-randomized research.
- To give a conceptual work with several examples and the way forwarding to benefit-risk assessment of medical products.
- To describe how to use external information to control for unmeasured confounders in the main study with propensity score calibration.

Course Faculty/Presentations
K Arnold Chan, FISPE, National Taiwan University College of Medicine, Post-Marketing Safety Signal Detection and Refinement for Medical Products
Edward Chia-Cheng Lai, Duke Clinical Research Institute & National Cheng-Kung University College of Medicine, Comparative Safety and Effectiveness Research: Challenges and Proposed Solutions
Chia-Hsien Chang, Takeda Pharmaceutical Company, Limited, Benefit and Risk Assessment of Medical Product: What Can We Learn From Healthcare Databases?
Jin-Liern Hong, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Adjustments for Unmeasured Confounders with External Information using Propensity Score Calibration

Clinical Practice Research Datalink
Gold sponsor

WE'RE PROUD TO BE SPONSORING ISPE’S FIRST INTERNATIONAL CONFERENCE IN ASIA

Visit our stand to learn how our increased data population and real-time feasibility tools are adding more dimensions to our data.
PRE-CONFERENCE EDUCATIONAL SESSIONS  (Registration required)

2:00–6:00pm
Pharmacovigilance (Chinese) (103)

**Content**
- An overview of principles, hot topics, research scopes and essential methods regarding pharmacovigilance with a focus on quantitative aspects.
- The latest US FDA pharmacovigilance practice.
- Classical pharmacovigilance signal detection using multiple data streams for safety surveillance.
- Spontaneous adverse event reports.
- Quantitative signal detection methods for electronic medical record and claims data.
- US FDA’s Mini-Sentinel program.
- Evaluation methods and examples for drug safety surveillance policies.

**Educational Objectives**
Upon completing this course, participants will be able to:
- Explain the need for pharmacovigilance and its component activities with a focus on safety surveillance.
- Describe the potential data sources (e.g., spontaneous reports, electronic medical records, claims etc.) for safety surveillance in pharmacovigilance.
- Understand the array of basic and advanced analytic methods for pharmacovigilance in spontaneous adverse events reports and signal detection and active monitoring in electronic healthcare databases.
- Know how to use quantitative regulatory science methods to evaluate the impacts of pharmacovigilance policies.

**Course Faculty/Presentations**
- **Min Chu Chen**, US Food & Drug Administration, *Introduction to the Latest US FDA Pharmacovigilance Practice and Multiple DataStreams for Safety Surveillance*
- **Cliff Ke**, Taiwan Drug Relief Foundation, *Spontaneous ADR Reporting in Taiwan: Lessons Learned and the Future Perspective*
- **Jason C Hsu**, Department of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Taiwan, *Pharmaceutical Policy and Regulatory Science Research Methods for Evaluation of Drug Safety Surveillance Policies*

---

6:00–7:30pm
**Welcome Reception/Academic Showcase/International Chapter Showcase (Banquet Hall, 3rd Floor)**
- **Yea-Huei Kao Yang**, FISPE, Chair, 2014 Local Host Committee
- **Soko Setoguchi**, FISPE, Chair, 2014 Scientific Program Committee
- **Til Stürmer**, FISPE, ISPE President

**ACADEMIC SHOWCASE/INTERNATIONAL CHAPTER PARTICIPANTS** (as of September 1, 2014)
- Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University, UK
- Gulf Region Chapter
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- University of Florida, Department of Pharmaceutical Outcomes and Policy
- University of Illinois at Chicago
CALL for ABSTRACTS

Abstracts Due: February 16, 2015
Meeting info: pharmacoepi.org

You are Invited to Submit an Abstract
ISPE invites you to submit an abstract for an oral/poster presentation, workshop or symposium at the 31st ICPE in Boston, MA USA. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and will allow you to experience Boston’s dynamic and lively personality.

Guidelines For Submissions
The deadline for receipt of all abstracts is February 16, 2015. Please visit pharmacoepi.org, for submission guidelines. The online submission site will be operational by mid-December 2014.

Questions about abstract submissions and technical issues should be directed to Coe Truman at c4asupport@coetruman.com or by telephone +1.507.403.2305. Note, submissions will not be accepted until the online submission site is open in December 2014.

Reviewing/Registration
The ISPE Scientific Program Committee will review all abstracts in April 2015. All submitters will be notified by email in early June 2015. All presenters and panelists (workshop/symposia) must register to attend the 2015 ICPE.

Scholarships & Student Awards
ISPE will award a limited number of scholarships to help defray conference expenses. Information will be posted on pharmacoepi.org

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The Scientific Program Committee oversees the selection of awards, which will be presented at the 2015 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

Sponsorships, Exhibits & Academic Showcase
ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on pharmacoepi.org/meetings/31ICPE.

SAVE THE DATES!
August 23-26, 2015
Hynes Convention Center
Boston, MA USA

Please visit pharmacoepi.org/meetings/31ICPE for updated conference information.
Pharmacoepidemiology – The Next 30 Years
From Where Have We Come, Where Are We Going in the Next 30 Years?

Faculty:
- Byung-Joo Park, FISPE, Korean Institute of Drug Safety & Risk Management
- Judith K Jones, FISPE, The Degge Group, Ltd.
- Hubert GM Leufkens, FISPE, Utrecht Institute of Pharmaceutical Sciences, Dutch Medicines Evaluation Board

Moderators:
- Frank May, FISPE, Drug & Therapeutics Information Service
- Susana Perez-Gutthann, FISPE, RTI Health Solutions

Thirty years have passed since the first annual scientific meeting of the International Society for Pharmacoepidemiology. An intrepid group of epidemiologists, clinicians and mathematicians from North America and Europe came together in the mid-1980’s, focused primarily on the problematic field of medicine safety.

Much has changed in the intervening years. Inevitably effectiveness of medicines, (as a corollary to medicine safety) quickly came sharply into focus in the early years, and the science soon attracted deep interest of drug regulators and academics, as well as scientists in safety departments of the pharmaceutical industry. Rather more recently practitioners from clinical disciplines have been attracted to the science because of its focus on benefits and harms of medicines, as well as the way it naturally extends perspectives gained from controlled trials to more fully illuminate clinical experience in evidence-based medicine.

Methods of observational research in therapeutic strategies have radically evolved in the past 30 years. These improvements in methods have occurred in parallel with the rise of large datasets and their relative accessibility for systematic investigation. As a matter of policy ISPE has avoided deeper entanglement in the still-evolving economic sciences, which have become associated with estimates of relative value of different therapeutic approaches.

At this moment of generational-change in the development of pharmacoepidemiology during ISPE’s 30th annual scientific meeting, this keynote session will focus on the next 30 years of the field's development.

Three eminent speakers will address possible futures for pharmacoepidemiology in this session. These speakers, all of whom have been eminent researchers and thinkers in our field, represent the globe’s three principal regions, the Americas, Europe/Africa and Asia. They will draw on their own past experiences, as well observations of the development of our science up until 2014 so that they can predict future directions for pharmacoepidemiology, and its likely position at the next generational transition in 2044.
**AGENDA Saturday, October 25**

**10:30am-Noon CONCURRENT ORAL PRESENTATION SESSIONS**

**All About Statins (201BC)**
*Moderators: Robert Glynn & Ching-Lan Cheng*

- **10:30am**
  - Effect of Statin Use on Acute Kidney Injury Following Elective Cardiac Surgery: A Population Cohort Study in Denmark [1]
  - Perioperative Utilization of Statins in Patients Undergoing Intermediate to High Risk Non-Cardiac Surgery [2]
  - Elisabeta Patornu, Shirley Wang, Sebastian Schneeweiss, Jun Liu, Brian Bateman. (United States)

- **11:00am**
  - Pattern of Risks of Rheumatoid Arthritis among Patients Using Statins: A Cohort Study with the Clinical Practice Research Datalink [3]

- **11:15am**
  - Statin Use and Cholesterol Levels among US Adults with Age-Related Macular Degeneration (AMD): Findings from the 2005-2008 National Health and Nutrition Examination Survey (NHANES) [4]
  - R A Cantrell, C I Kiu Weber, P Delmar, M Gleeson, Q Doan. (United States)

- **11:30am**
  - Statin Initiation in a Closed Cohort of U.S. Women over Two Decades [5]
  - Tracy L Kinsey, Til Stürmer, Robert J Glynn. (United States)

- **11:45am**
  - Pharmacoepidemiologic and In Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonyleureas with Fibrates and Statins [6]
  - Hedi Schelleman, Xu Han, Colleen M Bresniser, Sara K Quinney, Warren B Bilke, David A Flockhart, Lang Li, Sean Hennessy. (United States)

**Biologics Bouillabaisse (201AF)**
*Moderators: David Miller & Cheryl Enger*

- **10:30am**
  - Meng-Ju Chan, Chien-Ning Hsu, Yen-Hsia Wen, Yu-Chin Lily Wang. (Taiwan)

- **10:45am**
  - Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis from the Perspective of the Taiwanese Healthcare System [8]
  - Ching-Chi Chi, Shu-Hui Wang. (Taiwan)

- **11:00am**
  - Regional Differences in Utilisation of Biologics in Portugal [9]
  - Joelle M Hoebert, Sofia Oliveira-Martins, Hubert GM Leufkens, José Cabrita, Helder Mota-Filipe, Patrick C Souverein. (Netherlands)

- **11:15am**
  - Risk of Incident Heart Failure among Established Rheumatic Arthritis Patients Treated with TNF-alpha Inhibitors in Taiwan [10]
  - Tzu-Chieh Lin, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

- **11:30am**
  - Development of an Algorithm to Identify Denosumab 60 Milligram Users in Health Insurance Claims Data [11]
  - Veena Thyagarajan, Fei Xue, Betsey Gardstein, Kathleen Skerry, Cathy W Critchlow, Cheryl Enger. (United States)

- **11:45am**
  - Payer-Level Differences in the Response to Regulatory Actions Regarding Bevacizumab [12]
  - Stacie B Dusetzina, Aaron N Winn, Haiden A Huskamp, G Caleb Alexander, Nancy L Keating. (United States)

**Continuing the Discussion on Antipsychotic Safety (201DE)**
*Moderators: Alejandro Arana, FISPE & John Jackson*

- **10:30am**
  - Antipsychotics and Mortality: Adjusting for Mortality Risk Scores to Address Confounding by Terminal Illness [13]
  - Yoonyoung Park, Jessica Franklin, Sebastian Schneeweiss, Raisa Levin, Stephen Crystal, Tobias Gerhard, Krista Huybrechts. (United States)

- **10:45am**
  - Mediators of the Causal Pathway to Mortality in Older Adults Who Use Antipsychotics [14]
  - John W Jackson, Tyler J VanderWeele, Deborah Blacker, Sebastian Schneeweiss. (United States)

- **11:00am**
  - Concomitant Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) during Antipsychotic Treatment in Incident Cases of Schizophrenia and Risk of 1-Year Psychiatric Hospitalizations [15]
  - Ole Koehler, Ole Mors, Liselotte Petersen, Christiane Gasse. Denmark)

- **11:15am**
  - Incidence of Weight Gain with Seroquel XL™ in Primary Care in England: Results from an Observation Post-Marketing Cohort Study [16]
  - Deborah Layton, Miranda Davies, Vicki Osborne, Saad A W Shakir. (United Kingdom)

- **11:30am**
  - Detecting Potential Adverse Reactions of Sulpiride in Schizophrenic Patients by Prescription Sequence Symmetry Analysis [17]

- **11:45am**
  - Course and Outcome of Clozapine Treatment in Patients with Incident Schizophrenia in Denmark [18]
  - Christiane Gasse, Aske Astrup, Henrik Støvering, Theresa Wimberley. (Denmark)
Saturday, October 25

10:30am-Noon CONCURRENT ORAL PRESENTATION SESSIONS

Improving Strength and Balance (4th Floor VIP)
Moderators: Olaf Klungel & Ian Douglas

10:30am
- Improving Empirical Variable Selection in Propensity-Score Models with High-Dimensional Covariate Space Using Healthcare Databases [19]
  Sebastian Schneeweiss, Wesley Eddings, Robert J Glyn, Jessica M Franklin. (United States)

10:45am
- Penalized Regression for Fitting High Dimensional Propensity Score Models in Small Samples [20]
  Carl de Moor, Ed Malka. (United States)

11:00am
- Improving Propensity Scoring through Machine Learning [21]
  John A Rigg, Huma Lodhi, John Gregson, Joseph Kim. (United Kingdom)

11:15am
- Propensity Score Matching and Unmeasured Covariate Imbalance: A Simulation Study [22]
  M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitser, Arno W Hoes, A de Boer, Olaf H Klungel. (Netherlands)

11:30am
- Use of Propensity Score Methodology to Assess Comparability of Treatment Groups in a Registry Program [23]

11:45am
- Applying High Dimensional Propensity Score (HDPS) in an Exploratory Data Analysis with a US Claims Database for Recent Medicinal Products [24]
  Bing Cai, Sundaresan Murugesan, Jamie Geier, Andrew Bate. (United States)

The Good, the Bad, and the Ugly of Anti-Infectives (103)
Moderators: Florence Wang & Suzanne West, FISPE

10:30am
- Increased Risk of Hip Fracture Associated with Dually-Treated HIV/ Hepatitis B Virus Coinfection [25]
  Dana D Byrne, Craig W Newcomb, Dena M Carbonari, Melissa S Nezamzadeh, Kimberly BF Leidl, Maximilian Herlim, Yu-Xiao Yang, Sean Hennessy, Jay R Kostman, Mary B Leonard, Russell Localio, Vincent Lo Re III. (United States)

10:45am
- Antiretroviral Adherence among Patients Enrolled in an AIDS Drug Assistance Program [26]
  Jenna Parrett, Alice C Thornton, Emily S Brouwer. (United States)

11:00am
- Adherence to Antiretroviral Drugs and Its Determinants among Human Immunodeficiency Virus (HIV) Patients Attending HIV Clinic in a Teaching Hospital in Nigeria [27]
  Chioma Stella Ejekam, Adebayo Temitayo Onajole, Charles C Okany, OA Lesi, ES Oridota. (Nigeria)

11:15am
- Predictors of Receiving Guideline Recommended Antiretroviral Treatment: Type of Provider Influences the Provision of Optimum HIV Treatment [28]
  Emily S Brouwer, Sarah Wixson, Daniela C Moga. (United States)

11:30am
- Seasonal Variation in Penicillin Use in Brazil and Mexico: An Analysis of the Impact of Over-the-Counter Regulations [29]
  Yared Santa-Ana-Tellez, Aukje K Mantel-Teeuwisse, Hubert GM Leufkens, Veronika J Wirtz. (Netherlands)

11:45am
- The Effects of Obesity on the Comparative Effectiveness of Linezolid and Vancomycin in MRSA Pneumonia [30]
  Aisling R Caffrey, Eunsun Noh, Haley J Morrill, Kerry L LaPlante. (United States)

Women’s Health (102)
Moderators: Michele Jonsson-Funk & Jennita Reefhuis

10:30am
- Use of Triptans and Risk of Hemorrhagic Stroke in Women [31]
  Klaus K Andersen, Christian Dehlendorff, Charlotte Skriver, Søren Friis, Tom S Olsen. (Denmark)

10:45am
- Women’s Perception of Risks in Pregnancy [32]
  Irene Petersen, Rachel McCrea, Angela Lupattelli, Michael Twigg, Hedvig Nordeng. (United Kingdom)

11:00am
- Procedure-Related Issues Associated with the Nexplanon Contraceptive Implant: Interim Results from the Nexplanon Observational Risk Assessment Study (NORA) [33]
  Suzanne Reed, Klaas Heinemann. (Germany)

11:15am
- Unwanted Pregnancies in Women Using Intrauterine Devices: Final Results from the EURAS-IUD Study [34]
  Klaas Heinemann, Sabine Moehner, Thai Do Minh. (Germany)

11:30am
  Mitchell M Conover, Jennifer M Wu, Alan C Kinlaw, Jennifer O Howell, Michele Jonsson Funk. (United States)

11:45am
- Persistent Opioid Use Following Cesarean Delivery: Patterns and Predictors among Opioid Naive Women [36]
  Brian T Bateman, Jessica M Franklin, Katsiaryna Bykov, Krista F Huybrechts, Michael A Fischer, Niteesh K Choudhry. (United States)
27th ICPE  |  TAIPEI, TAIWAN

Saturday, October 25

Noon -1:30pm

Lunch/Poster Session A/Roundtable Discussions
(Banquet Hall, 3rd Floor)

Roundtable Discussions
To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Saturday and Sunday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange and networking. Seating is limited; first-come, first-served.

- Ulf Bergman, FISPE, Drug Utilization – The Importance of Pharmacology in Pharmacoepidemiology Research
- Syed Rizwanuddin (Rizwan) Ahmad, FISPE, Challenges in including Patient’s Perspective in Pharmacovigilance
- Wei Zhou, Career Paths Between Academic and Industry Pharmacoepidemiology in Developing Countries: Opportunities and Challenges

Noon -1:30pm

ISPE Committee/Council Meetings
Open to all participants.

- Development Committee (South Lounge, 3rd Floor)
- Fellowship & Awards Committee (South Lounge, 3rd Floor)
- Finance Committee (South Lounge, 3rd Floor)
- Public Policy Committee (South Lounge, 3rd Floor)
- Student Council (North Lounge, 3rd Floor)

12:15-1:15pm

Spotlight Poster Sessions (101)

- Best of the Day
- Drug Utilization/Health Services Research
- Methods
- Pediatrics
- Vaccines

More Than Data. Answers.

TRUVEN
HEALTH ANALYTICS

25 Years Using Big Data for Healthcare Research

The Truven Health MarketScan® Research Databases are considered the gold standard in U.S. research data. With longitudinal integrity that allows tracking of more than 200 million patients through the healthcare system, Big Data doesn’t get much bigger.

To learn more about the MarketScan Research Databases and our unique strengths in oncology and rare disease research, stop by our booth or email us at lifesciences@truvenhealth.com.
1:30-3:00 pm CONCURRENT ORAL PRESENTATION SESSIONS

**Antibiotics and Other Exposures in Pregnancy (102)**

Moderators: Sonia Hernandez-Diaz, FISPE & Andrea Margulis

1:30 pm
- Antibiotic Use among Dutch Pregnant Woman and the Development of Toddler Asthma: The Influence of Confounding [37]
  Bianca Mulder, Koen B Pouwels, Nynke CM Schuiling-Veninga, Jens Bos, Tjalling W de Vries, Susan S Jick, Eelko Hak. (Netherlands)

1:45 pm
- Genital Herpes Infection and Its Treatment in Relation to Preterm Delivery Among 662,913 Births [38]
  De-Kun Li, Marsha A Raebel, T Craig Cheetham, Craig Hansen, Lyndsay Avalos, Hong Chen, Robert Davis. (United States)

2:00 pm
- Erythromycin in Early Pregnancy and Fetal Safety: A Register Based Nationwide Cohort Study [39]
  Jon T Andersen, Nadia L Andersen, Arendse Torp-Pedersen, Vanja Cevjanovic, Henrik E Poulsen, Espen Jimenez-Solem. (Denmark)

2:15 pm
- Antiepileptic Drug Use Before, During and After Pregnancy: A Study in 7 European Regions [40]

2:30 pm
- Medications and Other Risk Factors for 2nd and 3rd Degree Hypospadias in the National Birth Defects Prevention Study, 1997-2009 [41]
  Jennita Reefhuis, Sander Groen in’t Woud, Iris van Rooij, Marleen van Gelder, Richard Olney, Suzan Carmichael, Nel Roeleveld. (United States)

2:45 pm
- Statins during Pregnancy and the Risk of Congenital Malformations: A Cohort Study [42]
  Brian T Bateman, Sonia Hernandez-Diaz, Helen Mogun, Michael A Fischer, Krista F Huybrechts. (United States)

---

**RTI Health Solutions**

Announcing the Expansion of Our Barcelona Office

With four recent senior hires (three epidemiologists with medical specialties and a statistician) to our Barcelona office, we’ve deepened our therapeutic expertise—including oncology, neurology, ophthalmology, respiratory, and cardiovascular—and added capacity and experience in pharmacoepidemiology and risk management consultation and research services.

Visit our exhibit booth to learn more about our new staff, what they bring to our growing 30+ person epidemiology team and how we can help you meet your epidemiological, risk management, and drug safety needs.

www.rtihs.org

LEADING RESEARCH... MEASURES THAT COUNT
## AGENDA  Saturday, October 25

### 1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

#### Cancer Care Continuum (201DE)
**Moderators:** Danica Marinac-Dabic & Geoffrey Liu

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Validation of Pancreatic Cancer Diagnosis Claims Within SEER-Medicare</td>
<td>Mary E Ritchey, Jinhua He, Samuel S Engel, Mellissa Yong, Kimberly G Brodovicz. (United States)</td>
</tr>
<tr>
<td>1:45pm</td>
<td>An Analysis of Biomarker Testing and Appropriate Treatment Among Women with Breast Cancer Using Oncology EMR Data</td>
<td>Kathleen A Foley, Leigh G Hansen, Richard Bizier. (United States)</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Comparative Persistence to Oral Hormonal Agents in Women with Breast Cancer</td>
<td>Edward Chia-Cheng Lai, Winson Y Cheung, Yinghong Zhang, Soko Setoguchi. (Taiwan)</td>
</tr>
<tr>
<td>2:15pm</td>
<td>Elderly Breast Cancer Patient’s Pill Burden and Adherence to Hormonal Therapy</td>
<td>Kitaw Demissie, Joel N Swerdel, Kim M Hirshfield, Sheenu Chandwani, George G Rhoads. (United States)</td>
</tr>
<tr>
<td>2:30pm</td>
<td>The Impacts of Competing Risks on Assessing the Association between Switch and Interruption of Adjuvant Hormone Therapy in Breast Cancer Women</td>
<td>Kun-Pin Hsieh, Li-Chia Chen, Kwok-Leung Cheung, Yi-Hsin Yang. (Taiwan)</td>
</tr>
<tr>
<td>2:45pm</td>
<td>Prognostic Impact of Tumor MET Expression among Patients with Stage IV Gastric Cancer: A Danish Cohort Study</td>
<td>Rune Erichsen, Michael A Kelsh, Anthonius de Boer, Hélga Gardarsdottir, Elisa Martin, Gianmarino Candore, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)</td>
</tr>
</tbody>
</table>

#### CER and Safety in CV TX/Care (201BC)
**Moderators:** Cynthia Girman & J Bradley Layton

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Comparative Effectiveness of Drug-Eluting Stents for Patients with Coronary Diseases: A Nationwide Population-Based Study in Taiwan</td>
<td>Grace Hui-Min Wu, Yu-chiao Wang. (Taiwan)</td>
</tr>
<tr>
<td>1:45pm</td>
<td>Real-World Effectiveness of Primary ICDs Implanted during Unplanned Medicare Hospitalizations</td>
<td>Chih-Ying Chen, Garrick C Steward, Lynne W Stevenson, Deepak I Bhatt, Manisha Desai, John D Seeger, Lauren Williams, Jessica J Albright, Soko Setoguchi. (United States)</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Concomitant Use of Clopidogrel with Calcium Channel Blockers and Cardiovascular Outcomes in Patients Received Percutaneous Coronary Intervention</td>
<td>Chen-Yu Wang, Fei-Yuan Hsiao, Zhen-Fang Lin, Li-Juan Shen. (Taiwan)</td>
</tr>
<tr>
<td>2:15pm</td>
<td>Integration of Healthcare Delivery System Characteristics into Pharmacoepidemiologic Research: An Analysis of Acute Stroke Care Effectiveness</td>
<td>Mark O Loveless, Andrew Wilson, Stephen Agbor, Drew Levy, Aaron WC Kamaunu. (United States)</td>
</tr>
</tbody>
</table>

#### Pseudorandom Exposures (4th Floor VIP)
**Moderator:** Mary E Ritchey

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Instrumental Variable Analysis Using Multiple Databases: An Example of Antidepressant Use and Risk of Hip/Femur Fracture</td>
<td>Md Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Helga Gardarsdottir, Elisa Martin, Gianmarino Candore, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)</td>
</tr>
<tr>
<td>1:45pm</td>
<td>Using Simulation to Explore the Properties of IV Bias Amplification and Unmeasured Confounding</td>
<td>Jonathan V Todd, M Alan Brookhart. (United States)</td>
</tr>
<tr>
<td>2:00pm</td>
<td>Instruments and Doubly Robust Estimation: Bias and Efficiency Compared to Conventional Estimators</td>
<td>Michele Jonsson Funk, Virginia Pate, Til Stürmer. (United States)</td>
</tr>
<tr>
<td>2:15pm</td>
<td>Evaluating Different Physician’s Prescribing Preference Based Instrumental Variables in the Study of Beta2-Agonist Use and the Risk of Acute Myocardial Infarction</td>
<td>Md Jamal Uddin, Rolf HH Groenwold, Anthonius de Boer, Ana Afonso, Paola Primatera, Claudia Becker, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)</td>
</tr>
<tr>
<td>2:30pm</td>
<td>The Performance of Different Disease Risk Score Methods for Estimating Unbiased Odds Ratio in the Presence of Multiple Confounders</td>
<td>Chien-Chang Lee, Chen-Fang Chen. (Taiwan)</td>
</tr>
<tr>
<td>2:45pm</td>
<td>Accounting for Cumulative Exposure Effects in Comparative Effectiveness and Safety Analyses</td>
<td>Michal Abrahamowicz, Rolina D van Gaalen, Marie-Pierre Sylvestre, Marie-Eve Beauchamp. (Canada)</td>
</tr>
</tbody>
</table>
1:30-3:00pm CONCURRENT ORAL PRESENTATION SESSIONS

Understanding Antidepressant Use and Safety (103)

Moderators: Ole Köehler & Tobias Gerhard, FISPE

1:30pm
- Use of Antidepressants and Age: A Comparatively High Risk of Suicide Attempts but Not of Suicide among the Young [61]
  Fabian Temorshuizen, Marco P Boks, Hugo M Smeets, Eibert R Heerdink. (Netherlands)

1:45pm
- Drug Use Patterns and Characteristics of Elderly Users of Antidepressants in Germany [62]
  Kathrin Jobski, Niklas Schmedt, Tania Schink, Edeltraut Garbe. (Germany)

2:00pm
- Treatment Patterns among US Veterans Treated with Selegiline Transdermal System [63]
  Scott L DuVall, Kimberly B Portland, Terry Painter, Andrew Wilson, Stephen Agbor, Aaron WC Kamauu. (United States)

2:15 pm
- Neighborhood Material and Social Deprivation and Adherence to Antidepressant Treatment in Depression [64]
  Sophie Lauzier, Hichem Kadachi, Jocelyne Moisan, Marie-Josée Fleury, Alain Lesage, Alain Vanasse, Josiane Courteau, Jean-Pierre Grégoire. (Canada)

2:30pm
- Understanding Inconsistent Results from Observational Pharmacoepidemiological Studies: the Case of Antidepressant Use and Risk of Hip Fracture [65]

2:45pm
- (Non)availability of Dosage Instructions in Electronic Health Care Databases and Exposure (mis)classification: the Example of Antidepressants [66]
  Patrick C Souverein, Helga Gardarsdöttir. (Netherlands)

Committed to bringing therapies to people that extend and significantly improve their lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

> The Epidemiology group at Pfizer is proud to support the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Taipei, Taiwan.
**AGENDA**  Saturday, October 25

### 1:30-3:00pm  CONCURRENT ORAL PRESENTATION SESSIONS

**Watch Closely (201AF)**

**Moderators:** Joshua Gagne & Hsueh-Yung Tai

**1:30pm**
- A Paradigm Shift for Screening Individual Case Reports: Accounting for Quality and Content [67]
  - Ola Castor, Kristina Juhlin, Sarah Watson, G Niklas Norén. (Sweden)
- Sequential Analysis After a Signal in Safety Surveillance of Drugs or Vaccines [68]
  - Bruce H Fireman, Edwin M Lewis. (United States)

**1:45pm**
- Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries [69]
  - Jude Nwokike, Elisabeth Ludeman, Melissa Thumm, Louis An. (United States)
- SAFEGUARD Results: Analysis of Pharmacovigilance Databases [70]
  - Lorna Hazell, Niklas Schmedt, Lorenza Scotti, Ingrid Leal, Gianluca Trifiro, Miriam Sturkenboom, Saad Shakir. (United Kingdom)

**2:00pm**
- Validation of Signal Impact Assessment Tool in Order to Explore Pharmacovigilance Signals’ Follow-Up Actions [72]
  - Leän Rolfes, Judith Kolfshoten, Florence van Hunsel, Eugene van Puijenbroek, Kees van Groothest. (Netherlands)

**2:30pm**
- Beyond Traditional “Observed Versus Expected” Analyses: A Sensitivity Analysis Integrating Uncertainties Around Reporting Bias and Background Incidence Rate [71]
  - Lionel Van Holle, Olivia Mahaux, Vincent Bauchau. (Belgium)

**2:45pm**
- Comparative Analysis of Pharmacovigilance Systems in Five Asian Countries [69]
  - Jude Nwokike, Elisabeth Ludeman, Melissa Thumm, Louis An. (United States)
- SAFEGUARD Results: Analysis of Pharmacovigilance Databases [70]
  - Lorna Hazell, Niklas Schmedt, Lorenza Scotti, Ingrid Leal, Gianluca Trifiro, Miriam Sturkenboom, Saad Shakir. (United Kingdom)

### 3:00-3:30pm  Break/Posters/Exhibits

(101/Main Entrance Lobby)

### 3:30-5:00pm  PLENARY SESSION  (Plenary Hall, 3rd Floor)

**Development in Pharmacoepidemiological Methods: Current Status and Future Direction**

**Speakers:**
- Ken Rothman, FISPE, RTI Health Solutions
- Alec Walker, FISPE, World Health Information

**Panelists:**
- Miguel Hernan, Harvard School of Public Health
- Robert Glynn, Harvard Medical School/Brigham and Women’s Hospital
- Olaf Klungel, Utrecht University, Utrecht Institute for Pharmaceutical Sciences

**Moderators:**
- Soko Setoguchi, FISPE, Duke Clinical Research Institute
- Til Stürmer, FISPE, Gillings School of Global Health, University of North Carolina at Chapel Hill

Advancing epidemiologic methods has been a major focus of International Society for Pharmacoepidemiology (ISPE). ISPE researchers have made tremendous contributions to the methodological developments in the field of pharmacoepidemiology, device epidemiology, and health services, outcomes, and comparative effectiveness research. To celebrate 30 years of ISPE’s development since its first annual conference and to recalibrate us in ISPE for further development and contributions to the field of epidemiologic methods, this plenary session will address questions about where we are and where we are going with respect to methods. Prominent speakers/panelists from ISPE will review recent developments and current status of pharmacoepidemiology and discuss future directions in pharmacoepidemiological methods.
AGENDA  Saturday, October 25

5:00-6:30pm  SYMPOSIA AND WORKSHOPS

A Guide to Guidelines. A Symposium Sponsored by the ISPE Public Policy Committee [73] (201DE)
- Jesper Hallas, Kenneth J Rothman, Kiyoshi Kubota, Stella Blackburn, Alejandro A Navarro, Gerald Dal Pan. (Denmark)

Academic Detailing: Putting Pharmacoepidemiology into Practice [74] (103)
- Jerry Avorn, Stephen Chapman, Frank May, Loren Regier, Debra Rowett. (Australia)

Biospecimens From Asia in Pharmacoepidemiology Research: Opportunities and Challenges in a Global Environment [75] (4th Floor VIP)
- Arnold KW Chan, Bruce Carleton, Daniel FC Tsai, Mao Mao. (Taiwan)

Challenges in Risk Minimization Evaluation: CIOMS Working Group IX Consensus and Recent Field Experience [76] (102)

Gender Differences in Pharmacoepidemiology [77] (201BC)
- Björn Wettermark, Yea-Huei Kao Yang, Mikael Hoffmann, Vera Vlahovic-Palcevski, Mia von Euler, Soko Setoguchi-Iwata. (Sweden)

Impact of Methodological Choices on Findings from Pharmacoepidemiological Studies: Final Results of the IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Project [78] (Plenary Hall, 3rd Floor)
- Olaf Klungel, Mark de Groot, Helga Gardarsdottir, Ruth Brauer, Lamiae Grimaldi-Bensouda, Xavier Kurz, Christiane Gasse, Robert Reynolds. (Netherlands)

The New ISPE Vaccine Special Interest Group (VAXSIG):
Helping to Advance the Global Vaccine Agenda [79] (201AF)
- Huiying Sun, Hak Elko, Ajit Pal Singh, Jan Bonhoeffer, Daniel Weibel, Miriam Sturkenboom. (United States)

6:30-7:30pm

Special Interest Groups (SIGs)
Open to all interested participants
- Adherence (201DE)
- AsPEN (201BC)
- Biologics (Elegance Lounge, 4th Floor)
- BRACE (102)
- Comparative Effectiveness Research (North Lounge, 3rd Floor)
- Databases (103)
- Drug Utilization/Health Services Research (4th Floor VIP)
- Medical Devices (Elegance Lounge, 4th Floor)
- Medications in Pregnancy (201AF)
- Molecular Epidemiology (South Lounge, 3rd Floor)
- Pediatrics (Elegance Lounge, 4th Floor)
- Vaccines (Elegance Lounge, 4th Floor)

7:30pm

Students/Young Professionals Night Out
SOLD OUT

7:30-9:00pm

PDS Editorial Board (202) - By Invitation
Prepare to unleash the power of RWE

IMS Real-World Evidence Solutions is your scientifically credible partner to pursue more impactful research and increase the reach of your insights.

IMS Health is committed to helping you succeed

- **Largest multi-disciplinary team** of RWE experts, including leading scientists in epidemiology, drug safety and risk management, based in 18 countries worldwide
- **Credible scientific voice** and deep therapy area knowledge, captured in over 2,500 publications
- **Most advanced capabilities in RWE** management and analysis, leveraging relevant IMS Health proprietary and other key external, third-party data assets
- **Proven expertise** in generating and communicating RWE to advance stakeholder engagement at all levels
- **Cutting-edge technology** to power scientific and commercial insights

Come and meet the IMS Health team in the exhibition area at ICPE in Taiwan.

We are excited to share our unique lens on the future of RWE.

Asia Pacific +65 6412 7365
USA +1 (703) 837 5150
Europe +44 (0) 20 3075 4800
Latin America +52 (55) 50 62 52 00
RWEinfo@imshealth.com
www.imshealth.com/rwe
8:00-9:30am CONCURRENT ORAL PRESENTATION SESSIONS

**Antidepressants During Pregnancy and Diverse Outcomes (103)**

**Moderators:** Li Ling Liu & Darren Toh

- **8:00am**
  - Impact of Right Truncation in Studies of Drug Safety during Pregnancy [313]
  - Sonia Hernández-Díaz, Brian Bateman, Krista Huybrechts. (United States)

- **8:15am**
  - Comparative Safety of Depression Treatments in Late Pregnancy for the Neonate [314]
  - Krista Huybrechts, Brian Bateman, Raisa Levin, Helen Mogun, Sonia Hernández-Díaz. (United States)

- **8:30am**
  - Teratogenicity of Selective Serotonin-Reuptake Inhibitors and Venlafaxine – A Population-Based Study of 2.3 Million Births in Five Nordic Countries [315]
  - Kari Furu, Helle Kieler, Bengt Haglund, Helga Zoega, Mika Gissler, Mette Nørgaard. (Norway)

- **8:45am**
  - Use of Antidepressants during Pregnancy and the Risk of Pregnancy-Induced Hypertension [316]
  - Fianne MAM van Loveren, Monique Boekema, Eelko Hak, Jens HJ Bos, Jan G Aarnoudse, Catharina CM Schuiling-Veninga. (Netherlands)

- **9:00am**
  - Use of Antidepressants and Induced Abortions: Population Based Case-Control Study from Three Nordic Countries [317]
  - Helle Kieler, Kari Furu, Mika Gissler, Mette Noergaard, Unnur Valdimarsdottir, Bengt Haglund. (Sweden)

- **9:15am**
  - Selective Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: Comparative Cohort Studies [584]
  - Irene Petersen, Stephen Evans, Louise Marston, Ruth Gilbert, Irwin Nazareth. (United Kingdom)
Diabetes and Cancers: The Double Whammy (201BC)

Moderators: Marie De Bruin & Brian Strom, FISPE

8:00am
- Electronic Health Data Capture of Clinical Evaluation and Pancreatic Cancer (PC) Diagnosis (DX) in Patients with Type 2 Diabetes (T2DM) [319]
  Mary E Ritchey, Yong Chen, Jinghua He, Samuel S Engel, Weifeng Xu, Melissa Yong, Kimberly G BRODOVICH. (United States)

8:15am
- Proteinuria Testing Among Patients with Diabetes Mellitus Is Associated with Bladder Cancer Diagnosis: Potential for Unmeasured Confounding in Studies of Pioglitazone and Bladder Cancer [320]

8:30am
- The Risk of Colorectal Cancer in Patients with Type 2 Diabetes: Associations with Treatment Stage and Obesity [321]
  Paulus JHL Peeters, Marloes T Bazelier, Hubert GM Leufkens, Frank de Vries, Marie I De Bruin. (Netherlands)

8:45am
- Colorectal Cancer Risk in Metformin Initiators – A Matched Cohort Study [322]
  Anne S Geier, Ina Wellmann, Jürgen Wellmann, Jessica M Franklin, Hiltraud Kajüter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

9:00am
- Duration of Metformin Use and Risk of Prostate Cancer in Men with Diabetes [323]
  Laurel A Habel, Stephen K Van Den Eeden, Lori C Sakoda, Ninah S ACHACOSO, Charles P Quesenberry, Tiffany Peng, Samantha F Ehrlich, Assiamira Ferrara. (United States)

9:15am
- Exposure to Pioglitazone and Risk of the 10 Most Common Cancers [324]
  Assiamira Ferrara, Charles P Quesenberry, James D Lewis, Samantha F Ehrlich, Stephen K Van Den Eeden, Tiffany Peng, Brian L Strom, Laurel A Habel. (United States)

Think of the possibilities.
Visit us at booth #17

Posters and Oral Presentations:
“Treatment Patterns among US Veterans Treated with Selegiline Transdermal System”
“Integration of Healthcare Delivery System Characteristics into Pharmacoepidemiologic Research: An Analysis of Acute Stroke Care Effectiveness”
“Clinical Burden of ANCA Associated Vasculitis”
“Methods and Guidelines for Integrity of Multivariable Analysis of Real World (observational) Data”
“Interactive Web-based Tool for Cohort Creation and Disease Outcome Feasibility”
anolinx.com
Concurrent Oral Presentation Sessions

**Equity, Elderly & Ecclecticism (201AF)**

**Moderators:** Meng-Ting Wang & Anna Almarsdottir

**8:00am**
- Disparities in the Use of Prescription Medications: A Population-Based Approach [325]
  Dima Qato. (United States)

**8:15am**
- Racial/Ethnic Disparities in US Prescribing Patterns of Sleep Medications from 1996-2010 [326]
  Christopher N Kaufmann, Adam P Spira, Sarah L Canham, Lian-Yu Chen, G Caleb Alexander, Pia Mauro, Ramin Mojtahai. (United States)

**8:30am**
- Sex Differences in Utilization of Cardiovascular Drugs in Sweden and Taiwan [327]
  Desirée Loikas, Marlin Isteifo, Ching-Lan Cheng, Yea-Huei Kao Yang, Karin Schenck-Gustafsson, Björn Wettermark, Mia von Euler. (Sweden)

**8:45am**
- Cross-National Comparison of Prescribing Patterns in Australian and Dutch Nursing Homes [328]
  Katja Taxis, Sjoerd Kochen, Sanne Geerens, Hans Wouters, Froukje Boersma, Jan G Maring, Hans Mulder, Jugoslav Pavlovic, Gerard Stevens, Andrew J McLachlan, Lisa Pont. (Netherlands)

**9:00am**
- Bladder Antimuscarinics and Cognitive Decline in Elderly Patients Enrolled in the National Alzheimer’s Coordinating Center Cohort [329]
  Daniela C Moga, Erin Abner, Gregory Jicha. (United States)

**9:15am**
- Utilization and Predictors of Active Surveillance among Elderly Men with Low-Risk Localized Prostate Cancer [330]
  Huei-Ting Tsai, Arnold Potosky, George Philips, Katherine Taylor. (United States)

**How Thin Is Your Blood? (201DE)**

**Moderators:** Kiliana Suzart-Weischnik & Tzu-Chieh Lin

**8:00am**
- Avoiding “Crystal Ball” Epidemiology: The Case of Low-Dose Aspirin and Major Bleeding [331]
  Jennifer L Lund, Til Sturmer, Erzsebet Horvath-Puho, Szimonetta Szépligeti, Lars Pedersen, Vera Ehrenstein, Henrik T Sorensen, John A Baron. (United States)

**8:15am**
- AUDIT-C Alcohol Misuse Screening Score and Major Bleeding in Warfarin Therapy: An Evaluation of Main Effects and Interaction with VKORC1 Genetic Status [332]
  Joshua A Roth, Katharine Bradley, Kenneth Thummel, David L Veenstra, Denise Boudreau. (United States)

**8:30am**
- An International Comparison of Spontaneous Adverse Event Reports and Potentially Inappropriate Medicine Use Associated with Dabigatran [333]
  Lisa M Kalisch Ellet, Cameron J McDonald, John D Barratt, Gillian E Caughey. (Australia)

**8:45am**
- Intravenous Thrombolytic Therapy Is Beneficial for Acute Stroke Patients with Renal Dysfunction [334]
  Cheng-Yang Hsieh, Chih-Hung Chen, Huey-Juan Lin, Sheng-Feng Sung, Yea-Huei Kao Yang. (Taiwan)

**9:00am**
- Adherence and Persistence to New-Users of Dabigatran Among Patients with Non-Valvular Atrial Fibrillation in an Administrative Claims Database [335]
  Mei-Jia Zhou, Hsien-Yen Chang, G Caleb Alexander, Sonal Singh. (United States)

**9:15am**
- Utilization of Anticoagulants in Atrial Fibrillation: Influences of Clinical Risk Scores in Real-World Practice [336]
  Julie C Lauffenburger, Joel F Farley, Denise H Rhoney, Anil K Gehi, M. Alan Brookhart, Gang Fang. (United States)

*Student Award Recipient – Third Best Abstract Submitted by a Student/Post-Doc*
### Sticks and Stones May Break My Bones (102)
**Moderators:** Patrick Souverein & Mitsuyo Kinjo

- **8:00am**
    - Seoyoung C Kim, Mi-Sook Kim, Gabriel Sanfélix-Gimeno, Hong Ji Song, Liu Jun, Isabel Hurtado, Salvador Peiró, Joongyub Lee, Nam-Kyong Choi, Byung-Joo Park, Jerry Avorn. (United States)
  - The Dual-Time-Adjusted Case-Crossover Design [343]
    - Joshua J Gagne, Sebastian Schneeweiss, Shirley V Wang. (United States)

- **8:15am**
  - Adapting and Evaluating Self-Controlled Case Series Method (SCCS) for Signal Screening of a Recently Marketed Drug Using a US Claims Database [344]
    - Xiaofeng Zhou, Rongjun Shen, Jamie Geier, Andrew Bate. (United States)

- **8:30am**
  - The Use of Prior Event Rate Ratio Adjustment Method for Controlling Unmeasured Confounding in Pharmacoepidemiologic Studies: A Cautionary Note [345]
    - Md Jamal Uddin, Rolf HH Groenwold, Tjeerd P van Staa, Anthonius de Boer, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)

- **8:45am**
  - Controlling Time-Dependent Confounding by Frailty: Restriction Versus Statistical Adjustment [346]
    - Leah J McGrath, Alan R Ellis, M Alan Brookhart. (United States)

- **9:00am**
  - Comparator Choice in Diabetes Drug Studies: Single Class or Non-User Comparator Group? [347]
    - Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Cynthia J Girman, Ravi Shankar, Zhiwen Liu, Samuel S Engel. (United States)

- **9:15am**
  - Comparing Estimation Strategies for Disease Risk Scores: A Simulation Study [348]
    - Richard Wyss, M Alan Brookhart, Virginia Pate, Til Strürmer. (United States)

### Well Adjusted by Design (4th Floor VIP)
**Moderators:** David Dore & Almut Winterstein, FISPE

- **8:00am**
  - The Dual-Time-Adjusted Case-Crossover Design [343]
    - Joshua J Gagne, Sebastian Schneeweiss, Shirley V Wang. (United States)
  - Adapting and Evaluating Self-Controlled Case Series Method (SCCS) for Signal Screening of a Recently Marketed Drug Using a US Claims Database [344]
    - Xiaofeng Zhou, Rongjun Shen, Jamie Geier, Andrew Bate. (United States)

- **8:30am**
  - The Use of Prior Event Rate Ratio Adjustment Method for Controlling Unmeasured Confounding in Pharmacoepidemiologic Studies: A Cautionary Note [345]
    - Md Jamal Uddin, Rolf HH Groenwold, Tjeerd P van Staa, Anthonius de Boer, Svetlana V Belitser, Arno W Hoes, Kit CB Roes, Olaf H Klungel. (Netherlands)

- **8:45am**
  - Controlling Time-Dependent Confounding by Frailty: Restriction Versus Statistical Adjustment [346]
    - Leah J McGrath, Alan R Ellis, M Alan Brookhart. (United States)

- **9:00am**
  - Comparator Choice in Diabetes Drug Studies: Single Class or Non-User Comparator Group? [347]
    - Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Cynthia J Girman, Ravi Shankar, Zhiwen Liu, Samuel S Engel. (United States)

- **9:15am**
  - Comparing Estimation Strategies for Disease Risk Scores: A Simulation Study [348]
    - Richard Wyss, M Alan Brookhart, Virginia Pate, Til Strürmer. (United States)

### Break/Posters/Exhibits
(101/Main Entrance Lobby)
10:00-11:30am  **CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

### Diverse Topics in Pediatric Populations (103)
**Moderators:** Timothy Beukelman & Wanning Xu

**10:00am**
- **Increasing Trend of Type 1 Diabetes in Dutch Children and Adolescents (1998-2010)** [349]
  Soulmaz Fazeli Farsani, Patrick C Souverein, Marja MJ van der Vorst, Catherrine AJ Knibbe, Ron MC Herings, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)

**10:15am**
- **Cancer Incidence among Infants in the United States, 2000-2010** [350]
  Logan Tyler, Jinghua He. (United States)

**10:30am**
- **Chronic Comorbidities in Children and Adolescents with Type 1 Diabetes** [351]
  Soulmaz Fazeli Farsani, Patrick C Souverein, Marja MJ van der Vorst, Catherrine AJ Knibbe, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)

**10:45am**
- **Antimuscarinic Utilization in the Pediatric Population in the United States, 2000-2011** [352]
  Alan Kinlaw, Jennifer Wu, Mitchell Conover, Virginia Pate, Michele Jonsson Funk. (United States)

### Don't Go Breaking My Heart (201BC)
**Moderators:** Emily Brouwer & K Arnold Chan, FISPE

**10:00am**
  Klaus K Andersen, Christian Dehlendorff, Charlotte Skriver, Søren Friis, Tom S Olsen. (Denmark)

**10:15am**
- **Comparative Cardiovascular Safety of Testosterone Formulations in the United States and United Kingdom** [356]
  J Bradley Layton, Julie L Sharpless, Christoph R Meier, Til Stärrmer, Susan S Jick, M Alan Brookhart. (United States)

**10:30am**
- **Dipeptidyl Peptidase-4 Inhibitors Do Not Increase the Risk of Cardiovascular Events in Type 2 Diabetes** [357]
  Seoyoung C Kim, Robert Glynn, Jun Liu, Brendan Everett, Allison Goldfine. (United States)

**10:45am**
- **Risk of Out-of-Hospital Sudden Cardiac Death with Use of Domperidone, Proton Pump Inhibitors, and Metoclopramide** [358]
  Alejandro Arana, Catherine Johannes, Cristina Varas, Kenneth J Rothman, Lisa J McQuay, Qing Yang, Daniel Fife. (Spain)

**10:45am**
- **Prevalence of Pediatric Chronic Hepatitis C Patients in the European Union (EU) in 2012** [353]
  Shih-Chen Chang, Katie M Miller, Gregory Hooper. (United States)

**11:00am**
- **Association between Use of Asthma Drugs in Children and Hepatotoxicity** [354]
  Carmen Ferrajolo, Marjolein Engelkes, Katia MC Verhamme, Gianluca Trifirò, Annalisa Capuano, Miriam CJM Sturkenboom. (Netherlands)

**11:00am**
- **Association of Azithromycin and Ventricular Arrhythmia: the ARITMO Project** [359]
  Gianluca Trifirò, Alessandro Oteri, Maria de Ridder, Peter Rijnbeek, Serena Pecchioli, Giampiero Mazzaglia, Irene Bezemter, Edeltraut Garbe, Tania Schink, Elisabetta Poluzzi, Trine Frøslev, Miriam Sturkenboom. (Netherlands)

**11:15am**
- **Risk of Hemorrhagic Stroke Associated with Combined Use of Antidepressants and Non-Steroidal Anti-Inflammatory Drugs** [360]
  Ju-Young Shin, Mi-Ju Park, Mi-Hee Kim, Nam-Kyong Choi, Joong-Yeup Lee, Byung-Joo Park. (Korea)
10:00am
- Comparison of Chronic Disease Burden of Chinese in US and in China: Findings from Two Large Nationally Representative Surveys in US and China [361]
  Chenghui Li. (United States)

10:15am
- Safety of Anticholinergic Medications in the Elderly: Anticholinergic Burden and Lower Urinary Tract Symptoms (LUTS) [362]
  Lisa G Pont, JTH (Yannick) Nielen, Andrew McLachlan, Danijela Gnijdic, Lewis Chan, Robert Cumming, Katja Taxis. (Australia)

10:30am
- Oral Corticosteroids and the Risk of Serious Infections in Patients with Elderly-Onset Inflammatory Bowel Diseases [363]
  Paul Brassard, Alain Bitton, Alain Suissa, Liliya Sinyavskaya, Valerie Patenaude, Samy Suissa. (Canada)

10:45am
- Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients Compared to Non-Psoriatic Arthritis Patients [835]
  Lin Li, Katrina W Hagberg, Michael M Peng, Susan Jick. (United States)

11:00am
- Incidence of Barrett’s Esophagus and Esophageal Adenocarcinoma in the United Kingdom and the Netherlands: Did We Reach a Plateau? [365]
  Gwen MC Masclee, Preci M Coloma, Marcel de Wilde, Ernst J Kuipers, Miriam CJM Sturkenboom. (Netherlands)

11:15am
- Incidence of Drug-Induced Acute Liver Failure: A Population-Based Study [366]
  David Goldberg, Kimberly Forde, Kevin Haynes, James D Lewis, Dena Carbonari, Kimberly Leidl, Rajender Reddy, Melissa Nezamzadeh, Jason Roy, Daohang Sha, Amy Marks, Jolanda De Boer, Jennifer Schneider, Brian Strom, Douglas Corley, Vincent Lo Re III. (United States)

Not All Diabetes Are Alike: Issues of Diagnosis (201DE)
Moderators: Deborah Layton & Kiyoshi Kubota, FISPE

10:00am
- Identification of Type 2 Diabetes Mellitus in Different Electronic Databases Within the SAFEGUARD Project [367]
  Ingrid Leal, Gwen MC Masclee, Lorenza Scotti, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martin, Cormac Sammon, Niklas Schmidt, John D Seeger, Gianluca Trifiro, Serena Pecchioli, Cristina Varas-Lorenzo, Mark M Smits, Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana Romio. (Netherlands)

10:15am
- Identification of Prediabetes, Healthcare Utilization and Progression to Diabetes in CPRD [368]
  Jin-Liern Hong, Ann Marie McNeil, Jinghua He, Kimberly Brodovicz. (United States)

10:30am
- Characteristics of Patients with Type 2 Diabetes (T2DM) Captured in Administrative Claims and Electronic Medical Records (EMR) [369]
  Mary E Ritchey, Samuel S Engel, Zhiwen Liu, Catherine Ntabadde, Michael Senderak, Ravi Shankar, Ying Qiu, Larry Radican, Swapnil Rajpathak, Kimberly G Brodovicz. (United States)

10:45am
- Monitoring for Proteinuria in Patients with Type 2 Diabetes Mellitus in the UK Clinical Practice Research Datalink [370]
  Paul Dolin, Huifang Liang, Carlos Vallarino, Sudhakar Manne. (United Kingdom)

11:00am
- Characteristics of Patients with Type 2 Diabetes Starting Sitagliptin vs. Other Oral Diabetes Medications and Propensity Score Balance [371]
  Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Samuel S Engel, Ravi Shankar, Zhiwen Liu, Cynthia J Girman. (United States)

11:15am
- Baseline Characteristics of Patients with Type 2 Diabetes Initiating Sitagliptin or GLP-1 Receptor Agonists [372]
  Kimberly G Brodovicz, Mary E Ritchey, Yong Chen, Michael Senderak, Jane Liao, Cynthia J Girman, Ravi Shankar, Zhiwen Liu, Samuel S Engel. (United States)
**10:00am - 11:30am CONCURRENT SESSIONS: CONTRIBUTED PAPERS**

**PS or What???(4th Floor VIP)**
Moderators: Til Stürmer, FISPE & John D Seeger, FISPE

- **10:00am**
  - Comparison of Matching on Key Confounders, High-Dimensional Propensity Score (HDPS) and a Combination of Both to Adjust for Confounding [373]
    Fei Xue, Patrick Ventura, Trevor McMullan, Paul Petraro, Violeta Hennessey. (United States)
  - Head to Head Comparison of the Propensity Score and High-Dimensional Propensity Score Matching Methods in Reducing Potential Indication Bias [374]
    Jason R Guertin, Elham Rahme, Colin R Dormuth, Jacques LeLorier. (Canada)

- **10:30am**
  - High-Dimensional Propensity Score Versus Lasso Outcome Regression for Confounding Adjustment [375]
    Jessica M Franklin, Wesley Eddings, Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

- **10:45am**
  - Trimming on Propensity or Disease Risk Scores to Enhance Validity in the Design of Comparative Effectiveness Studies [376]
    Robert J Glynn, Mark Lunt, Til Stürmer. (United States)

- **11:00am**
  - Antidepressant Use and Risk of Hip Fracture: A Comparison of Marginal Structural Models, Conventional Regression and Propensity Score Methods [377]
    M Sanni Ali, Rolf HH Groenwold, Svetlana V Belitsier, Patrick C Souverein, Helga Gardarsdottir, Arno W Hoes, A de Boer, Olaf H Klungel. (Netherlands)

- **11:15am**
  - Preference and Propensity: Evaluating Oral Treatment of Type 2 Diabetes (T2DM) [378]
    Mary E Ritchey, Yong Chen, Cynthia J Girman, Kimberly G Brodovicz. (United States)

**To Use or Not to Use Psychotropic Medications (201AF)**
Moderators: Paul Stang, FISPE & Karolina Anderson-Sundell

- **10:00am**
  - Do Patients Initiate Therapy? Primary Non-Adherence to Statins and Antidepressant in Iceland [379]
    Gudrun Thengilsdottir, Anton Portegárd, Anna B Almarsdottir, Helga Gardarsdottir. (Netherlands)
  - Patterns of Statin Prescribing for the Primary Prevention of Cardiovascular Disease in People with Severe Mental Illness [380]
    Ruth Blackburn, David Osborn, Irene Petersen, Kate Walters, Irwin Nazareth. (United Kingdom)

- **10:30am**
  - Drug Utilization Pattern in Children with Autism Spectrum Disorder (ASD) in Asian Countries: A Population Based Study [381]
    Ching-Lan Cheng, Kenneth KC Man, Yingfen Hsia, Yea-Huei Kao Yang, Ian CK Wong. (Taiwan)

- **10:45am**
  - Sex Differences in Utilization of Nervous System Drugs in Sweden and Taiwan [250]
    Mia von Euler, Maria Sperling, Ching-Lan Cheng, Yea-Huei Kao Yang, Björn Wettermark. (Sweden)

- **11:00am**
  - The Impacts of Non-Adherence on Hospitalizations in Patients with Schizophrenia in Thailand [383]
    Piyameth Dilokthornsakul, Oraluck Patanaprateep, Ronnachai Kongsakon, Nutnorn Chaiyakunapruk. (Thailand)

- **11:15am**
  - Discontinuation of Somatic Medication during Psychiatric Hospitalisation [384]
    Heshu Abdullah-Koomees, Helga Gardarsdottir, Lennart J Stoker, Judith Vuyk, Toine CG Egberts, Eibert R Heerdink. (Netherlands)

**Lunch/Poster Session B/Roundtable Discussions**
(Banquet Hall, 3rd Floor)

**Roundtable Discussions:** To foster the ability of the more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting several informal lunchtime discussion roundtables on Saturday and Sunday. The facilitators are listed below. There will be NO formal presentations made at the roundtables. The objectives are discussion, information exchange and networking. Seating is limited; first-come, first-served.

- **11:30am-1:00pm**
  - Til Stürmer, FISPE, Challenges and Approaches to Controlling for Confounding in Pharmacoepidemiology
  - Susana Perez-Gutthann, FISPE, The Conduct of Well-Designed Multi-Country Observational Studies in Databases
  - Yea-Huei Kao Yang, FISPE, Publishing in Pharmacoepidemiology

**ISPE Committee/Council Meetings**
–Open to all participants, unless otherwise specified.

- **Bylaws and Policies - By Invitation** (Banquet Hall, 3rd Floor)
- **Education** (South Lounge, 3rd Floor)
- **Global Development** (North Lounge, 3rd Floor)
- **Membership** (South Lounge, 3rd Floor)
- **Publications** (South Lounge, 3rd Floor)
Using Patient-Centered Information in Pharmacoepidemiology: A Global Perspective

Faculty:
- Priya Bahri, Pharmacovigilance, EMA
- Nancy Dreyer, FISPE, Quintiles
- Francois Houyez, Director of Treatment Information & Access, Eurordis; Co-Chair of ISPOR Patient Centered Advocacy Group
- Lynn Weekes, CEO NPS Medicinewise

Moderators:
- Kate Lapane, FISPE, University of Massachusetts Medical School

Patient-centered information (PCI) has gained increasing recognition in recent years, particularly in the realm of comparative effectiveness and safety research. While clinicians have routinely utilized social, behavioral, functional, and symptom-related PCI from their patients to make informed clinical decisions, there is an increasing emphasis from regulatory and payer organizations to supplement traditional outcomes measures with patient reported ones. The idea behind this emphasis is that events need to be interpreted in the context of the impact that they have on patients. A good example for this concept is palliative cancer treatment, where extensions of lifespan need to be weighed against the side effects of the treatment itself on quality of life. The majority of databases used in pharmacoepidemiologic studies today, however, do not capture PCI. This plenary session will help to clarify what part of pharmacoepidemiologic research would benefit most from inclusion of PCI and provide examples from various settings where PCI has been successfully included in the evaluation of medicines.

Through personal reflections and experiences, regional and global examples will be presented that describe how and why PCI has been used in the evaluation of medicines, the impact PCI made, the challenges and opportunities to consider when collecting and assessing PCI, and a vision for the role of PCI in future pharmacoepidemiology studies.

Visit Booth #19 to learn more about Degge’s services:
- Pharmacoepidemiology
- Pharmacovigilance
- Oversight Group Management
- Risk Management
- Regulatory/Legal
- Safety Analysis

Tel: +1 571.490.8020    E-mail: info@deggegroup.com    Web: www.deggegroup.com

Consulting in Drug Safety Research and Pharmacoepidemiology since 1988

Identify databases by subscribing to our online compendium of ~250 population database profiles from 33 countries

- Search, compare, organize, and export database profiles
- Access specialized glossary and interactive map of database lists

Profiles are reviewed by database managers and frequently updated

www.BRIDGETODATA.org    +1 571.490.8400

Your connection to healthcare databases worldwide

B.R.I.D.G.E. TO DATA® is an online service provided by DGI, LLC, a non-profit organization
ANNUAL MEETING | ISPE

Sunday, October 26
2:30-4:00pm (Open to all participants) (Plenary Hall, 3rd Floor)

ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY

ANNUAL MEETING

- **Call to Order and Presidential Address**
  - Til Stürmer, FISPE, ISPE President

- **Financial Report**
  - Kate Lapane, FISPE, Vice President Finance

AWARDS CEREMONY

The Ronald D. Mann Best Paper Awards for Manuscripts Published in Volume 22 (2013), PDS

**First Prize**

Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control.
Adriana M Hung, Christianne L Roumie, Robert A Greevy, Xulei Liu, Carlos G Grijalva, Harvey J Murff and Marie R Griffin

**Honorable Mentions**

- Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years.
  Shahed Iqbal, John P Barile, William W Thompson and Frank DeStefano


- Use of case–time–control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly.
  Sylvie D Price, C D’Arcy, J Holman, Frank M Sanfilippo and Jon D Emery

**Presenters**

- Brian L Strom, FISPE, Editor-in-Chief
- Sean Hennessy, FISPE, Regional Editor for the Americas
- BJ Park, FISPE, Regional Editor for Asia-Pacific and ROW

30th ICPE

- Yea-Huei Kao Yang, FISPE, Chair, Local Host Committee
- Soko Setoguchi, FISPE, Chair, Scientific Program Committee

The Andrew McAfee Award

(Best abstract submitted from a developing country)

- Hisham Aljadhey

Student Awards

- **Best Methods Abstract**: Md Jamal Uddin
- **Third Best Abstract**: Julie Lauffenburger
- **Second Best Abstract**: Kirstine Søgaard

The Stanley A. Edlavitch Award & Oral Presentation

(Best abstract submitted by a student/post-doc):

- Jin-Liern Hong
  Assessment of Prediabetes in the United Kingdom CPRD and Its Association with Incident Cancers [385]
  Jin-Liern Hong, Ann Marie McNeill, Jinghua He, Kimberly Brodovicz. (United States)

Induction of ISPE Fellows (FISPE)

- Alison Bourke, FIPSE
- Jennifer B Christian, FISPE
- Kevin Haynes, FISPE
- Andrew Leigh Gilbert, FISPE
- John D Seeger, FISPE

BOARD TRANSITION

Retiring Board Members & Officers

- Ariel E Arias
- Edeltraut Garbe
- Kate Lapane, FISPE, Vice President Finance
- Stella Blackburn, FISPE, Immediate Past President

Induction of New Board Members

- Andrew Bate
  Industry/Service Provider; Europe/Africa
- Helga Gardarsdóttir
  Academic/Europe/Africa
- Marie Linquist
  Government/Regulatory/Americas
- Almut Winterstein, FISPE
  Academic/Americas
- Wei Zhou
  Industry/Service Provider/Asia/Pacific

Installation of 2014-2015 Officers

- Allison Bourke, FISPE, Vice President Finance
- Til Stürmer, FISPE, Immediate Past President
- Sonia Hernandez-Diaz, FISPE, President-Elect
- John D Seeger, FISPE, President

ADJOURNMENT
AGENDA Sunday, October 26

4:00-4:30pm
Break/Posters/Exhibits (101/Main Entrance Lobby)

4:30-6:00pm
SYMPOSIA AND WORKSHOPS

Adherence to Drug Treatment: A Practical Look at Complex Measurement Issues [386] (201DE)
- Jean-Pierre Grégoire, Petra Denig, Colin Dormuth, Gillian Caughey. (Canada)

Databases in China: Are We Ready Yet? [387] (201AF)
- Xiaofei Ye, Siyan Zhan, Wei Zhou, Xin Sun. (China)

Evaluating the Drug Regulatory System: Lessons from the Escher Project Challenges in Implementing Findings of Regulatory Science to Evaluate and Improve the Drug Regulatory System [388](103)
- Xavier Kurz, David Martin, Jarno Hoekman, Jacoline C Bouvy, Andrew Roddam, Hans Eibbers, Hubert GM Leufkens, K Arnold Chan, Gerald Dal Pan, Robert Reynolds, Marie L De Bruin. (United States)

Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods: International Assessment and Exchange [389] (Plenary Hall, 3rd Floor)
- Eunsun Noh, Nancy A Dreyer, Jeonghoon Ahn, Thamir M Alshammari, Mary E Ritchey, J Bradley Layton, Aisling R Caffrey. (United States)

Leveraging Electronic Health Data for Medical Device Epidemiology: Approaches To Post-Market Surveillance of Joint Replacement Surgery [390] (102)
- Stephen Graves, Nicole Pratt, Liz Paxton, Tzu-Chieh Lin, Maria Inacio. (Australia)

Primary Data Collection in Pharmacoepidemiology: Design, Practical, and Methodologic Considerations [391] (201BC)
- Jessica J Jalbert, Kiyoshi Kubota, Gurumurthy Parthasarathi, Soko Setoguchi, Lamiae Grimaldi-Bensouda. (United States)

Tracking of Adverse Drug Reactions in Social Media: Current Status of Requirements, Best Practices, Methods and Tools [392] (4th Floor VIP)
- Massoud Toussi, Carl de Moor, Siva Nadarajah, Alasdair Breckenridge. (France)

6:00-7:00pm
Council Meetings
Open to all members and new members.
- Academic (201DE)
- Government/Regulatory (201AF)
- Industry/Service Provider (201BC)

7:30-10:30pm
Gala Dinner at the Grand Hotel*
(*Registration required)
- Buses will shuttle between the Taipei International Convention Center (TICC) and the Grand Hotel. The first bus will leave the TICC at 6:30pm, and the last one from the TICC is 7:10pm. The last bus from the Grand Hotel to TICC is 10:30pm.
- Shuttle pick up from TICC is South Entrance at 1F
- Shuttle pick up from Grand hotel is Main Entrance or Lobby

The Grand Hotel retains the elements of classical Chinese architecture in its building. It is a splendid landmark of Taipei, and representative of contemporary palatial architecture.

Join your colleagues for a superb Chinese banquet and traditional entertainment in a unique venue. Performance Group: Ming Hwa Yuan, a Ge Zai Xi performance group - 80 years of establishment, documenting the legend musical of the Orient.

- Performance sponsored by Ming Hwa Yuan
AGENDA  Monday, October 27

7:00am-4:00pm  CONCURRENT ORAL PRESENTATION SESSIONS

Kids Up and Down and All Around (103)
Moderators: Miriam Sturkenboom, FISPE & Ian Wong

8:30am
- Second Generation Antipsychotics and Risk of Type 2 Diabetes in Publicly Insured Children and Adolescents [596]
  Tobias Gerhard, William V Bobo, Mark Olfson, Christoph U Correll, Cecilia Huang, Stephen Crystal. (United States)

8:45am
- Attention-Deficit/Hyperactivity Disorder (ADHD) Pharmacological Treatment and Its Effect on Accident and Emergency Admission Due to Injury: A Self-Controlled Case-Series Study [597]
  Kenneth KC Man, Esther W Chan, Ian Douglas, Patrick Ip, Wilfred HS Wong, David Coghill, Ian CK Wong. (Hong Kong)

9:00am
- Antidepressants and Risk of Suicide or Self-Harm in Canadian Youth: A Study Involving a Common Data Model in Quebec and British Columbia [598]
  Larry L Lynd, Thierry Ducruet, Kathy Li, Marie Tourrier, Brian Greenfield, Yola Moride. (Canada)

9:15am
- Trend in the Prescribing of Antipsychotics for Children and Adolescents in Japan: A Descriptive Epidemiological Study from the Large-Scale Pharmacy Database [599]
  Sayuri Nakane, Chika Nishiyama, Kenji Kochi, Yusuke Ogawa, Toshiaki A Furukawa, Koji Kawakami. (Japan)

9:30am
- Does Physicians’ Treatment of Pediatric Depression Reflect Evidence-Based Practice? Findings from a National Sample of Privately Insured Children and Adolescents [600]
  Rene Soria-Saucedo, Heather J Walter, Howard Cabral, Mary Jane England, Lewis Kazis. (United States)

9:45am
- Development of a Novel Approach to Assess Psychotropic Polypharmacy in Administrative Databases [601]
  Xinyue Liu, Paul Kobilis, Regina Bussing, Almut G Winterstein. (United States)

8:30-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:30am-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:00am-4:00pm  REGISTRATION

Registration
(Main Entrance Lobby)

7:00am-3:30pm  SPEAKERS’ READY ROOM (105)

7:00-8:00am  POSTER SESSION C
Set-up (101/Main Entrance Lobby)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:30am-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:30am-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:30am-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:25am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

8:30am-10:00am  POSTER SESSIONS

Poster Session C
Set-up (101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)

7:30-8:00am  2015 ICPE Scientific Program Committee Meeting (401)

8:00am-1:45pm  EXHIBITS/POSTERS

8:00am-1:45pm  EXHIBITS/POSTERS

(101/Main Entrance Lobby)
AGENDA  Monday, October 27

8:30-10:00am  CONCURRENT ORAL PRESENTATION SESSIONS

**On or Off Course (201BC)**

Moderators: Felin Lin & Jean-Pierre Gregoire, FISPE

- **8:30am**
  - Does a Cardiovascular Event Change Adherence to Statin Treatment in Patients with Type 2 Diabetes? A Matched Cohort Design [602]
    Dianna de Vries, Petra Denig, Stefan Vegtter, HJ Bos, Maarten J Postma, Eelko Hak. (Netherlands)

- **8:45am**
  - Factors Associated with Patients' Adherence to Antihypertensive Drug Classes in the UK [603]
    Amanj Baker, Li-Chia Chen, Rachel Elliott. (United Kingdom)

- **9:00am**
  - Factors Associated with β-Blocker Initiation and Discontinuation among Seniors with Heart Failure (HF) [604]
    Catherine Girouard, Jean-Pierre Grégoire, Paul Poirier, Jocelyne Moisan. (Canada)

- **9:15am**
  - A Cross Country Comparison of the Impact of Cost-Sharing Policies on Adherence to Prescription Medicines [605]
    Sarah-Jo Sinnott, Helen Whetton, Jessica M Franklin, Jennifer M Polinski. (Ireland)

- **9:30am**
  - Primary Care Prescriptions and Subsequent Pharmacy Dispensing: A Population-Based Study [606]
    Daniel Prieto-Alhambra, Josep M Elorza-Ricart, Eduard Hermosilla, Jordi Rodriguez-Ruiz, Leonardo Mendez-Boo, Manuel Medina-Peralta. (Spain)

- **9:45am**
  - Statin Adherence and Treatment LDL-Cholesterol Response in Type 2 Diabetes Patients [607]
    Dianna de Vries, Jaco Voorham, Eelko Hak, Petra Denig. (Netherlands)

**Steroids With a Twist! (201DE)**

Moderators: Gianluca Trifirò & Jesper Hallas, FISPE

- **8:30am**
  - Effect of Long-Term Aspirin Use on the Risk for Neovascular Age-Related Macular Degeneration [608]
    Ruben G Duijnhoven, Redmer van Leeuwen, Sabine M Straus, Saskia M Imhof, Arno W Hoes, Anthonius de Boer, Marie L De Bruin. (Netherlands)

- **8:45am**
  - Preadmission Non-Steroidal Anti-Inflammatory Drug Use and 30-Day Stroke Mortality [609]
    Morten Schmidt, Erzsébet Hovath-Puho, Christian F Christiansen, Karin L Petersen, Hans E Botker, Henrik T Sørensen. (Denmark)

- **9:00am**
  - Chemoprevention of Esophageal Adenocarcinoma among Patients with Barrett’s Esophagus [610]
    Gwen MC Masclée, Preci M Coloma, Ernst J Kuipers, Miriam CJM Sturkenboom, Jan A Kors. (Netherlands)

- **9:15am**
  - Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study [611]
    Gianluca Trifirò, Ylenia Ingrasciotta, Francesco Giorgianni, Janet Sultan, Daniele Ugo Tari, Margherita Perrotta, Claudio Linguitti, Andrea Fontana, Fabio Pellegrini, Achille P Caputi. (Italy)

**Strings Making Sense (SMS) Harvesting Data (201AF)**

Moderators: Martijn Schuemie & Brian Sauer

- **8:30am**
  - Statistical Natural Language Processing Can Accurately Identify Venous Thromboembolism (VTE) Events from Narrative Electronic Health Record Data [614]
    Christian M Rocheort, Aman D Verma, David L Bucheridge. (Canada)

- **8:45am**
  - Validity of Current Procedural Terminology (CPT) Codes and Natural Language Processing of Infusion Notes to Identify Outpatient Infliximab Infusion [615]
    Chao-Chin Lu, Chia-Chen Teng, Jianwei Leng, Grant Cannon, Tao He, David Harrison, Derek Tang, Neel Shah, Brian Sauer. (United States)

- **9:00am**
  - Linguistic Variability and Clinical Terminology in a Large Dutch General Practitioners Database [616]
    Zubair Afzal, Martijn J Schuemie, Miriam CJM Sturkenboom, Jan A Kors. (Netherlands)

- **9:15am**
  - Generating and Evaluating a Propensity Score Model Using Textual Features from Electronic Medical Records [617]
    Zubair Afzal, Gwen MC Masclée, Miriam CJM Sturkenboom, Jan A Kors, Martijn J Schuemie. (Netherlands)

- **9:30am**
  - Handling Missing Exposure: A Simulation Study [618]
    Andrea V Margulis, Alejandro Arana. (Spain)

- **9:45am**
  - Assessment of Daily Dose of Domperidone in the Clinical Practice Research Datalink (CPRD) Using Multiple Information Sources [619]
    Alejandro Arana, Catherine Johannes, Cristina Varas, Kenneth J Rothman, Lisa J McQuay, Qing Yang, Daniel Fife. (Spain)
AGENDA
Monday, October 27

8:30-10:00am CONCURRENT ORAL PRESENTATION SESSIONS

Translating Policy into Practice (102)
Moderators: Susana Perez-Gutthann, FISPE & Peter Mol

8:30am
Impact of Direct-To-Consumer Advertising on Asthma Prescriptions [620]
Susan Hurfless, Matthew Daubresse, Yoonsang Kim, Rachel Kornfield, Dima Qato, Jidong Huang, Kay Miller, Sherry Emery, Caleb G Alexander. (United States)

8:45am
Pierre Engel, Michelle Bulliard, Louise Parmenter, Kathryn Starzyk, Nancy Dreayer. (France)

9:00am
Hospital Based Electronic Medical Record Databases in China [622]
Wei Zhou, Ting Wu, Zhiwen Liu, Ronghua Chen. (China)

9:15am
Development of Thailand Rational Drug Use Indicators [623]
Penkarn Kanjanarat, Sirikwan Boriharn. (Thailand)

9:30am
Prevalence of Suboptimal Processes of Care Prior to Hospitalisation [624]
Gillian E Caughey, Lisa M Kalisch Ellett. (Australia)

9:45am
Understanding Patterns of Drug Utilization Studies (DUS) Requested By the European Medicines Agency (EMA) [625]
Claudia Schroeder, Jacco Keja, Ben Hughes, Birgit Ehlken, Massoud Toussi. (France)

Bayer HealthCare

Bayer HealthCare is a globally operating company with sites on all five continents. Approximately 55,700 people work for the Bayer subgroup in more than 100 countries at all stages of the value-added chain. Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG.

We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products.

We concentrate on five big therapeutic groups in which we make essential contributions to medical progress:

- Cardiovascular and blood diseases
- Oncological diseases
- Ophthalmology
- Women’s healthcare
- Imaging techniques

Our Global Epidemiology organization is currently establishing its operations around the world. Opportunities for Epidemiologists with pharmaceutical experience exist at the Associate Director/Senior Epidemiologist and Director level in the US and Europe. To learn more, contact: Montse Soriano-Gabarró at +49 30 468 194270

For Information about Bayer Healthcare go to

Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.
Treatment of Diabetes: Is It Safe Enough?
(4th Floor VIP)
Moderators: Syed Ahmed, FISPE & Chih-Ying (Natasha) Chen

8:30am
- Comparison of Clinical Measures between Those with and Without a Diagnosis of Diabetes among Patients Prescribed Antidiabetic Drugs Within the Humedica EHR Database [626]
  Donnie P Funch, Anthony P Nunes, Yan Ding, Robin C Clifford, Nicholas J Everage, David D Dore. (United States)

8:45am
- Patterns and Determinants of New First-Line Antihyperglycaemic Drug Use in Patients with Type 2 Diabetes Mellitus [627]
  Anne S Geier, Ina Wellmann, Jürgen Wellmann, Hiltraud Kajüter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

9:00am
- Incretin Therapy and Risk of Pancreatitis in Type 2 Diabetes Mellitus: Systematic Review of Randomized and Non-Randomized Studies [628]
  Ling Li, Jiantong Shen, Malgorzata M Bala, Shanil Ebrahim, Per Olav Vandvik, Jason W Busse, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani, Gordon H Guyatt, Xin Sun. (China)

9:15am
- Incidence of New Onset Type 2 Diabetes (T2DM) with Seroquel XL™ in Primary Care in England: Results from an Observational Post-Marketing Cohort Study [629]
  Miranda Davies, Deborah Layton, Vicki Osborne, Saad AW Shakir. (United Kingdom)

9:30am
- Glitazone Antidiabetics and the Risk of Parkinson’s Disease [630]
  Ruth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, David Dexter, Liam Smeeth, Ian Douglas. (United Kingdom)

9:45am
- Postmarketing Evaluation of the Safety of Saxagliptin: An Interim Analysis [631]
  Kevin Haynes, Melissa S Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Sean Hennessy, Serena Cardillo, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Tjeerd Van Staa, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re. (United States)

10:00-10:30am
Break/Posters/Exhibits
(101/Main Entrance Lobby)

10:30am-Noon
SYMPOSIA AND WORKSHOPS

Comparative and Clinical Effectiveness Studies Based on Taiwan National Health Insurance Research Database [632] (201BC)
- I-Shou Chang, Mei-Shu Lai, Chung-Yi Li, Jung-Der Wang, Li-Kwang Chen, Tseng-Ji Chen. (Taiwan)

Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepidemiology (PE) Studies [633] (402)
- Gerald Dal Pan, Vera Ehrenstein, Seeger John, Veena Thyagarajan, Nicole C Wright, Hairong Xu, Fei Xue. (United States)

Drugs and Devices: Challenges and Opportunities for the Evaluation of Combination Medical Products [634] (201DE)
- Michael E Matheny, Irene B Murimi, Mary E Ritchey, Ted Lystig, Myoung Kim, Danica Marinac-Dabic, Michael Steinbuch. (United States)

HOT, HOT, HOT and Getting HOTTER?- Climate Change and Pharmacoepidemiology [635] (102)
- Debra S Rowett, Richard Hill, Genevieve Gabb, Peng Bi, Soko Setoguchi. (Australia)

How Do We Overcome Challenges of Diverse Views in Multi-Disciplinary Collaboration on CER? [636] (4th Floor VIP)
- Cynthia J Girman, Sebastian Schneeweiss, Leona E Markson, Til Stürmer, Stella Blackburn. (United States)

Improving the Science of Regulatory Decision-Making – Advances in 2013/2014 [637] (201AF)
- Stanley A Edlavitch, Gerald J Dal Pan, June M Raine, Hubert G Leufkens, Byung-Joo Park, Jerry Avorn. (United States)

International Collaboration on Pharmacogenomics in Epidemiology Research [638] (103)
- Wei Zhou, Issam Zineh, Bruce Carleton, Fredrik Nyberg, Wen-Hung Chung. (China)

Noon-1:30pm
Lunch/Poster Session C/Exhibits (Banquet Hall, 3rd Floor)
ISPE Board of Directors Luncheon (401)
(Meeting open to all members; check with staff if you wish to attend)

12:15-1:15pm
Spotlight Poster Sessions (101)
- Best of the Day
- Database
- Asian Pharmacoepidemiology Network (AsPEN)
- Biologics
- Device
CONCURRENT ORAL PRESENTATION SESSIONS

From Epilepsy to Dementia (201BC)

Moderators: Rob Heerdink & Churn-Shiouh Gau

1:30pm
- Lithium Treatment and Risk for Dementia Among Patients with Bipolar Disorder [639]
  Tobias Gerhard, Davangere P Devanand, Cecilia Huang, Stephen Crystal, Mark Olfson. (United States)

1:45pm
- Incidence of Antipsychotic Use in Relation to Diagnosis of Alzheimer's Disease among Community-Dwelling Persons: Nationwide Population Based Study [640]
  Sirpa Hartikainen, Marjaana Koponen, Heidi Taipale, Anna-Maija Tolppanen, Jari Tiihonen, Antti Tanskanen, Kristuna Johnell, Johan Fastbom. (France)

2:00pm
- Psychotropic Use among Patients with Dementia Receiving Donepezil in Japan [641]
  Kasumi Daidoji, Yukinori Sakata, Kenta Sumitomo, Toshihisa Arai, Mika Ishii. (Japan)

1:30-3:00pm CURRICULAR PRESENTATIONS

2:15pm
- Comparative Risk of Pneumonia among Different Cholinesterase Inhibitors [642]
  Edward Chia-Cheng Lai, Monera Wong, Isao Iwata, Yinghong Zhang, Cheng Yang Hsieh, Yea-Huei Kao Yang, Soko Setoguchi. (Taiwan)

2:30pm
- Comparative Effectiveness of Antiepileptic Drugs in Adult Patients with Epilepsy [643]

2:45pm
- Recent Trends in Antiepileptic Drug Prescribing in UK Primary Care [644]
  Jesca Brouwer, Irene Petersen, Irwin Nazareth, Linda Wijlaars. (United Kingdom)
### Gain on Pain (201AF)
**Moderators:** Gunnar Brobert & Abraham Hartzema, FISPE

- **1:30pm**
  - Trends of Substance Misuse and Pharmaceutical Treatment Recorded in England and Wales Primary Care (1994-2012) [645]
  - Hilary R Davies, Irene Petersen, Irwin Nazareth. (United Kingdom)
- **1:45pm**
  - Impact of Abuse-Deterrent OxyContin on Prescription Opioid Utilization in the United States [685]
  - Catherine S Hwang, Hsien-Yen Chang, G Caleb Alexander. (United States)
- **2:00pm**
  - Effect of Facility Opioid Treatment Availability on Opioid Analgesic Overdose Deaths [647]
  - Ting-Ying J Huang, Linda Simoni-Wastila. (United States)
- **2:15pm**
  - The Impact of Opioid Substitution Therapy on Mortality Post-Release from Prison: A Retrospective Data Linkage Study [648]
- **2:30pm**
  - Treatment Utilisation and Retention with Opioid Substitution Therapy between 2001 and 2010: A Comparison of Buprenorphine and Methadone Users [649]
  - Natasa Gisev, Louisa Degenhardt, Sarah Larney, Timothy Dobbins, Briony Larance, Amy Gibson, Jo Kimber, Tony Butler, Richard Mattick, Lucy Burns. (Australia)
- **2:45pm**
  - The Misuse, Abuse and Diversion of Opioid Replacement Therapies (ORT): A Study of Street Abusers [650]
  - Scott P Novak, Lynn Wenger, Lorvick Jennifer, Kral H Alex. (United States)

### Probably a Good Link (201DE)
**Moderators:** Arlene Gallagher & Soko Setoguchi, FISPE

- **1:30pm**
  - When To Conduct Probabilistic Linkage vs. Deterministic Linkage? A Simulation Study [651]
  - Ying Zhu, Yutaka Matsuyama, Yasuo Ohashi, Soko Setoguchi. (Japan)
- **1:45pm**
  - Performance of Methods for Linking Registry Data to Insurance Claims When Unique Identifiers Are Unavailable [652]
  - Stacie B Dusetzina, Seth Tyree, Anne-Marie Meyer, William Carpenter. (United States)
- **2:00pm**
  - Comparing Validity of Methods to Select Appropriate Cutoff Weight for Probabilistic Linkage Without Unique Identifiers [653]
  - Ying Zhu, Chih-Ying Chen, Yutaka Matsuyama, Yasuo Ohashi, Jessica M Franklin, Soko Setoguchi. (Japan)
- **2:15pm**
  - Incorporating Linked Outpatient Data to Improve Confounding Control in a Study of In-Hospital Medication Use [654]
  - Jessica M Franklin, Wesley Eddings, Sebastian Schneeweiss, Jeremy A Rassen. (United States)

### Predicting Linkage Within a Validated Algorithm That Identifies Mother-Infant Pairs Within the Medicaid Analytic EXtract (MAX) Database [655]
- Caitlin A Knox, Kristin Palmsten, Soko Setoguchi, Richard Segal, Almut G Winterstein. (United States)

### Accounting for Outcome Misclassification in Pharmacoepidemiologic Studies [656]
- Xiaojuan Li, Nihan Potas, Anne M Butler, Jason Edwards, Jason Fin, M Alan Brookhart. (United States)

### The Answer Is Not Clear (4th Floor VIP)
**Moderators:** James Lewis, FISPE & Wei Zhou

- **1:30pm**
  - Five-Year Safety Results from the ENCORE Registry: Malignancies in Patients with Crohn’s Disease Treated with Infliximab, Standard Therapy, or Switched from Standard Therapy to Infliximab [657]
  - G D’Haens, W Reinisch, J-F Colombel, J Panes, S Ghosh, C Prantera, S Lindgren, DW Hommes, Z Huang, S Huyck, DK Chitraka. (United States)
- **2:00pm**
  - Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Risk of Non-Hodgkin’s Lymphoma (NHL): A Systematic Review and Meta-Analysis [659]
  - Xibiao Ye, Natalie Casaclang, Salaheddin Mahmud. (Canada)
- **2:15pm**
  - Calcium Channel Blockers and Cancer Risk Using the UK CPRD [660]
  - Lamiae Grimaldi-Bensouda, Mark de Groot, Robert Reynolds, Olaf Kungel, Michel Rossignol. (France)
- **2:30pm**
  - Spironolactone and Incidence of Cancers: A Propensity Score Matched Cohort Study in the Clinical Practice Research Database (CPRD) [661]
  - Isla S Mackenzie, Alastair M Thompson, Li Wei, Steve Morant, Thomas M MacDonald. (United Kingdom)
1:30-3:00pm CONCURRENT SESSIONS: CONTRIBUTED PAPERS

World War V: Vaccines and Viruses (102)
Moderators: Lawrence Baril & Vincent Lo Re, III, FISPE

1:30pm
- Effectiveness of Herpes Zoster Vaccination for Prevention of Post-Herpetic Neuralgia among Individuals with Herpes Zoster [663]
  Hung Fu Tseng, Sara Tartof, Bruno Lewin, Craig Hales, Lina Sy, Rafael Harpaz, Stephanie Bialek, Kavya Reddy, Po-ying Huang, Jeff Zhang, Sean Anand, Erin Mary Bauer, Jennifer Chang, Steven Jacobsen. (United States)

1:45 pm
- Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination [664]
  Huifeng Yun, Shuo Yang, Lang Chen, Kevin Winthrop, Fenglong Xie, John W Baddley, Kenneth G Saag, Singh Jasvinder, Jeffrey R Curtis. (United States)

2:00pm
- Utilization of Nordic Countries National Registries to Monitor the Impact of HPV Vaccination [665]
  Kai-Li Liaw, Susanne Kruger Kjaer, Mari Nygard, Joakim Dillner. (United States)

2:15pm
- Accuracy of Administrative Claims Data to Identify Dose Specific Rotavirus Vaccination Information: Implications for Studies of Vaccine Safety [666]
  T Christopher Mast, Scott Quinlan, Nancy Santanello, Steve Lanes. (United States)

2:30pm
- Narcolepsy and Pandemic H1N1 Vaccine: A Simulation Study to Explore the Effect of Bias [667]
  Caitlin N Dodd, Leonoor Wijnans, Maria AJ de Ridder, Silvana A Romio, Daniel Weibel, Jan Bonhoeffer, Miriam CJM Sturkenboom. (Netherlands)

- Safety of Seasonal Influenza Vaccination in Solid Organ Transplant Recipients [668]
  Gaël Dos Santos, François Haguinet, Germano LC Ferreira, Dave Webb, John Logie, Dominique Rosillon, Vivek Shinde, Catherine Cohet. (Belgium)
For Better or for Worse (103)
Moderator: Jessica Jalbert

1:30pm
• Modelling the Predicted Net Impact of Contraindication: the Example of Glaucoma Treatment [669]
  Andrew Maguire, Francisco J de Abajo. (United Kingdom)

1:45pm
• Patients’ Preferences for Benefits and Risks of Anticoagulant Therapy: A Discrete Choice Experiment (DCE) [670]
  Mehdi Najafzadeh, Joshua J Gagne, Niteesh K Choudhry, Jennifer M Polinski, Jerry L Avorn, Sebastian Schneeweiss. (United States)

2:00pm
• Comparing Incremental Net Benefit (INB) of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Patients with Atrial Fibrillation (AF) [671]
  Mehdi Najafzadeh, Sebastian S Schneeweiss, Niteesh K Choudhry, Amanda R Patrick, Jennifer M Polinski, Jerry L Avorn, Joshua J Gagne. (United States)

2:15pm
• Comparison of ATRIA and CHA2DS2-VASc Risk Stratification Schemes for the Prediction of Stroke in the Individual Patient with Atrial Fibrillation and the Impact on Treatment Decisions [672]
  Hendrika A van den Ham, Olaf H Klangel, Daniel E Singer, Hubert GM Leufkens, Tjeerd P van Staa. (Netherlands)

2:30pm
• Testosterone Laboratory Testing and Testosterone Supplementation Use among Adult Males in Denmark [673]
  Thomas Bojer Rasmussen, Helene Nørrelund, Sinna Pilgaard Ulrichsen, J Bradley Layton, M Alan Brookhart, Henrik Toft Sørensen, Christian Fynbo Christiansen. (Denmark)

2:45pm
• Time-Dependent Impact of Pre-Infarction Angina Pectoris and Intermittent Claudication on Mortality Following Myocardial Infarction as Measures of Inherent Local and Remote Ischemic Preconditioning: A Danish Nationwide Cohort Study [674]
  Morten Schmidt, Erzsébet Hovath-Puho, Lars Pedersen, Hans E Bøtke, Henrik T Sørensen. (Denmark)

3:00-3:15pm
Break

3:15-4:45pm SYMPOSIA & WORKSHOPS

The Common Data Model: Lessons from Past Projects and Ongoing Initiatives [675] (201DE)
• Patrick Ryan, Morten Anderson, Martijn Schuemie, Alison Burke, Kevin Haynes, Kenneth Man, Helga Gardarsdottir, Marie L De Bruin.

Comparisons in Pharmacoepidemiology: New Challenges and Limitations of Current Approaches [676] (4th Floor VIP)
• Saad AW Shakir and Deborah Layton (United Kingdom), Joshua Gagne, Bob Glynn (United States)

How to Bridge the Gap between Requirements of Regulatory and Health Technology Assessment Authorities for Post Authorization Studies’ Examples from Europe and Asia [677] (103)
• Massoud Toussi, Nicholas Moor, K Arnold Chan, Ian CK Wong. (France)

• Edward Chia-Cheng Lai, Ian Douglas, Kiyoshi Kubota, Byung Joo Park, Nicole Pratt, Ian Wong, Yea-Huei Kao Yang, Soko Seroguchi. (Taiwan)

Special Issues in Pharmacovigilance in Emerging Countries [679]
• Syed Rizwanuddin Ahmad, David Lee, Gloria Shalviri, Marie Lindquist. (United States)

The Patient’s Voice in the Heart of BRACE (Benefit-Risk Assessment, Communication and Evaluation) [680] (201AF)
• Meredith Smith, Priya Bahri, Gerald Dal Pan, Swapu Banerjee, Peter Mol, Debashish Deyp. (United States)

Using Pharmaceutical Data for Evaluating Medicines Policy and Informing Quality Use of Medicines [681] (102)
• Libby Roughead, Flora Haaijer-Ruskamp, Veronika Wirtz, Parthasarathi Gurumurthy, Lisa G Pont. (Australia)

4:45-5:30pm
THE FINAL WORD (4th Floor VIP)

Poster Walk Awards
• Mary E Ritchey, 2014 Poster Walk Chair

2015 Meetings

Mid-Year Meeting - Bordeaux
• Annie Fourrier-Réglat, Co-Chair, Program Committee

ICPE 2015 - Boston
• John D Seeger, Chair, 2015 Scientific Program Committee

5:30pm
Adjournment of 2014 ICPE

SEE YOU NEXT YEAR IN BOSTON!
Poster Session Guidelines

OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE:
Neither ISPE nor the TICC will be responsible for any poster that is left up overnight or is lost or damaged.

POSTER SESSION

Posters will be displayed in Room 101 of the Taipei International Convention Center (TICC) August 25-27. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- **Saturday, October 25** poster session A
- **Sunday, October 26** poster session B
- **Monday, October 27** poster session C

1. **Set Up:**
   - 7:00am-8:00am; all posters must be in place by 8:00am. Poster sessions will be held in room Room 101 of the TICC.

2. **Hours:**
   - Posters will be displayed from 8:00am-6:00pm on Saturday and Sunday, and 8:00am-1:45pm on Monday.

3. **Discussion Time:**
   - Presenters should be at their posters between 12:15-1:15pm on Saturday (A) and Monday (C); and between 11:45am-12:45pm on Sunday (B)
   - **Spotlight Sessions** – Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters at the following times: Saturday (A) & Monday (C) 12:15-1:15pm; Sunday (B) 11:45am-12:45pm.

   - **Saturday**
     - Best of the Day
     - Drug Utilization/Health Services Research
   - **Sunday**
     - Best of the Day
     - Adherence
     - Benefit Risk Assessment, Communications & Evaluation (BRACE)
   - **Monday**
     - Best of the Day
     - Database
     - Asian Pharmacoepidemiology Network (AsPEN)

   The spotlight sessions offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research.

   A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced during The Final Word session at 4:30pm, Monday, October 27.

4. **Take Down:**
   - All posters must be taken down by 6:30pm on Saturday and Sunday, and by 5:00pm on Monday.

NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster on that day in the Final Program. The poster number is the first number listed. The abstract number, for use in locating abstracts in the Final Program, is listed after the abstract title in brackets [ ]. The Abstracts2View site, accessible on a mobile device, also indicates the poster number and abstract number.

POSTER CONDITIONS

1. **Poster Specifications**
   - Posters must be designed to fit a freestanding poster board approximately **3 feet WIDE x 7 feet HIGH (1 meter WIDE x 2.4 meters HIGH)**. Only VERTICAL/PORTRAIT posters will be allowed.

2. **Disclosure Statement**
   - A disclosure statement must accompany each abstract submission and each presentation. This statement should follow the title page of your presentation and should be a positive disclosure statement. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.

3. **Call4Posters**
   - Posters ordered through Call4Posters/Learner’s Digest can be picked up in Room 101.
Spotlight Session- Top 8 Abstracts (A)

1. Risk of Hip Fractures Associated with Benzodiazepines: Applying Common Protocol To a Multi-Database Nested Case-Control Study. The PROTECT Project [80]
   - Gema Requena, John Logie, Rocio González-González, Helga Gardarsdottir, Ana Afonso, Patrick C Souverein, Elisa Martin Merino, Nada Boudiaf, Consuelo Huerta, Andrew Bate, Yolanda Alvarez, Luisa A García-Rodríguez, Robert Reynolds, Raymond G Schlenger, Mark CH de Groot, Olaf H Klungsøyr, Francisco J de Abajo. (Spain)

2. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study [81]
   - Kasper S Larsen, Anton Portegás, Hanne M Lindegard, Jesper Hallas. (Denmark)

3. Opioids and Breast Cancer Recurrence: A Danish Population-Based Cohort Study [82]
   - Deirdre P Cronin-Fenton, Mette Nørgaard, Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlersen, Per Sjøgren, Henrik Kehlet, Henrik T Sørensen. (Denmark)

4. Intrauterine Devices and the Risk of Uterine Perforations: Final Results from the EURAS-IUD Study [83]
   - Klaas Heinemann, Sabine Moehner, Thai Tang, Wai-Ping Yau. (Singapore)

5. Prevalence of Potentially Inappropriate Medication Prescribing Among Older US Adults Using STOPP Criteria [84]
   - Marcela Jirón, Virginia Pate, Michele Jonsson Funk, Til Stürmer. (Chile)

6. Use of Antipsychotics and Risk of Acute Respiratory Failure in COPD: A Case-Crossover Study [85]
   - Meng-Ting Wang, Che-Li Chu, Bi-Jui Hwu. (Taiwan)

   - Hisham Aljadhey, Mansour A Mahmoud, Michael D Murray, David W Bates. (Saudi Arabia)

8. Understanding Pharmacy Compounding in the Retail Setting: Practice and Role of Pharmacists in Singapore [87]
   - Yuen-Teng Choo, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

Burden of Disease/ Epidemiology of Illness

9. Is There Geographic Variation of the Frequency and the Profile of Adverse Drug Reactions? [88]
   - Krunal Pawar, Tanja Tran, Joerg Hasford. (Germany)

10. Rates of Opportunistic Infections in Psoriatic Arthritis Patients Compared to Non-Psoriatic Arthritis Patients [89]
    - Katrina W Hagberg, Lin Li, Michael M Peng, Susan Jick. (United States)

11. Increased Benzodiazepine Abuse Among HIV-Infected Individuals in the United States [90]
    - Sarah E Wixon, Emily S Brouwer. (United States)

    - Shih-Chen Chang, Jeffrey M Harris, Andrew McKee, Roman Barbalat, Tracy Burgess, Jose M Trevejo. (United States)

13. Etiologic Features of Stevens-Johnson Syndrome (SJS) and Toxidermal Necrolysis (TEN) with Ocular Involvement [92]
    - Kotone Matsuyama, Chie Sotozono, Mayumi Ueta, Satomi Sakabayashi, Shigeru Kinoshita. (Japan)

14. Childhood Atopic Dermatitis and Antidepressant Drug Use in Young Adults: A Nationwide Population-Based Cohort Study [93]
    - Jette L Riis, Mette Deleuran, Christian Vestergaard, Morten Olsen. (Denmark)

15. Epidemiology of Hepatic Impairment among Diabetes Patients in Japan [94]
    - Chia-Haen Chang, Motonobu Sakaguchi. (Japan)

16. Prevalence and Demographic Characteristics of Acromegaly in the United States [95]
    - R A Cantrell, R Walls, N Singh, P Napalkov, A Surinach, Y Mu, E Fisheleva. (United States)

17. Health Outcomes for Older Australians After Transient Ischaemic Attack (TIA) or Ischaemic Stroke (IS) [96]
    - Janet K Sluggett, Gillian E Caughey, Michael A Hsu-Chih Chien, Po-Ting Yeh, Sun-Huei Tseng, We-Li Chen, Yu-Chih Hou, I-Jong Wang, Hsiao-Sung Chu, Kwong Ng, Yea-Huei Kao Yang, Fung-Rong Hu. (Taiwan)

18. Cataract in Cystic Fibrosis Patients [97]
    - Nicholas J Everage, Yan Bai, Brett Loop, Natalya Volkova, Nan Liu, Cheryl Enger. (United States)

19. Longitudinal Analysis of Dengue Fever Infections Reported in the UK between 2002 – 2013 Using the Health Improvement Network (THIN) Primary Care Database [98]
    - David Ansell, Caroline O’Leary, Ahmed Nasser. (United Kingdom)

20. Regional Variation in Serum Urate amongst Patients Recruited for the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [99]
    - Robert W Flynn, Claudine G Jennings, Ilsa S Mackenzie, George Nuki, Ian Ford, Thomas M MacDonald. (United Kingdom)

21. Prevalent Conditions among Elderly and Non-Elderly Patients with Type 2 Diabetes (T2DM) [100]
    - Catherine Ntabadde, Mary E Ritchey, Zhiwen Liu, Michael Senderak, Samuel Engel, Ravi Shankar, Kimberly G Broduvicz. (United States)

22. Incremental Direct and Indirect Cost of Untreated Vasomotor Symptoms (VMS) [101]
    - Philip Sarrel, Patrick Lefebvre, Marie-Hélène Lafeuille, Jonathan Gravel, Mei Sheng Duh, Peter Applerose, David Portman. (Canada)

23. Clinical Characteristics of Patients with Lupus Nephritis [102]
    - Huifang Liang, Jennifer H Lin, Sudhakar Manne, Ryuo Nakaya, Motonobu Sakaguchi, Ali Hariri. (United States)

24. Epidemiology of Parkinson’s Disease in China [103]
    - Wilson HH Low, Siau Lin Yee, Soraya Azmi, Lan Ge, Dominique Milea. (Malaysia)

25. Adverse Drug Events in Medical and Surgical Patients of an Academic Hospital [104]
    - Hisham Aljadhey, Mansour A Mahmoud, Thamir Alshammari. (Saudi Arabia)

26. Severity and Patient Reported Outcomes of Dry Eye Disease in Taiwan [105]
    - Hsu-Chih Chien, Po-Ting Yeh, Sun-Huei Tseng, We-Li Chen, Yu-Chih Hou, I-Jong Wang, Hsiao-Sung Chu, Kwong Ng, Yea-Huei Kao Yang, Fung-Rong Hu. (Taiwan)

    - Aaron J Katz, Victoria M Chia, Michael A Kelsh. (United States)

28. Prescriptions, Nonmedical Use and Emergency Department Visits of ADHD Stimulants [107]
    - Lian-Yu Chen, Rosa Crum, Eric C Strain, Gregory Alexander, Christopher N Kaufmann, Ramin Mojtabai. (United States)
29 Medical Comorbidities and Drug Utilization of Sickle Cell Disease Patients in a Large US Health-Claims Database [108]
Lauren Oliva, Made Wenten, Jin Wang, Anne Dilley. (United States)

30 Risk Modification of Dementia in Patients Aged ≥75 Years - Influence of PPIs [109]
Britta Haenisch, Klaus von Holt, Birgitt Wiese, Karl Broich, Frank Jussen, Gabriele Dobhlammer, Wolfgang Maier. (Germany)

31 The Inappropriate Prescribing of Antibacterial Medicines in Sudan; a National Study at National Health Insurance Fund Setting [110]
Isam Eldin Mohammed Ali Mustafa. (Sudan)

32 Predictors of G-CSF Prophylaxis in the First Cycle of Chemotherapy in Non-Hodgkin's Lymphoma Patients [111]
Julius Asubonteng, Sally Wetten, Pieternella J Lugtenburg, Lucy DeCosta, Zsolt Szabo, John H Page. (United States)

33 Do Case-Only Designs Yield Consistent Results Between Them and Across Different Databases (DB)? Hip Fractures Associated with Benzodiazepines (BZD) as a Case Study [112]
Gerna Requena, John Logie, Elisa Martin, Consuelo Huerta, Rocío González-González, Nada Boudiaf, Arturo Álvarez, Andrew Bate, Luis A García-Rodríguez, Robert Reynolds, Raymond G Schlienger, Mark CH de Groot, Olaf H Klungel, Francisco J de Abajo, Ian Douglass. (Spain)

34 Use of Antidepressant Medications in Depressed Older Adults and Predictors of Discontinuation of Antidepressant Use [113]
Eunsa Noh, Brian J Quilliam. (United States)

35 Therapeutic Inertia and Intensified Treatment in Diabetes Prescription Patterns: A Nationwide Population-Based Study [114]
Huang Li-Ying, Shau Wen-Yi, Su Syi, Lai Mei-Shu. (Taiwan)

36 AHRQ/HCUPNet-Derived Pharmacoepidemiologic Evidence on Ventilation-Associated Iatrogenic Pneumothorax [115]
Yelizaveta Torosyan, Qianlai Luo, Sarah Hoffman, Danica Marinac-Dabic. (United States)

37 Disparities in Oral Antidiabetic Agents for Newly Diagnosed Type 2 Diabetes in Taiwan [116]
Chia-Hung Liu, Chia-Hsuan Chang, Shu-Ting Chen, Mei-Shu Lai. (Taiwan)

38 Differential Healthcare Utilization in Metformin Versus Sulfonylurea Users Pre- and Post-Initiation [117]
Jin-Liern Hong, Michele Jonsson Funk, Jennifer L Lund, Virginia Pate, Til Stürmer. (United States)

39 The Pattern and Prescription Cost of Diabetes in a Municipal Hospital in Ghana [118]
Archibald N Boye Okotah. (Ghana)

40 Treatment Patterns and Comorbidities in Adult Patients Treated for Gaucher Disease in the US [119]
Stephanie Tcherny-Lessenot, Lili Wang, Taylor Wang, Cristina Chang, Juhaeri Juhaeri. (France)

41 Anti-Diabetic Medication Pattern during Inpatient Care for Patients with Diabetes in West China Hospital [120]
Sheyu Li, Chuan Yu, Yun Li, Rui Zhang, Qingtao Hou, Tao Zheng, Yi Ma, Miye Wang, Na Su, Ting Wu, Xia Sheng, Nan Li, Guanjian Liu, Yong Huang, Xin Sun, Haoming Tian. (China)

42 Three Years Antibacterial Consumption in the Indonesian Public Primary Health Care Centers: The Application of ATC/DDD and DU90% Method To Monitor Antibiotic Use [121]
Ivan Surya Pradipita, Elis Ronasih, Arrum Dyah Kartikawati, Hattarto Hartanto, Rizki Amelia, Eli Halimah, Ajeng Diantini, Keri Lestari, Riszy Abdulah. (Indonesia)

43 Using Drug Case Studies for Individual Case Management to Enhance Appropriateness of Vancomycin and Amikacin [122]
Ming-Shen Lin, Jen-Wei Liu, Chun-Yu Wang. (Taiwan)

44 Inappropriate Initial Dosing of Fluconazole in Patients with Candidemia [123]
Wen-Liang Lin, Pheng-Ying Yeh-Liu, Hui-Jen Chang. (Taiwan)

45 Different Use of Antibiotics in Rural and Urban Regions in the Netherlands, an Observational Drug Utilization Study [124]
Josta de Jong, Jens HF Bos, Tjalling W de Vries, Lokkje TW de Jong-van den Berg. (Netherlands)

46 Perspectives and Experiences of Community Pharmacists about Antibiotic Dispensing in Riyadh, Saudi Arabia [125]
Husam Aljadhey, Mohammed Al-Dhaefi, Mansour A Mahmoud, Aziz Sheikh. (Saudi Arabia)

47 Systemic Antimicrobials Consumption and Expenditures in Russian Multi-Profile Hospitals: the Results of Multicenter Trial [126]

48 Comparison of Outpatient Antibiotic Use Between Portugal and 5 European Countries in 2012 – There Is (Much) Room for Improvement! [127]
Carla Torre, José Guerreiro, Marta Gomes, Suzete Costa. (Portugal)

49 Empirical Antimicrobial Therapy or Directed To Hemoculture and Mortality in Patients with Sepsis in ICU: A Retrospective Cohort [128]
Camila Schultz Cordeiro, Celso Nakagawa, Luciane Cruz Lopes. (Brazil)

50 Analysis of Prescriptions Before and After Intervention of Evidence-Based Drug Formulary in Private Hospital in South Sumatra, Indonesia: A Quasi-Experimental Study [129]
Erna Kristin, Iwan Dwiprahasto, Dwi Indria Anggraini, Jarir At Thobari, Alfi Yasmina. (Indonesia)

51 Endocrine Therapy for Breast Cancer Patients in South Africa [130]
Yasar T Bazargani, Anthonius de Boer, Hubertus GM Leufkens, Aukje K Mantel-Teeuwisse. (Netherlands)

52 Utilization Trends of Anti-Tumor Necrosis Factor Therapy in Taiwan [131]
Meng-Ju Chan, Chien-Ning Hsu, Yen-Hsia Wen, Yu-Chin Lily Wang. (Taiwan)

53 Trends in the Use of Maintenance Immunosuppressive Drugs among Liver Transplant Recipients in Taiwan: A Nationwide Population-Based Study [132]
Chia-Chen Hsu, Ying-Yu Huang, Yuh-Lih Chang, Che-Chuan Loong, Yeuh-Ching Chou. (Taiwan)
Julien Zeitin, Régis Lassalle, Sophie Brousse, Pernelle Noize, Nicholas Moore, Annie Fourrier-Réglat. (France)

46 Safety and Efficacy Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Adavagraft) in Stable Liver Transplant Recipients [136]
Chiu-Yen Li, Chih-I Wu, Yao-Li Chen, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

47 Blood Cell, Renal and Liver Function Monitoring among Psoriasis Patients Who Initiated Methotrexate Use in Taiwan [137]
Hsin-Chun Chou, Wen-Wen Chen, Wei-Ming Ke, Pi-Hui Chao, Fei-Yuan Hsiao. (Taiwan)

48 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [138]
Hairong Xu, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Chunj Chao. (United States)

49 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [139]
Chun Chao, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Hairong Xu. (United States)

50 Utilisation and Baseline Risk of Bleeding in Patients Prescribed Rivaroxaban: Interim Results from a Post-Marketing Observational Cohort Study [140]
Vicki Osborne, Miranda Davies, Deborah Layton, Saad AW Shakir. (United Kingdom)

51 Trends in Cardiovascular Risk Factors and Change over Time across Education Levels, and the Influence from Medicine Use and Gender. The Tromsø Study 1994-2008 [141]
Anne Elise Eggen, Ellisiv B Mathiesen, Inger Njøstad, Bjørne K Jacobsen, Tom Wilsgaard. (Norway)

52 Drug Utilization Studies of Antihypertensive Drugs for Hospitalized Patients with Hypertension in Shenyang [142]
Jian Gong, Wen Pan, Feng Guo, Kaishun Bi. (China)

53 Utilization of Oral Anticoagulants in Patients with Non Valvular Atrial Fibrillation [143]
Layla Saliba, Pierre Mondoly, Alexandre Duparc, Marc Delay, Philippe Maury, Anne Rollin, Violaine Calmels, Atul Pathak, Alessandra Bura-Riviere, Jean-Louis Montastruc, Halle Bagheri. (France)

54 Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients [134]
Yi-Han Liu, Tzu-Chieh Lin, Yea-Hui Kao Yang, Hui-Jen Chang. (Taiwan)

55 Outpatient Use of Oral Anticancer Drugs in the United States [138]
Breast Cancer Patients Treated with chemotherapy in 2000-2013 [139]
Kimberly Cannavale, Roberto Rodriguez, Chun Chao, (T aïwan)

56 Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients [134]
Yi-Han Liu, Tzu-Chieh Lin, Yea-Hui Kao Yang, Hui-Jen Chang. (Taiwan)

57 Safety and Efficacy Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Adavagraft) in Stable Liver Transplant Recipients [136]
Chiu-Yen Li, Chih-I Wu, Yao-Li Chen, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

58 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [138]
Hairong Xu, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Chunj Chao. (United States)

59 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [139]
Chun Chao, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Hairong Xu. (United States)

60 Utilisation and Baseline Risk of Bleeding in Patients Prescribed Rivaroxaban: Interim Results from a Post-Marketing Observational Cohort Study [140]
Vicki Osborne, Miranda Davies, Deborah Layton, Saad AW Shakir. (United Kingdom)

Anne Elise Eggen, Ellisiv B Mathiesen, Inger Njøstad, Bjørne K Jacobsen, Tom Wilsgaard. (Norway)

62 Drug Utilization Studies of Antihypertensive Drugs for Hospitalized Patients with Hypertension in Shenyang [142]
Jian Gong, Wen Pan, Feng Guo, Kaishun Bi. (China)

63 Utilization of Oral Anticoagulants in Patients with Non Valvular Atrial Fibrillation [143]
Layla Saliba, Pierre Mondoly, Alexandre Duparc, Marc Delay, Philippe Maury, Anne Rollin, Violaine Calmels, Atul Pathak, Alessandra Bura-Riviere, Jean-Louis Montastruc, Halle Bagheri. (France)

64 Persistence on Disease Modifying Anti-Rheumatic Drugs Among Taiwan Established Rheumatoid Arthritis Patients [134]
Yi-Han Liu, Tzu-Chieh Lin, Yea-Hui Kao Yang, Hui-Jen Chang. (Taiwan)

65 Outpatient Use of Oral Anticancer Drugs in the United States [138]
Breast Cancer Patients Treated with chemotherapy in 2000-2013 [139]
Kimberly Cannavale, Roberto Rodriguez, Chun Chao, (T aïwan)

66 Safety and Efficacy Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Adavagraft) in Stable Liver Transplant Recipients [136]
Chiu-Yen Li, Chih-I Wu, Yao-Li Chen, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

67 Blood Cell, Renal and Liver Function Monitoring among Psoriasis Patients Who Initiated Methotrexate Use in Taiwan [137]
Hsin-Chun Chou, Wen-Wen Chen, Wei-Ming Ke, Pi-Hui Chao, Fei-Yuan Hsiao. (Taiwan)

68 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [138]
Hairong Xu, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Chunj Chao. (United States)

69 Treatment Patterns for Anemia among Patients with Non-Hodgkin Lymphoma Treated with Chemotherapy in 2000-2013 [139]
Chun Chao, Langfang Xu, John H Page, Kimberly Cannavale, Roberto Rodriguez, Hairong Xu. (United States)

70 Utilisation and Baseline Risk of Bleeding in Patients Prescribed Rivaroxaban: Interim Results from a Post-Marketing Observational Cohort Study [140]
Vicki Osborne, Miranda Davies, Deborah Layton, Saad AW Shakir. (United Kingdom)

71 Trends in Cardiovascular Risk Factors and Change over Time across Education Levels, and the Influence from Medicine Use and Gender. The Tromsø Study 1994-2008 [141]
Anne Elise Eggen, Ellisiv B Mathiesen, Inger Njøstad, Bjørne K Jacobsen, Tom Wilsgaard. (Norway)

72 Excellent Outcome of Intensive Medical Care for Type B Aortic Dissection – A Single-Center Retrospective Study [151]
Shih-Han Wang, Chaw-Chi Chiu, Jann-Woei Huang, Chung-Yu Chen, Yaw-Bin Huang. (Taiwan)

73 A Population-Based Study of the Drug Interaction between Clarithromycin and Statins [152]
Bita Megapour, Ghazaleh Gouya, Harald Herkner, Berthold Reichardt, Michael Wolzt. (Islamic Republic of Iran)

74 Regional Variations in Physician Case Volume and Outcomes for Carotid Artery Stenting (CAS) vs. Carotid Endarterectomy (CEA) [153]
Hiraku Kumatamaru, Jessica J Albright, Louis L Nguyen, Sok Setoguchi. (United States)

75 Treatment with Statins and Fibrate in Chinese Type 2 Diabetes Mellitus Patients Initiating Hospitalization at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in Qingdao, China [154]
Lei Zhang, Xiao Li Wu, Wei Guo Qiao, Qing Qiao, Niklas Hammar, Claudia Cabrera, Yanhu Dong, Jia Wei. (China)

76 Evaluation for Statin Usage in Taiwan by Using National Health Insurance Claim Database [155]
Grace Hui-Min Wu, Yu-chiao Wang, Yong-chen Chen. (Taiwan)

77 Patterns of Chronic Use of Angiotensin- Converting Enzyme Inhibitor or Angiotensin Receptor Blocker in Pre-Dialysis Chronic Kidney Disease Patients with Anemia [156]
Chi-Tai Yen, Ming-Cheng Wang, Tzu-Chieh Lin, Ye-Fu Kao Yang. (Taiwan)

78 The Incidence of Actinic Keratosis and Risk of Non-Melanoma Skin Cancer in Taiwan [157]
Chi-Feng Hsieh, Wen-Foung Huang, Yi-Ting Chiang. (Taiwan)

79 Compliance with Pregnancy Prevention Recommendations in 7,663 French Women of Childbearing Age Exposed to Acetretin [158]
Fanny Raguideau, Myriam Mezzarobba, Mahmoud Zureik, Alain W star, Flora M Haaijer-Ruskamp, Kidane Lahcene, Jean-Claude Tardif, Mario Talajic, Mailloux, Nawal Bouchama, Halima Devi, (Canada)

80 Utilization Pattern of Phosphodiesterase Type 5 (PDE5) Inhibitors for Erectile Dysfunction among Commercially Insured Adults in the United States [159]
Wei Liu, Philipp Dahm, Tobias Gerhard, Patrick Antonelli, Joseph Chris Delaney, Almurg Winterstein. (United States)
Poster Session A

81 A Survey on the Utilization Pattern and Adverse Events of Oral Contraceptives in Korean Women Aged 20 to 49 Years [160]
Hye-Yeon Um, Hyun-Jung Kim, Hyun-Joo Jung, Sun-Young Jung, Byung-Joo Park. (Republic of Korea)

Corinne Klopf, Deborah Gibson-Smith, Petra JM Elders, Natasja van Schoor, Paco MJ Welsing, Hubert GM Leufkens, Nicholas C Harvey, Tjeerd P van Staa, Frank de Vries. (Netherlands)

83 Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects with Type 2 Diabetes Mellitus [162]
Yi Wen Huang, Hui Ju Tsai, Yueh Han Hsu, Yu Kang Chang, Jia Sin Liu, Chih Cheng Hsu. (Taiwan)

84 Comparing Prescribing Pattern between Bisphosphonate and Raloxifene in Osteoporosis Patients [163]
Jungmee Kim, Joongyub Lee, Ju-Young Shin, Hong-Ji Song, Nam-Kyong Choi, Byung-Joo Park. (Republic of Korea)

85 Research on Asian Psychotropic Prescription Patterns for Antidepressants II: REAP–AD 2013 [164]
Shu-Yu Yang, Mian-Yoon Chong, Yi-Hsin Yang, Shih-Ku Lin, Kuan-Pin Su, Tsung-Ming Hu. (Taiwan)

86 The Insomnia Treatment, Drug Usage and Their Side Effects in Taiwan: Analysis of 2009-2011 Nationwide Health Insurance Database [165]
Ching-Hu Chung. (Taiwan)

87 Resource Utilisation of Patients with Alzheimer’s Disease in Taiwan [166]
Yong-Chen Chen, Raoh-Fang Pwu, Yu-Chiao Wang, Yi-Ju Chen, Robert Chao-Jen Huang, Jung-Chun Wang, Grace Hui-Min Wu. (Taiwan)

88 Use of Psychotropic Medication for People with Learning Disability or Autism in England: A Descriptive Study Using the Clinical Practice Research Datalink [167]
Rachael Boggon, Gyles Glover, Keith Ridge, Ray Avery. (United Kingdom)

89 Disease Progression, Treatment Patterns, and Outcomes in Schizophrenia Over a 3-Year Period: Results from the Cohort for the General Study of Schizophrenia (CGS) [168]
Jessica J Jalbert, Michel Rossignol, Frederic Rouillon, Bernard Astruc, Benoit David, Jacques Benichou, Lucien Abenhaim, Lamiae Grimaldi-Bensouda. (United States)

90 Factors Associated with the Use of Pain Management-Related Medications among the Non-Cancer Elderly Patients Ever Utilized Traditional Chinese Medicine Services: A Retrospective Population-Based Cohort Study [169]
Hsiang-Wen Lin, Li-Ping Chen, Chih-Hsueh Lin, Chi-Yi Chou, Hsin-Hui Tsai. (Taiwan)

91 Association between Antipsychotic Treatment and Risk of Hip Fracture in Subjects with Schizophrenia [170]
Yu-Ting Tsai, Chi-Shin Wu, Chia-Ming Chang, Ya-Wen Huang, Hui-Ju Tsai. (Taiwan)

92 Healthcare Utilization Prior to Self-Poisoning: Variation by Age and Gender [171]
Fei-Yuan Hsiao, Shu-I Wu, Chia-Yi Wu. (Taiwan)

93 Differences in ADHD Medication Usage Patterns in Children and Adolescents from Different Ethnic Backgrounds in the Netherlands [172]
Els F van den Ban, Patrick C Sourveein, Herman van Engeland, Hanna Swaab, Toine CG Egberts, Eibert R Heerdink. (Netherlands)

94 Evaluating the Safety of Atypical Antipsychotic Drugs among Patients in Jos University Teaching Hospital [173]
Rachel U Odesanya, Moses D Audu, Silas Fwangshak. (Nigeria)

Hiraku Kumamaru, Jessica J Jalbert, Louis L Nguyen, Jun Liu, Marie D Gerhard-Herman, Chih-Ying Chen, Lauren A Williams, John D Seeger, Jessica M Franklin, Sokoke Seoguchhi. (United States)

96 Drug Use Patterns of Elderly Neuroleptic Users in Germany [175]
Niklas Schmedt, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Denmark)

97 Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]
Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

98 Follow-Up of Psychoactive Drug Use in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada) [177]
Caroline Croteau, Laurent Mottron, Marc Dorais, Jean-Éric Tarride, Sylvie Perreault. (Canada)

99 Characterization of Potential Pharmacodependence of Zolpidem, Zopiclone and Zaleplone Users [178]
Pei-Hua Hsieh, Chia-Yi Wu, Fei-Yuan Hsiao. (Taiwan)

100 Testing the Robustness of Background Knowledge Confounder Selection in a Case-Control Study [179]
Johnny Kahler, Reimar W Thomsen, Lars Pedersen, Morten Madsen, Niels Møller, Henning Beck-Nielsen, Henrik T Sørensen. (Denmark)

Keri J Donaldson, Thomas A Abendroth. (United States)

102 Medication and Patient Safety in a Community Teaching Hospital [181]

103 The Association between Long-Term Bisphosphonate Use and the Risk of Fracture among Females with Osteoporosis in Taiwan [182]
Chung-Huaen Wu, Chi-Chuan Wang, Hsiens-Tsung Lu. (Taiwan)

104 Evaluate the Effectiveness of Preventive Medicine Curriculum among Medical Students of Public Universities in Malaysia [183]
Kavitha Devi, Shukry Zawahir, Mohd Fadli Mohd Asmani, R Rekarani, Dashnilatha Permal, Redhwan Ahmed Al-Naggar. (Malaysia)

105 Evaluate the Effectiveness of Preventive Medicine Curriculum among Pharmacy Students of Private Universities in Malaysia [184]
Dashnilatha Permal, Shukry Zawahir, Redhwan Ahmed Al-Naggar, Eddy Yusuf. (Malaysia)

106 Are Prescription Drugs Substitutes for Inpatient Services? Evidence from Medicare Part D [185]
Robert Kaestner, Cuiping Long, G Caleb Robinson, R Rekarani, Dashnilatha Permal, Redhwan Ahmed Al-Naggar. (Malaysia)

107 Misuse, Abuse, and Diversion of Instanyl® (Fentanyl Nasal Spray) in France [186]
Patrick Blin, Caroline Dureux, Stéphanie Lamarque, Marie-Agnès Bernard, Philip Robinson, Régis Lassalle, Adeline Groleau, Cécile Droz, Nicholas Moore. (France)
108 Is Preventive Medicine Curriculum among Medical Students of Private Universities in Malaysia Effective? [187]
Rekarani Rajanatharan, Shukry Zawahir, Redhwan Ahmed Al-Naggar, Eddy Yusuf. (Malaysia)

109 The Utilization Pattern of Glucocorticoids in Taiwan Established Systemic Lupus Erythematosus Patients [188]
Chun-Ming Chen, Yea-Huei Kao Yang, Tsu-Chieh Lin, Shu-Hua Tai, Hui-Jen Chang. (Taiwan)

110 Evaluating the Impact of the Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain in Utah [189]
Brian C Sauer, Chai-Chen Teng, Christy Porusnik, Erin Johnson, Robert Rolfs, Jonathan Nebeker. (United States)

111 Examining the Impact of the Utah Opioid Guideline Based Intensive Educational Intervention on Opioid Prescribing in Utah [190]
Brian C Sauer, Chai-Chen Teng, Christy Porusnik, Erin Johnson, Robert Rolfs, Jonathan Nebeker. (United States)

112 Use of Bipolar Disorder Medications Prior to Diagnosis [191]
Zhilwen Liu, Melissa Whipple, Jane Liao, Edward A Bortnichak, Mellissa Yong, Herve Besson. (United States)

113 Assessment of Appropriateness and Safety of Dihydroergotoxine Use [192]
Ching Yu Chang. (Taiwan)

114 The Utilization and Safety of Abxranex* for the Treatment of Metastatic Breast Cancer in the USA: Results from Health Insurance Claims Data [193]
Caihua Liang, Ling Li, Cindy Duval, Amy Ko, Debra Patt, Deyanira Corzo, Cheryl Enger. (United States)

115 Patterns of Analgesic Initiation among Hemodialysis Patients [194]
Magdalene M Assimon, Anne M Butler, Lily Wang, Abhijit V Kshirsagar, M Alan Spertus. (United States)

116 Prevalence of Inappropriate Prescribing of Inhaled Corticosteroids for Respiratory Tract Infections in the Netherlands [195]
Martina Teichert, Andre Wissenburg, Peter de Smet, Michel Wensing, Tjard Schermer. (Netherlands)

117 Impact of Tuberculosis Treatment on Health-Related Quality of Life of Pulmonary Tuberculosis Patients: A Follow-Up Study [196]
Muhammad Atif, Syed Azhar Syed Sulaiman, Asrul Akmal Shafie, Muhammad Asif, Zaheer Ud-Din Babar. (Malaysia)

118 Characteristics Associated with Use of Oral or Inhaled Respiratory Medications at Initiation for Patients with Chronic Obstructive Pulmonary Diseases [197]
Yaa-Hui Dong, Chia-Hsuan Chang, Shu-Ting Chen, Mei-Shu Lai. (Taiwan)

119 Changes in Drug Prescriptions After the SMART Trial – Secondary Data Analysis of Bavarian Asthma Patients [198]
Marietta Rottenkolber, Rainald Fischer, Luisa Ibáñez, Joan Fortuny, Robert Reynolds, Roman Gerlach, Martin Tauscher, Petra Thuermann, Joerg Hasford, Sven Schmiedl. (Germany)

120 Changes in Thiazolidinedione Utilization and Outcomes Following Safety Warning and Risk Evaluation & Mitigation Strategies (REMS) in Taiwan [199]
Jason C Hsu, Dennis Ross-Degnan, Ching-Lan Cheng, Anita K Wagner, Fang Zhang, Yea-Huei Kao Yang, Li-Ling Liu, Hsueh-Yung Tai, Ke-Hsin Chen, Po-Wen Yang, Yi-Chen Juan, Christine Y Lu. (Taiwan)

121 The Prescribing Pattern of Postnatal Steroids on Preterm Infants in Taiwan [200]
Tzu-Ling Kuo, Ching-Lan Cheng, Yea-Huei Kao Yang, Yung-Chieh Lin. (Taiwan)

122 Prescribing of Drugs in the Therapy of Acute and Chronic Pain in Family Medicine Practice in Croatia [201]
Danjela Stinmac, Meri Margreitner, Zvonimir Sostar. (Croatia)

123 Utilization and Government Cost of Antisecretory Drugs among Elderly in Australia and New Zealand [202]
Suvimol Niyomnaitham, Alesha Smith. (Australia)

124 Hospital Length of Stay for Patients with Acute Myocardial Infarction in China [203]
Qian Li, Zhenqiu Lin, Frederick A Masoudi, Xi Li, Sonia Fernández-Díaz, Sadhakar V Nuni, Lingling Li, Qing Wang, John A Spertus, Harlan M Krumholz, Lixin Jiang. (United States)

125 Hospital Registry of Stroke or Transient Ischemic Attack (LIS-2), Design and Prehospital Medical Treatment Analyses [204]

126 The Efficacy and Safety of Liraglutide for Patients with Type 2 Diabetes Mellitus in Changhua County, Taiwan [205]
Lih-Jen Shyu, Yu-Mei Hsu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

127 Adherence to Treatment Guidelines in Type 2 Diabetes (T2DM) Patients Treated with Metformin (MET) Monotherapy with Suboptimal Glycemic Control in Israeli Managed Care [206]
Inbal Goldshein, Kaan Tunceli, Larry Radican, Harvey Katzeff, Shengsheng Yu, Bernd Voss, Ofer Sharon, Noga Gadir, Kimberly Brodovicz, Varda Shalay, Gabriel Chodik, Avraham Karasik. (Israel)

128 Geriatric Homecare Patients' Awareness on the Side-Effects of NSAID Abuse [207]
Andjelija Arandjelovic, Valentina Stankovic-Cekic. (Serbia)

129 The Impact of Diabetes on Mortality in Non-ICU Impatients from a Chinese Tertiary Hospital [208]
Chuan Yu, Sheyu Li, Yun Li, Miye Wang, Rui Zhang, Qingtao Hou, Yi Ma, Tao Zheng, Nan Li, Ting Wu, Nu Su, Xia Sheng, Qianrui Li, Yong Huang, Xin Sun, Haoming Tian. (China)

130 Drug Safety Education among Outpatient Using Teriparatide:Improving Patients Care [209]
Meichi Chang, Tsuyun Huang, Hsinlin Liang, KuoSheng Fan. (Taiwan)

131 A Pilot Analysis of a Pharmacist Initiated Home Medication Review Programme with Type 2 Diabetes Patients in Penang, Malaysia [210]
Ee Pin Chow, Mohamed Azmi Hassali. (Malaysia)

132 Predictors of Prescription Drug Importation by United States Adults [211]
Andrew R Zullo, David D Dore, Omar Galarraga, Tim Rocafort, Vincent Mor. (United States)

133 Prevalence and Treatment of Pain in Emergency Departments in the United States, 2000-2010 [212]
Hsien-Yen Chang, Matthew Daubresse, Andrew R Zullo, David D Dore, Omar Galarraga, Tim Rocafort, Vincent Mor. (United States)

134 Continuous Use of Medicines: Pattern and Characteristics Associated among Participants of the ELSA-Brasil Study [213]
Roberta Carvalho de Figueiredo, Francisco de Assis Acuciro, Sandhi Maria Barreto, Sotero Mengue, Maria de Jesus Mendes da Fonseca. (Brazil)

135 Regional Variation in Strong Opioid Prescribing in UK Primary Care Settings [214]
Muna Adan, Li-Chia Chen, Roger Knaggs. (United Kingdom)
136 Attitudes in Antidepressants Use in Greece [215]
Paraskevi Papaioannidou, Achilleas Ntaralas.
(Greece)

137 Asthma Prevalence and Utilization of Antiasthmatic Drugs among All Children in Stockholm, Sweden [216]
Elin Dahlén, Ramin Zarrinkoub, Björn Wettermark. (Sweden)

138 Bone Density Screening and Reduced Risk of Hip Fracture: Effectiveness or Confounding? [217]
Jie Zhang, Jeffrey R Curtis, Hong Zhao, Kenneth G Saag, Meredith I Kilgore, Nicole C Wright, Huifeng Yun, Luqin Deng, Elizabeth Dzellel. (United States)

139 Long Term Usage of Opioids by Chronic Intractable Non Cancer Pain Patients in TAIWAN from 2003 to 2012 [218]
Wen-Ing Tsay, I-Chen Cheng, Chih-Shiuh Chang, Ping-Chang Hsu. (Taiwan)

140 Over-the-Counter Aspirin Use, Comorbidities, and Timing of Aspirin Therapy Initiation in Multiple Myeloma Patients [219]
Syd Phillips, Nancy A Brandenburg, Kimberley J Woodcroft, Karen E Wells, Susan A Oliveria. (United States)

141 Ophthalmologists Practice Patterns on Performing Intravitreal Injections in Europe [220]
Kui Huang, Marla B Sultan, Duo Zhou, Charles S Treasler, Jingping Mo. (United States)

142 Temporal Changes in Polypharmacy, Hyperpolypharmacy and Exposure to Anticholinergic and Sedative Drugs: A Five-Year Study of Community-Dwelling Older Men [221]
Clara Leung, Sarah Hilmer, Sallie-Anne Pearson, Danijela Gnjidic. (Australia)

143 The Validity of a Patient-Reported Adverse Drug Event Questionnaire Using Different Recall Periods [222]
Siets T de Vries, Flora M Haaijer-Ruskamp, Dick de Zeeuw, Petra Denig. (Netherlands)

144 Analyzing the Short-Term Social Media Impact of a Drug Safety Publication - A Case Study Approach [223]
Ingrid S Sketris, Anatoliy Gruzd, Philip Mai, John M Gamble, Colin Dormuth. (Canada)

145 A Qualitative Study Exploring Perspectives towards Generic Medicines among Medical Specialists and Consultants at a District Hospital in Malaysia [224]
Zhi Yen Wong, Mohamed Azmi Hassali, Abdulk Halifiyah Yaahaya, Fahad Saleem, Hisham Aljadhey, Tahir Mehmood Khan. (Malaysia)

146 Practices and Self Confidence towards Antibiotic Prescribing: An Exploratory Study Focusing Prescribers in the District of Kota Setar, Kedah, Malaysia [225]
Rabiatul Salmi Rezal, Mohamed Azmi Hassali, Fahad Saleem. (Malaysia)

147 A Qualitative Study Exploring Perspectives towards Generic Medicines among Medical Specialists at a District Hospital in Malaysia [226]
Zhi Yen Wong, Mohamed Azmi Hassali, Fahad Saleem, Abdul Halifiyah Mohd Yaahaya, Hisham Hisham, Tahir Mehmood Khan. (Malaysia)

148 Prescribing Drug Use and Costs among Adult Outpatients with Type 2 Diabetes in Taiwan: A Nationwide Population-Based Study [227]
Chi Wen Chiang, Chiu Chi Chiu, Zon Min Lee, Yuh Min Cheng. (Taiwan)

149 Drug Discrepancy and Medication Error of Admitted Patients by Medication Reconciliation Process [228]
Jaruwan Unin, Pramote Tragulpiankit, Thida Ningsananda, Rattana Nilpetchploy. (Thailand)

150 Drug-Related Hospital readmission in Community Hospital, Thailand [229]
Jaruwan Unin, Pramote Tragulpiankit, Chaweewan Moungnoi, Porntip Channalao. (Thailand)

151 Post Authorization Safety Studies (PASS): Application of Prospective Observational Study Methodology [230]
Irene Pan, Amy Walton, Gretchen Dieck. (Canada)

152 European Drug Lists for Integration in a Decision Support Tool for Optimization of Drug Therapy in Older Persons [231]
Anna Birna Almarsdottir, Shane Cullinan, Birna Bjorg Massdottir, Stephen Byrne. (Denmark)

153 Registry: Its Use in Real-World Data Collection [232]
Irene Pan, Gretchen Dieck, Annette Stenham. (Canada)

Dara Stein, Irene Pan, Krista A Playne. (Canada)

155 Utilization Trend and Management of Oral Anticancer Medicines Using Nationwide Pharmacy Database and Questionnaire Survey at Pharmacies in Japan [234]
Osamu Takizawa, Hisashi Urushihara, Shiro Tanaka, Koji Kawakami. (Japan)

Christian M Rochefort. (Canada)

157 Associations of Drug Burden Index with Falls, General Practitioner Visits, and Mortality in Older People [236]
Prasad S Nishatala, Sujita W Narayan, Ting Wang, Sarah N Hilmer. (New Zealand)

158 Drug Utilization Pattern for the Treatment of Septic Shock in the ICU: A Comparison between Survivors and Non-Survivors in a Tertiary Care Teaching Institute [237]
Anirban Hom Choudhuri, Rajeev Uppal. (India)

159 Development of Pharmacy-Based Patient Registry for Long-Term Medication Use Monitoring [238]
Manabu Akazawa, Shinichi Yamamura, Hironyasu Ogata. (Japan)

160 The Incidence of Adverse Drug Events among the Critically Ill Patients: A Prospective Multicenter Study [239]
Hisham Aljadhey, Mansour A Mahmoud. (Saudi Arabia)

161 Drug Use Study of Heparin Using Japanese Claim Data of Inpatients [240]
Maki Noguchi, Ayumi Endo, Kaori Yamada, Kazuhiro Matsui, Shinichi Watanabe. (Japan)

162 Utilization and Predictors of Ophthalmic Steroids in Patients with Dry Eye Disease: A Nationwide Population-Based Study in Taiwan [241]
Mei-Chieh Chen, Chia-Hsien Chang, Yee-Huei Kao Yang, Yi-Sheng Chang. (Taiwan)

163 Longitudinal Changes of Polypharmacy in the Elderly: A Population-Based Study over a 10-Year Period in Taiwan [242]
Wan-Hsuan Lu, Liang-Kung Chen, Fei-Yuan Hsiao. (Taiwan)
Poster Session A

164 Find the Risk of Drug Usage from the Surveillance Results of the Electronic Media Advertisements [243]
Chao-Yi Wang, Chia-Ping Liu, Ping-Chang Hsu, Shwu-Huey Her, I-Hsuan Wu, Ming-Kung Yeh. (Taiwan)

165 Use of Ezetimibe in Australia [244]
Samantha A Hollingworth, Remo Ostini, David Michael, Jennifer Martin, Tett Susan. (Australia)

166 Appropriate Prescribing of Medications among Diabetic Medicare Patients Treated by Nurse Practitioners or Physicians [245]
Yong-Fang Kuo, Nai-Wei Chen, Mukaila A Raji. (United States)

167 Using Routinely Collected Administrative Health Claims Data to Improve the Uptake of Primary Healthcare Services [246]
Vanessa T Le Blanc, Andrew L Gilbert, Lisa M Kalisch Elllet, Nicole L Pratt, John D Barratt, Emmae N Ramsay, Mhairi K Kerr, Robert Peck, Graeme Killer, Elizabeth E Roughhead. (Australia)

168 Assessment of Clinical Features and Medical Treatment of Patients with Atrial Fibrillation in Outpatient Registry in Moscow [247]

169 Do Rational Use Meet Reality in a Country in Jos, Nigeria [262]
Isaac O Abah, Meshak SA Dayol, Noel N Chokshi, Sakthivel Selvaraj. (India)

170 Surveillance of New Drug Adoption in Hospital in Ado-Ekiti, South-West Nigeria [258]
Joseph O Fadare, Obitade Obimakinde. (Nigeria)

171 Using Administrative Healthcare Data to Study the Treatment of Inflammatory Bowel Disease in the Region of Stockholm, Sweden [257]
Thomas Cars, Mikael Lördal, Björn Wettermark. (Sweden)

172 Evaluation of Control Activities of Antibiotic Prescribing Practices and Multidrug-Resistant Bacteria in Healthcare Organizations of Paris City and Inner Suburbs [251]
J-Frederic Westphal. (France)

173 Analysis of Essentiality of the Medicines from the “Pharmaceutical Program in Brazil” [252]
Sueli Miyuki Yamauti, Silvio Barberato-Filho, Luciane Cruz Lopes. (Brazil)

174 Influenza Vaccination According to Dementia Diagnosis in French Nursing Homes [253]
Adeline Gallini, Virginie Gardette, Maryse Lapeyre-Mestre, Philippe De Souato Barreto, Bruno Vellas, Sandrine Andrieu, Yves Rolland. (France)

175 Sex, Gender and Drugs – A Tool for Gender-Conscious Prescribing [254]
Desirée Loikas, Emma Hultén, Linnéa Karlsson, Seher Korkmaz, Fadiea Al-Aieshy, Mia von Euler, Björn Wettermark, Eva Andersén Karlsson, Karin Schenck-Gustafsson. (Sweden)

176 Comparison of Medication Use in Taipei with Non-Taipei City by Beers Criteria in Elderly Based on the National Health Insurance Research Database in Taiwan [255]
Mei-Hsiouh Guan, Su-Yu Yang, Li-Chi Chen. (Taiwan)

177 Erythropoietin Stimulating Agent Prescribed Pattern for the Incident Uremia Patients in Taiwan [256]
An-Bang Wu, Tzu-Chieh Lin, Ming-Cheng Wang, Ye-Huei Kao Yang. (Taiwan)

178 Using Administrative Healthcare Data to Study the Treatment of Inflammatory Bowel Disease in the Region of Stockholm, Sweden [257]
Thomas Cars, Mikael Lördal, Björn Wettermark. (Sweden)

179 An Audit of Prescriptions from the Dental Outpatients Department of a Tertiary Hospital in Ado-Ekiti, South-West Nigeria [258]
Joseph O Fadare, Obiade Obimakinde. (Nigeria)

Dima Qato. (United States)

181 Psychotropic Utilization in Ribeirao Preto, Brazil [260]
Iahel Manon Lima Ferreira, Manuela Roque Siani Morello, Leonardo Régis Leira Pereira, Marcela Jirón. (Brazil)

182 Rational Usage of Medicines at the Public Health Facilities in Rajasthan, India [261]
Ravi Kumar Bahu, Preeti Kumar, Maulik Chokahi, Sachthivel Selvaraj. (India)

183 Interactions between Pharmaceutical Company Representatives and Physicians in Jos, Nigeria [262]

184 What Makes Prescribers Switch to Fixed-Dose Combination Therapy for Japanese Hypertensive Patients? [263]
Makiko Kusama, Shigeki Zeniya, Katsushi Fukuoka, Manabu Akazawa. (Japan)

185 Investigation of Drug Safety Information of Ethnic Medicine from 622 Drug Instructions in Guizhou [264]
Chen Ao, Lei Xiaoping. (China)

186 Persistence Rate and Adherence Level To Oral Antidiabetics and Their Associated Determinants [265]
Patrice Simard, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault. (Canada)

Spotlight Session - Methods

187 Investigating Time-Varying Factors Associated with Lipid Lowering Medications for Primary CVD Prevention Using Multistate Markov Modeling [266]
Suzanne L West, Barry S Eggleston, Marianne Kluckman, Amanda Hansen, Eric Solano, Kenneth LaBresh, Vincent Bufalino, Michael F O’Toole. (United States)

188 Dimension Reduction and Shrinkage Methods for Improving High Dimensional Disease Risk Score Estimation in a Historical Cohort [267]
Hiraku Kumamaru, Joshua J Gagne, Robert J Glynn, Soket Sotoguchi, Sebastian Schneeweiss. (United States)

189 Diabetogenic Effects of Atypical Antipsychotics – Exploration of Measurement Bias [268]
Almkr G Winterstein, Rhonda Cooper-DiHoff, Paul Kublis, Gregory A Nichols, Joseph A Delaney. (United States)

190 Construction of Treatment Episodes in Elderly Neuroleptic and Antidepressant Users [269]
Niklas Schmedt, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)

191 Manual Versus Automated Coding of Free-Text Self-Reported Drug Use in the 45 and Up Study: A Validation Study [270]
Danijela Gnjidic, Sallie-Anne Pearson, Sarah Hilmer, Jim Basilakis, Fiona Blyth, Emily Banks. (Australia)

192 Composite Testing in Pharmacovigilance: The Benefit of Window Shopping [271]
Rolina D van Gaalen, Michal Abrahamowicz, David L Buckeridge. (Canada)
202 Measurement Bias in Billing Data – A Simulation Study [281]  
Almut G Winterstein, Paul Kubilis. (United States)

Spotlight Session-Pediatrics SIG

203 The Use of Complementary Medicines for HIV-Infected Children in Lagos, Nigeria [282]  
Kazeem A Oshikoya, Mubarak Hassan, Ibrahim A Oreagba, Olayinka O Ogunleye, Idowu O Senbanjo. (Nigeria)

Pediatrics

211 Epidemiology of Rotavirus Gastroenteritis (RGE) in Young Children in Rural Guangxi, China [290]  
Yi Nong, Xu Yang, Yimei Wu, Qinglin Yang, Yan Liang, Minmei Chen, Zhaojun Mo, Shusen Liu, Christopher Mast, Rongcheng Li. (China)

212 Adverse Effect of Reactions in Time of Hospital Stay and Delay in Pediatric Patients with Chemotherapy Leukemia [291]  
Fabiola Patricia Medina Barajas, Fernando Antonio Sanchez Zubiera, Sergio Sanchez Enriquez, Carmen Zavala Sanchez, Ana Rosa Rincon Sanchez. (Mexico)

213 PMSI Database Consultation: Evaluation of Hospital Stay Length for Infantile Haemangioma in France Previous To and Subsequent To Propranolol Use [292]  
Charles Taieb. (France)

214 Medical and Economic Impact of Infantile Haemangioma in France Previous To Propranolol Use [293]  
Charles Taieb. (France)

215 Infantile Haemangioma: A Burden for Families [294]  
Charles Taieb. (France)

216 Adolescent Asthmatics’ Needs and Preferences Regarding Medication Counseling: Results from Online Focus Groups [295]  
Ellen S Koster, Daphne Philbert, Liset L van Dijk, Tjalling W de Vries, Marcel L Bouvy. (Netherlands)

217 Pediatric Drug Safety Surveillance in Italian Pharmacovigilance Network: An Overview over the Years 2001-2012 [296]  
Carmen Ferrajolo, Annalisa Capuano, Francoise Rossi, Ugo Moretti, Gianluca Trìfrìò, Carmela Santuccio. (Italy)

218 Adverse Drug Reactions of Spontaneous Reports in Shanghai Pediatric Population [297]  
Jia He, Hui Li, Xiaojing Guo, Xiaofei Ye, Hong Jiang. (China)

219 Adverse Reactions in Children: French Data [298]  
François Krabansky, Malak Abou Taam, Baptiste Demailly, Emmanuelle Herlem, Charles Taieb. (France)

220 Inhaled Corticosteroids for Preschool Children – A Norwegian Register Study [299]  
Øystein Karlstad, Knut Oymar, Kari Furu, Wenche Nystand. (Norway)
### Vaccines

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>221</td>
<td>Serious Adverse Drug Reactions Associated with Pneumococcal Vaccine: Experience in Thailand [300]</td>
<td>Pakawadee Sriphromya. (Thailand)</td>
</tr>
<tr>
<td>222</td>
<td>Design of Randomized, Double-Blind, Controlled, Multi-Centre Phase IIb Trials as Part of the EU-Funded UNISEC Project to Assess the Safety, Immunogenicity and Clinical Efficacy of Cross-Seasonal Universal Influenza Vaccines with or Without Pandemic Influe [301]</td>
<td>Heng Liu, Stuart Robinson, Tamar Ben-Yedidia, Wilson Caparros-Wanderley, Tanya Gottlieb, Ron Babecoff, Ed Schmidt, Anke Huckriede, Eelko Hak. (Netherlands)</td>
</tr>
<tr>
<td>223</td>
<td>Tolerability Survey of a Two-Dose Pandemic Vaccine [Focetria®], Administered after the Seasonal 2009-2010 Influenza Vaccination in the Netherlands [302]</td>
<td>Sarah Godefrooij, Nicoline AT van der Maas, Hester E de Melker, Jeanet M Kemmeren. (Netherlands)</td>
</tr>
<tr>
<td>225</td>
<td>Impact of Vaccine Effectiveness on Signal Detection Based on Disproportionality [304]</td>
<td>Lionel Van Holle, Iris De Ryck. (Belgium)</td>
</tr>
</tbody>
</table>

### Spotlight Session-Vaccine SIG

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>226</td>
<td>Detection and Validation Strategy of Herpes Zoster (HZ) Cases for a Vaccine Effectiveness Study in a Managed Care Organization Database [305]</td>
<td>Patricia Saddier, John Hansen, Joan Bartlett, Edwin Lewis, Bruce Fireman, Laurie Aukes, Morgan Marks, Roger Baxter. (United States)</td>
</tr>
<tr>
<td>227</td>
<td>Effectiveness of the 2009 Pandemic H1N1 Influenza Vaccines in Preventing H1N1 Infection: A Meta-Analysis [306]</td>
<td>Songul Bozat-Emre, Xibiao Ye, Adrienne Morrow, Natalie Cazaclang, Salaheddin M Mahmud. (Canada)</td>
</tr>
<tr>
<td>228</td>
<td>Linkage of the Vaccination Registration Praeventis with the IPCI Medical Record Database in the Netherlands - A Pilot Study [307]</td>
<td>Jeanet M Kemmeren, Johan van der Lei, Petra Oomen, Hester E de Melker, Miriam Sturkenboom. (Netherlands)</td>
</tr>
<tr>
<td>230</td>
<td>Adverse Events Following Rabies Pre- and Post-Exposure Prophylaxis in Taiwan, July–December 2013 [309]</td>
<td>Wan-Ting Huang, Chi-Hsi Chang, Wei-I Huang, Ding-Ping Liu. (Taiwan)</td>
</tr>
<tr>
<td>231</td>
<td>The Association Between Pneumococcal Vaccine and Thrombocytopenia in Elderly Patients with Chronic Obstructive Pulmonary Disease: A Case-Crossover Study [310]</td>
<td>Piyameth Dilokthornsakul, Todd A Lee. (Thailand)</td>
</tr>
<tr>
<td>232</td>
<td>Uptake of Influenza Vaccination in Elderly People: Impact of Dementia Diagnosis [311]</td>
<td>Adeline Gallini, Virginie Gardette, Sandrine Andrieu, Maryse Lapeyre-Mestre. (France)</td>
</tr>
<tr>
<td>233</td>
<td>Design and Feasibility of a Study Using the Clinical Practice Research Datalink General Practice OnLine Database (CPRD GOLD) To Assess the Risk of New Onset of Auto-Immune Diseases (NOAD) Following Administration of the Human Papillomavirus (HPV)-16/18 AS [312]</td>
<td>Dominique Rosillon, Corinne Willame, Manel Pladevall, Julia Zima, Judith H van den Bosch, Eveline Bunge, Tjeerd van Staa, Rachael Boggon, Laurence Baril. (Belgium)</td>
</tr>
</tbody>
</table>
### Spotlight Session Adherence SIG

#### Adherence

9 Preventable Drug Related Problems and Factors That Affect Heart Failure Treatment at Maharaj Nakorn Chiangmai Hospital [401]
- Poukwun Arumanakul, Thanisa Kritsadathan, Thanyalak Poonsinrat, Rungrit Kanjanavanit. (Thailand)

10 Association between Generic Substitution and Refill Adherence to ACE-Inhibitors - Analysing the Impact of Using Multiple Medications [402]
- Pernilla Jonsson, Anna K Jönsson, Eva Lesén, Ann-Charlotte Mårdby, Karolina Andersson Sundell. (Sweden)

### Spotlight Session- Top 8 Abstracts (B)

1 Quantitative Benefit-Risk Assessment of the Quadrivalent HPV Vaccine for the Prevention of Anal Cancer in Males – Results [393]
- Lydie Marcelon, Thomas Verstraeten, Geraldine Dominaki-Felden, François Simonond. (France)

2 Application of Targeted Maximum Likelihood Estimation in Pharmacoepidemiology [394]
- Menglan Pang, Tibor Schuster, Kristian B Filion, Maria Eberg, Robert W Platt. (Canada)

3 Incidence of Gastrointestinal Perforation among Patients with Crohn’s Disease and Those Patients Dispensed with Anti-TNF Therapy [395]
- Xiaofeng Zhou, Yun Gu, Sundaresan Murugesan, Andrew Bate. (United States)

4 Idiopathic Thrombocytopenic Purpura After Seasonal Influenza Vaccination [396]
- Chunfu Liu, Laura Polakowski, Hozefa A Divan, Yun Lu, Hector Izurieta, Nandini Selvam. (United States)

5 30-Year Mortality Following Venous Thromboembolism: A Population-Based Cohort Study [397]
- Kirstine K Segard, Morten Schmidt, Lars Pedersen, Erzsébet Horváth-Puhó, Henrik T Sørensen. (Denmark)

6 Malignant Diseases in Swedish Person with Haemophilia: A Longitudinal Registry Study [398]
- Susanna Lövdahl, Karin M Henriksson, Fariba Baghaei, Margareta Holmström, Erik Berntorp, Jan Astermark. (Sweden)

7 The Risk of Malignant Melanoma among Patients with Multiple Sclerosis [399]
- Made Wenten, Sarah Gheuens, Sandra Richman, Susan Eaton, Li Li, Anne Dilley. (United States)

8 Combining Information from an Electronic Healthcare Database and Spontaneous Reporting Database for Enhancing Signal Detection [400]

9 Preventable Drug Related Problems and Factors That Affect Heart Failure Treatment at Maharaj Nakorn Chiangmai Hospital [401]
- Poukwun Arumanakul, Thanisa Kritsadathan, Thanyalak Poonsinrat, Rungrit Kanjanavanit. (Thailand)

10 Association between Generic Substitution and Refill Adherence to ACE-Inhibitors - Analysing the Impact of Using Multiple Medications [402]
- Pernilla Jonsson, Anna K Jönsson, Eva Lesén, Ann-Charlotte Mårdby, Karolina Andersson Sundell. (Sweden)

11 Effect of a Medication Adherence Program for Long-Acting Injectable Atypical Antipsychotics on Adherence and Psychiatric Hospitalizations [403]
- Frederic Rouillon, Jessica J Jalbert, Bernard Astruc, Michel Rossignol, Franck Bayle, Benoît David, Ryma Bennouné, Bernard Avouac, Lucien Abenhiam, Lamiae Grimaldi-Bensouda. (United States)

12 Associations between Generic Switch and Adherence - Do Patients’ Discomfort, Need of Information and Concerns about Medicine Influence Adherence: A Combined Cross-Sectional Questionnaire and Register Study [404]
- Jette Rathe, Dorte E Jarbøl, René dePont Christensen, Morten Andersen, Jens Søndergaard. (Denmark)

13 Physician Adherence to Antihypertensive Drug Treatment Guidelines and Cost of Antihypertensive Drugs in Indian Setting [405]
- Kapil Gudala, Dipika Bansal, Anil Bhansali. (India)

14 Predictive Validity of Four Self-Reported Measures of Medication Adherence in Patients with Type 2 Diabetes [406]
- Arsène Zongo, Line Guénette, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)

15 Evaluation of Adherence To Therapy in Patients with Chronic Kidney Disease [407]
- Smita Sontakke, Ritu Budania, Chaitali Kapil Gudala, Dipika Bansal, Anil Bhansali.

16 Factors Affecting the Regular Admission of Statins (according to the Register PROFILE) [408]
- Sergey Yu Martsevish, Oleg V Gaisenok, Alexander V Zagrebelnij. (Russian Federation)

17 Barriers to Medication Adherence among Outpatients in Jos University Teaching Hospital [409]
- Rachel U Odesanya, Ngozi Oragwu. (Nigeria)

18 A Medicines List Is a Simple Tool to Improve Adherence [410]
- Yeqin Zuo, Leanne Atkins, Stephen Morrell, James Reeve. (Australia)

19 Association between Adherence to Secondary Prevention Therapies and Mortality in Acute Myocardial Infarction (AMI) [411]
- Tzu-Chi Liu, Yea-Huei Kao Yang, Ching-Lan Cheng, Cheng-Han Lee. (Taiwan)

20 The Investigation of Potential Prescription Medications Waste in a Medical Center: A Pilot Study [412]
- Yi-Jung Chiang, Yen-Yu Hsieh, Wen-Hsin Chan, Yi-Syuan Lai, Su-Yu Chien. (Taiwan)

21 HIV/AIDS Clinical Care Program Certification International: Pharmaceutical Care Model Established and Efficacy Analysis [413]
- Shuie-Shiang Lin, Chun-Eng Liu, Yuan-Meng Liu, Su-Yu Chien. (Taiwan)

22 Pharmacist-Led Educational Interventions to Improve Inhalation Technique in Pediatric Asthma Patients [414]
- Hsin-Lien Lin, Sock-Ping Ng, Chien-Hui Chen, Su-Yu Chien. (Taiwan)

23 Self-Reported Adherence To Antiretroviral Therapy in Sub-Saharan Africa: A Meta-Analyis [415]
- Obinna Ikechukwu Ekwenife, Charles Ebuka Okafor. (Nigeria)
27 The Impact of Two Consecutive Prescription Charges on Adherence to Chronic Medications in the Irish General Medical Services Population [419] Sarah-Jo Sinnott, Stephen Byrne, Noel Woods, Helen Whelton. (Ireland)

28 The Influence of Anxiety and Depression on Barriers to Antiretroviral Treatment Adherence Reported by People Living with HIV in Brazil [420] Celline C Almeida, Maria das Graças B Cecatto, Maria Inês B Nemes, Mark DC Guimaraes, Francisco A Acurcio. (Brazil)


30 Erratic or Poor Psychiatric Medications Adherence and Prescribed Antipsychotics: Prime Components in a Clinical Prediction Rule for Suicide Attempt in Major Depressive Disorder Individuals [422] Chidchanok Ruengorn, Wilaiwan Chongruksut. (Thailand)

31 The Discrepancy of Perceived Medication Use Patterns among the Elderly from Patient-Related and Health Professionals’ Perspectives [423] Hsiang-Wen Lin. (Taiwan)

32 Consumption of Rosiglitazone and Pioglitazone Following Safety Warnings – A Time Series Intervention Analysis in Portugal [424] Carla Torre, Marta Gomes, José Guerreiro. (Portugal)

33 Safety of Azithromycin Therapy in Patients with High Cardiovascular Risk. A Meta-Analysis of Randomized Controlled Trials [425] Ziyad S Almalki, Jeff J Guo. (United States)


36 A Meta-Analysis of the Harms Associated with the Novel Oral Anticoagulants (NOACs) for Stroke Prevention in Atrial Fibrillation (AF) and the Treatment of Venous Thromboembolism (VTE) in the Elderly [428] Manuj Sharma, Victoria R Cornelius, Jignesh P Patel, J Graham Davies, Mariam Molokhia. (United Kingdom)

37 The Bleeding Risk with Warfarin-Based Antithrombotic Regimen among Acute Coronary Syndrome Patients with Atrial Fibrillation [429] Lai Yi-Shan, Cheng Ching-Lan, Yea-Huei Kao Yang, Ping-Yen Liu. (Taiwan)


39 Low Body Mass Index Predictor for Dabigatran Related-Bleeding [431] Tsu-Yu Lin, Chi-Hua Chen, Kuo-Chung Hung, Ming-Shien Wen, Cheng-Hung Lee. (Taiwan)

40 Improving the Use of Lipid Lowering Treatment in Primary Prevention: A Randomized Clinical Trial [432] Yolima Cossio, Eduardo Hermosilla, Francesc Fina, Daniel Prieto-Alhambra, Bonaventura Bollbar. (Spain)

41 Estimate of Venous Thromboembolism and Related-Deaths Attributable to the Use of Combined Oral Contraceptives in France [433] Aurore Tricotel, Fanny Raguideau, Cedric Collin, Mahmoud Zureik. (France)


43 Interferon β and Rate of Hospitalization Due to Infections among Multiple Sclerosis Patients [435] Cynthia Jones, Jawad Hasan, Jin Wang, Gary Bloomgren. (United States)


46 Use of Potentially Inappropriate Medications among Older Outpatient with Long-Term Prescription at a Medical Center in Taiwan [438] Hwei-Chao Lee, Min-Ling Tsai, Kuo-Jen Lee, Mao-Chung Weng, Shih-Chih Chen. (Taiwan)

47 Validation of a Refined Health Related Quality of Life Comorbidity Index in Populations through Cross-Sectional Surveys [439] Huang-tzu Ou, Steven R Erickson. (Taiwan)

48 Risk Factors of Colistin Nephrotoxicity and Severe Nephrotoxicity in the Clinical Setting [440] Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim, Jong-Myung Lee. (Republic of Korea)

49 Anti-Tuberculosis Drug Induced Liver Injury in a Regional Hospital [441] Shu-Tzu Chen, Sheng-Kang Huang. (Taiwan)

50 Safety Information, Boxed Warning, and Contraindications in Drug Labeling: A Comparison of the USA, the UK, and Canada [442] Joud K Alfraih, Lama S Alfehaid, Hisham S Alqadhey, Thamir M Allshammar. (Saudi Arabia)

51 Deployment and Evaluation of the Doctor-Consulting System for Home-Care Cases (DSHC) in a Medical Center [443] Yun-Chia Chang, Mei-Jr Huang, Shih-Jung Huang, Jung-Chuan Ko, Chun-Yu Wan. (Taiwan)

52 Inappropriate Prescribing Defined By Start and STOPP Criteria and Association with Adverse Drug Events in Elderly Hospitalized Patients [444] Mohd Taufiq Azmy, Mathumalar Loganathan, Yahaya Hassan, Noorul Afidza Muhammad, Christopher Lee, Azmillah Rosman. (Malaysia)
How the Transparency Data Regulations Are Changing the Communication Regarding Benefit-Risk of Medications [445] Sylvie Tocmyczyk. (United States)

Useability of Harm Profile Data in Product Descriptions: A Comparison between the US and Europe [446] Victoria R Cornelius, Kun Liu, Janet Peacock, Manuj Sharma, Odile Sauzet. (United Kingdom)

Evaluation of the Value of Web Data for Detecting Drug Adverse Events [447] Mei S Duh, Pierre Cremieux, Marc Van Audenrode, Francis Vekeman, Paul Karner, Philippe Gigure-Duval, Yongling Xiao, Joe Damron, Paul Greenberg. (United States)

A Regulators’ Challenge: the Transfer of New Scientific Knowledge into Regulatory Practice. The Example of PROTECT [448] Xavier Kurz, Peter Arlett. (United Kingdom)


The Application of the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Algorithm to Evaluate Suicidal Ideation and Behaviour Within a Post-Authorisation Safety Study [450] Deborah Layton, Nasser Qayum, Vicki Osborne, Miranda Davies, Saad AW Shakir. (United Kingdom)


Comparative Effectiveness Research

Comparative Effectiveness Research of Metformin-Based Oral Hypoglycemic Therapy in Taiwan’s Population-Based Database [458] Huang-Tze Ou, Yen-Ting Chen. (Taiwan)


Inverse-Probability-of-Selection Weighting of Rich Subsample Data Provides Informed Estimates of Treatment Effects for a Large Sample [464] Alan R Ellis, M Alan Brookhart. (United States)


Aspirin for Primary Prevention of Cardiovascular Disease in Diabetes Mellitus – A Retrospective Cohort Study in Taiwan [466] Ching-Ying Huang, Shun-Jin Lin, Wei-Hua Chen. (Taiwan)


Comparative Efficacy and Safety of New Oral Anticoagulants Versus Vitamin K Antagonists: Rationale, Design and Baseline Characteristics of the NACORA-BR Observational Study [469] Gérard Maura, Pierre-Olivier Bottiere, Kim Bouillon, Cécile Billionnet, Philippe Ricordeau, François Alla, Mahmoud Zureik. (France)


Poster Session B

80 Looking Both Ways Before Using the Disease Risk Score (DRS): Performance of the DRS in a Cohort with Known Selection Bias [472]
Mina Jadroux, Muhammad M Mamdani, David N Juurlink, Murray D Krahn, Linda E Lévesque, Suzanne M Cadarette. (Canada)

81 Effect of Conventional Enzyme-Inducing Antiepileptic Drugs on Cancer Mortality and Survival: An Exposed-Unexposed Study of Carcinoma Breast and Glioblastoma Multiforme [473]
Gagandeep Singh, Ley Sander, Gail Bell. (India)

82 Effectiveness, Tolerability and Impact on Quality of Life of Interventions Used for the Management of Patients with Chronic Low Back Pain [474]
Chirag s Shah, Dipika Bansal, Babita Ghai. (India)

83 Anticonvulsants or Antidepressants in Combination Pharmacotherapy for the Treatment of Neuropathic Pain in Cancer Patients: A Meta-Analysis [475]
Jia Guan, Shiro Tanaka, Koji Kawakami. (Japan)

84 Medication and Risk of Rehospitalization in Bipolar Disorder: A Nationwide Cohort Study [476]
Johan Reuters, Jari Tiihonen, Lena Brandt, Louise Scheen, Antti Tanikanen, Morten Andersen, Robert Bodén. (Sweden)

85 Proton-Pump Inhibitors Do Not Impair the Effect of Omitting a Variable from the Selection Bias [477]
Jonathan R Strosberg, Al B Benson, Lynn Hynih, Mei Sheng Duh, Jamie Goldman, Vaibhav Sahai, Alfred W Rademaker, Matthew H Kulkle. (United States)

86 Preference-Based Instrumental Variable Methods in the Comparative Effectiveness Research and Meta-Analysis of Randomized Controlled Trials [478]
Edward Chia-Cheng Lai, Ying Chen, Monera W ong, Melissa Clard, David R Matthews. (Taiwan)

87 Effect of Anti-Inflammatory Treatment on Depression and Side Effects: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [479]
Ole Koehler, Michael Benros, Merete Nordentoft, Ole Mors, Jesper Krogh. (Denmark)

88 Comparison of Re-Hospitalization and Emergency Room Visit Patterns Among Patients with Schizophrenia Receiving Paliperidone Palmitate or Oral Atypical Antipsychotics in an Inpatient Setting [480]
Marie-Hélène Lefebvre, Amanda Grittner, Erik Maser, John Fastenau, Mei Sheng Duh, Patrick Lefebvre. (Canada)

89 Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET) for Control of Carcinoid Syndrome Symptoms: A Multi-Center Retrospective Chart Review Study [481]
Jonathan R Strosberg, Al B Benson, Lynn Hynih, Mei Sheng Duh, Jamie Goldman, Vaibhav Sahai, Alfred W Rademaker, Matthew H Kulkle. (United States)

90 Vildagliptin Efficacy in Combination with MetfRoMln for EarlyY Treatment of Type 2 Diabetes Mellitus (VERIFY) [482]
Wayne Huey-Herrn Sheu, Stefano D Prato, James Foley, Wolfgang Kothny, Plamen Kozloko, Pawi Paldainius, Michael Stumvoll, David R Matthews. (Taiwan)

91 Exploring the Factors Associated with Self-Report of Health Status among the Elderly Diagnosed with Chronic Respiratory Diseases in Taiwan [483]
Ching-Yuan Chang, Shan-Chieh Wu, Wei-Erh Cheng, Hsia-Wen Lin. (China)

92 Comparative Treatment Failure Rates of Respiratory Fluoroquinolones in the Treatment of Community-Acquired Pneumonia: An Analysis of National Representative Claims Database [484]
Chien-Chang Lee, Meng-tse Gabriel Lee, Shih-Hao Lee, Tse-Chih Chou. (Taiwan)

93 Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) with Albuminuria Treated with Sitagliptin as Add-On Therapy to Metformin: A Real-World Data Study [485]
Cheli Melzer Cohen, Gabriel Chodick, Avraham Karasik, Larry Radican, Shengsheng Yu, Bernd Voss, Ofer Qizilbash, Nicholas Moore. (United Kingdom)

94 Use of High Dimensional Propensity Scores to Control for Confounding in Assessing the Association between Bone Density Screening and Hip Fracture Risk [486]
Jie Zhang, Jeffrey R Curtis, Hong Zhao, Luqin Deng, Kenneth G Saag, Merlin Muntner, Nicole C Wright, Elizabeth Delzell. (United States)

95 On the Use of Propensity Score Method in Case of Rare Exposure [487]
David Haje, Yann De Rycke, Florence Tübaxh. (France)

96 Marginal Structural Model Simulation: the Effect of Omitting a Variable from the Outcome Model When It Is Present in the Numerator Model [488]
Alan R Ellis, M Alan Brookhart. (United States)

97 Developing Alerting Thresholds for Active Drug Safety Monitoring [489]
Grace Wangge, Sebastian Schneweiss, Robert J Glynn, Joshua J Gagne. (United States)

98 Cognitive Health, Willingness to Live, and Social Support but Not Physical Function May Be the Source of Healthy User Bias [490]
Soko Setoguchi, Lauren Williams, Chih-Ying Chen, Monera Wong, Melissa Clard, Winson Cheung, Edward Chia-Cheng Lai. (United States)

99 Value of Information Methods for Choice of Study Design [491]
Drew G Levy, David C Norris. (United States)

100 Outcomes of Outpatient Integrated Medical Care Services across Times in a Medical Center [492]
Hsiang-Wen Lin, Chih-Hueh Lin, Chin-Kan Chang, Che-Yi Chou, Pin-Ting Chao, Chia-Nuan Hau, Ling-Yu Chang, Yow-Wen Hsieh, Jui Sung Hung, Wen-Liang Huang, Der-Yang Cho. (Taiwan)

101 ENCePP-HTA Working Group 2014 Survey of Members Experience in Conducting Research to Support HTA [493]
Kevin Blake, Massoud Toussi, Xavier Kurz, Yronne Lis, Vera Ehrenstein, Nawab Qizilbash, Nicholas Moore. (United Kingdom)

102 Medication Safety Improvement in Patients Transferred from Emergency Room to Medical Wards by Initiating Medication Reconciliation [494]
Chia-Lin Lin, Chi-Hui Lee, Chin-Lon Lin, Ning-Sheng Lai, Mei-Hua Chuang. (Taiwan)

103 The Effectiveness Evaluation of Laxis, Albumin, and Both Used in Liver Disease Patients with Ascites [495]
Chiu-Ju Chen, Hey-Yu Wang. (Taiwan)

Spotlight Session - Comparative Effectiveness Research (CER) SIG

104 Accounting for Treatment Complexity in Propensity Score Estimation: Case Study From T2DM [496]
Mary E Ritchey, Yong Chen, Michele L Jonsson Funk, Kimberly G Brodovicz. (United States)

105 A Propensity Score Matched Cohort Study to Measure the Effects of Orlistat or Bariatric Surgery on Health Outcomes in a General UK Population Sample [497]
Ian J Douglas, Krishnan Bhaskaran, Rachel L Batterham, Liam Smeeth. (United Kingdom)
### Poster Session B

**SUNDAY, OCTOBER 26, 2014**

8:00 am - 6:00 pm

**106** Indirect Comparison of Meta-Analysis Findings on Adverse Treatment Outcomes: Impact of Trial Heterogeneity and Effect Measure Selection [508]
- Aaron J Katz, Michael A Kelsh, Bin Yao, Dominik D Alexander, Deborah Arrindell, Douglas L Weed. (United States)

**107** Comparative Effectiveness of Contemporary Adjuvant Chemotherapy Options among Older Rectal Cancer Patients [499]
- Jennifer L Lund, Hanna K Sanoff, Til Stürmer. (United States)

**108** Reduced Mortality in Thai Peritoneal Dialysis Patients Using Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Propensity Score Analysis [500]
- Surapon Nochawong, Chidchanok Ruengorn, Sethaporn Panyathong, Yuraporn Kaisuwan, Sirisak Nanta. (Thailand)

**109** Incidence of Diabetes Complications in Patients on Insulin Analogues Against Those on Human Insulin [501]
- Rosa Gini, Giuseppe Roberto, Francesco Cipriani, Giuseppe Seghieri, Paolo Francesconi, Francesco Lapi. (Italy)

**110** Radiographic and Endoscopic Diagnostic Workup around Initiation of Oral Bisphosphonates [502]
- Xiaojian Li, Yong Chen, Mudha Gokhale, Julie Chandler, Annie McNeil, Cynthia J Girman, Til Stürmer. (United States)

**111** Using Refill Information to Improve the Performance of Preference-Based Instrumental Variables [503]
- Jane S Der, M Alan Brookhart, Cathy Critchlow, Vamsihdar Goli, Fei Xue. (United States)

### Classical Pharmacoepidemiology

**112** The Impact of Insulin Glargine vs. Human Insulin Use on Cancer Incidence [504]
- Anne S Geier, Ina W ellmann, Jessica M Franklin, Hiltraud Kajütter, Oliver Heidinger, Georg Hempel, Hans-Werner Hense. (Germany)

**113** Acute Pancreatitis in Type 2 Diabetic Patients Treated with Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: A Population-Based Nested Case-Control Study [505]
- Hsin-Chun Chou, Wen-Wen Chen, Fei-Yuan Hsiao. (Taiwan)

**114** Risk of Spontaneous Bacterial Peritonitis Associated with Gastric Acid Suppression [506]
- Chien-Chang Lee, Yi-Hsian Lin, Shih-Hao Lee, Teu-Ting Chen, Meng-tse Gabriel Lee. (Taiwan)

**115** Negative Control Study on the Risk of Acute Myocardial Infarction Associated with the Use of Antibiotics Using a US Database [507]
- Stephanie Tcherny-Lessenot, Yunxun Wang, Juhaeri Juhaeri, Xavier Kurz, Laurent Auclert, Patrick Caubel. (France)

**116** Does Use of Non-Steroidal Anti-Inflammatory Drugs Affect the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [508]
- Shih- Hao Lee, Meng-tse Gabriel Lee, Yi-Hsian Lin, Chien-Chang Lee. (Taiwan)

**117** Does Systemic Corticosteroids Use Increase the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [509]
- Meng-tse Lee, Yi-Hsian Lin, Shih-Hao Lee, Chien-Chang Lee. (Taiwan)

**118** Mortality of Hydroxyethyl Starch Versus Dextran for Resuscitation in Intensive Care [510]
- Lu-Huaan Wu, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

**119** Effect of Topical Steroids on the Eye [511]
- Michael D Murray, Shanshan Li, Evgenia Teal, Corey H Whitney. (United States)

**120** Severity of Stroke in Women Using Oral Contraceptives [512]
- Klaus K Andersen, Tom S Olsen. (Denmark)

**121** A Pilot Study on the Impact of Severe Photosensitivity Reactions Linked to Topical Ketoprofen in Europe [513]
- Luigi Naldi, Simone Cazzaniga, Marie Laure Kurzinger, Laurent Auclert, Mario Gori. (Italy)

**122** Bisphosphonate (BP) Treatment and Renal Impairment (RI) in Women with Postmenopausal Osteoporosis (PMO) in UK [514]
- Fei Xue, Charles Wentworth, Paul Petraro. (United States)

**123** Antipsychotic Drug and Seizure Risk among Patients with Psychotic or Mood Disorder in Taiwan [515]
- Chi-Shin Wu, Sheng-Chang Wang, Shi-Kai Liu. (Taiwan)

**124** An Observational Study of Upper Gastrointestinal Tract Bleeding Events in Patients Taking Duloxetine and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Case-Control Analysis [516]
- Hu Li, Yingkai Cheng, Jonna Ahl, Vladimir Skljarevski. (United States)

**125** Fracture Risk among Depressed Patients Initiating SNRIs vs SSRIs Antidepressants [517]
- Yi-han Sheu, Amy Lanteigne, Til Stürmer, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

**126** Lamotrigine and the Risk of Severe Cutaneous Adverse Drug Reactions: A Nationwide Cohort Study [518]
- Chi-Huan Chen, Edward Chia-Cheng Lai, Ching-Lan Cheng, Yea-Huei Yang Kao. (Taiwan)

**127** Use of Low-Dose Aspirin and Prostate Cancer Risk [519]
- Charlotte Schriber, Christian Dehledorff, Michael Borre, Klaus Brasso, Henrik T Sörensen, Klaus K Andersen, Søren Friis. (Denmark)

**128** Anti-Epileptic Drug Prescriptions and Attempted and Completed Suicide in Young Adults [520]
- Jesca Brouwer, Linda Wijaars, Irene Petersen, Irwin Nazareth. (United Kingdom)

**129** Association between Inhaled Corticosteroid Use and Diabetes & Other Endpoints in Chronic Obstructive Pulmonary Disease (COPD) [521]
- Robert W Flynn, Stuart Schembri, Adrian Hapca, Isla S Mackenzie, Thomas M MacDonald. (United Kingdom)

**130** Comparative Safety Profiles of Bevacizumab, Ranibizumab and Pegaptanib in the Treatment of Age-Related Macular Degeneration: the Analysis of the WHO Database of Adverse Drug Reactions [522]
- Chiara Biagi, Valentina Conti, Marta Bonioli, Mauro Melis, Elena Buccellato, Anna Cpezozzi, Roberta Amato, Linda Pazzi, Mauro Venegoni, Alberto Vaccheri, Domenico Motola. (Italy)

**131** Upper Gastrointestinal Bleeding in Patients with Schizophrenia in the United States [523]
- Nadia Foskett, Suellen Curkendall, Nicole Prince, Gregory Lenhart, Bogdan Balas, Smita Milsavajevic-Ristic. (United Kingdom)
132 Diabetes Drugs and Acute Pancreatitis: A Systematic Review of Observational Studies [524]
Lorna Hazell, Manel Pladevall-Vila, Lorenza Scotti, Giorgia De Berardis, Cristina Varas-Lorenzo, Susana Perez-Guttham, Miriam Sturkenboom, Saad Shakir. (United Kingdom)

133 Total Cholesterol Level and Risk of Gastrointestinal Bleeding for Patient Taking Warfarin [525]
Dahye Shin, Jin Soo Lee, Dukyoung Yoon, Rae Woong Park. (Republic of Korea)

134 The Risk of Acute Asthmatic Attacks Associated with Different Dosage Forms of Non-Steroidal Anti-Inflammatory Drugs: A Self-Controlled Case Series Study [526]
Yoshinori Takeuchi, Shingo Higa, Ayumi Endo, Kazuhiro Matsui, Shinichi Watanabe. (Japan)

135 Adverse Drug Reactions in Hospitalized Patients: A Comparative Study of Intensive Care and General Care Units [527]
Joo-Hae Kim, Seung Hun Jang, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung. (Republic of Korea)

136 Potential Drug-Drug Interactions in Oncology Patients Receiving Anti-Cancer Drugs in a Tertiary Medical Centre in Taiwan [528]
Chin-Chin Ho, Chen-Chang Yang, Yeh-Ching Chou. (Taiwan)

137 Psychiatric Health Care Utilisation and Related Costs in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada) [529]
Caroline Croteau, Laurent Mottron, Marc Dorais, Jean-Éric Tarride, Sylvie Perreault. (Canada)

Pharmacovigilance

138 The Positive False Discovery Rate Method to Control the Multiplicity Problem in Pharmacovigilance: the SAFEGUARD Project [530]
Lorenza Scotti, Silvana A Romio, Antonella Zambon, Lorna Hazell, Niklas Schmidt, Miriam Sturkenboom, Giovanni Corrao. (Italy)

139 Rifampicin-Associated with Thrombocytopenia in Dose Dependent Manner during Pulmonary Tuberculosis Treatment: A Case Report [531]
Sen Mei Chen, Chen Szu Lai, Ping Ya Wang, Hao Chih Hung, Ling Hui Chen, Hua Chi Chen. (Taiwan)

140 Drug Induced Liver Injury during TB Treatment in Indonesia [532]
JA Thebari, DA Perwitasari, UA Muliani. (Indonesia)

141 Utility of Social Media Surveillance for Drug Safety and Signal Detection Purposes [533]
Brian Dreyfus, Jaidev Dasgupta, Andres Gomez-Camino. (United States)

142 Exploring Adverse Event Reporting Patterns of Newly Approved Anti-Cancer Drugs in the Japanese Adverse Drug Event Report (JADER) Database [534]
Shinichi Matsuda, Kenji Hamada, Kotonari Aoki. (Japan)

143 Bisphosphonate Therapy and Osteonecrosis of the Jaw: A Case/Non-Case Study in the French National Pharmacovigilance Database [535]
Paul de Boissieu, Malak Abou Taam, Marie-Paule Roux, Lukache Kanagaratnam, Thierry Trenque. (France)

144 Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia [536]
Samantha A Hollingworth, Treasure McGuire, David Pache, Mervyn J Eadie. (Australia)

145 Analysis of Safety Profiles between Iodinated Contrast Media and Anaphylaxis Based on Korea Adverse Event Reporting System [537]
Yeonju Woo, Sooyoun Chung, Byung-Joo Park. (Republic of Korea)

146 Knowledge, Perception Attitude About Adverse Drug Reaction (ADR) and ADR Reporting Among Pharmacy Students’ in Malaysian Private University [538]
Mohamed Shukry Zawahir, Rodgne Alexis Sultan, Mohd Faizi Mohd Asmani, Eddy Yusuf. (Malaysia)

147 Side Effects Associated with Antiretroviral Therapy (ART) in Nepal [539]
Shyam P Lohani, Punita Rimal, Prakash Panta. (Nepal)

148 Case Review of Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents [540]
Pei-Tzu Lin, Ching-Ling Tai. (Taiwan)

149 Acute Topical ß-Blocker Exposure in Asthma: Meta-Analysis of Controlled Clinical Trials [541]
Daniel R Morales, Bruce Guthrie, Brian J Lipworth, Cathy Jackson, Tobias Dreischulte. (United Kingdom)

150 Cases of Anaphylaxis Associated with the Use of Drugs: Analysis of a Pharmacovigilance Database [542]
Diogo Mendes, Carlos Alves, Francisco Batel Marques. (Portugal)

151 Medications Prescribed and Occurrence of Falls in Inpatient Setting [543]
Ming-Fen Wu, Yen-Lin Chang, Wen-Shyong Liou, Sek-Kwong Poon, Li-Yin Chang. (Taiwan)

152 Common Causative Agents of Nephrotoxicity in a Regional Pharmacovigilance Center Based on an Academic Hospital in Korea, 2009-2013 [544]
Shin-Woo Kim, Hyun-Ha Chang, Su-Jung Kim, Jong-Myung Lee. (Republic of Korea)

153 Baseline Risk Factors for Cardiovascular Events: Differences between the USA and Russia in a Study Population of Combined Oral Contraceptive Users [545]
Suzanne Reed, Klaas Heinemann, Juergen Dinger. (Germany)

154 Improving Knowledge, Attitude and Practice of Pharmacovigilance among Traditional Medicine Practitioners in Lagos State, Nigeria [546]
Ibrahim Oregaiba, Khadija Ade-Abolade, Adeline Osakwe, Olayinka Ogunleye, Kazeem Oshikoya. (Nigeria)

155 Adverse Drug Event of Hospitalized Patients from Multi-Hospitals in Thailand [547]
Promate Tragulpiankit, Narak Yeosoonpan, Thida Ninsananda, AdCoPT Working Team, Busba Chindavijak, Suvatna Chulavattanatul, Us Chaikledkaew, Tikupon Uuwiseswong. (Thailand)

156 Analysis in Adverse Reactions of Radiocontrast Agent Using Association Rule Mining in Regional Pharmacovigilance Center [548]
Gyong Im Yu, Yoon Nyun Kim, Chang Sik Son, Hyeok Won Jang, Sang Hyon Kim, Dong Hoon Shin. (Republic of Korea)

157 Use of Social Media in Pharmacovigilance: Testing the Waters [549]
Preciosa M Coloma, Benus Becker, Erik van Mulligen, Jan A Kors. (Netherlands)

158 A Comparison of Active Adverse Event Surveillance Systems Worldwide [550]
Yu-Lin Huang, Jinhee Moom, Jodi B Segal. (United States)
Poster Session B

**Risk Management / Risk Minimization/Communication**

169 Potentially Inappropriate Medications Defined by STOPP Criteria on Nursing Home Residents of a Teaching Hospital in Taiwan [561]
Li-Chai Chen, Pei-Yu Chen, Jian-Cheng Li, Pili Chih-Min Mao. (Taiwan)

170 The Effectiveness of CPOE Drug Alerting System in NSAIDs Prescription for Patients with Renal Impairment [562]
Ching-Yao Cheng, Ying-Mei Liu, Wen-Shyone Liou, Ming-Ju Wu. (Taiwan)

171 Evaluation of the Relationship between BMI, Body Fat Percentage and Waist to Hip Ratio in Healthy Educated Young Indians [563]
Dipika Bansal, Palies S Ramakrishna. (India)

172 The Effectiveness of Varenicline Medication Guide for Conveying Safety Information to Patients: A 3-Year REMS Assessment Survey [564]
Kandace L Amend, Muhammad Younus, Kenneth R Petronis, Jingping Mo, Robert Gately, Cheryl Enger. (United States)

173 Real World Utilization and Management of Adverse Events in Patients Treated with Direct Acting Antivirals (DAAs) in a European Cohort of Chronic Hepatitis C (CHC) Patients [565]
Shirin Ahmed, Stephanie Chretin, T Christopher Mast. (United States)

Chien Hao Su, Chien Ning Hsu, Shu Chen Tsai, Yu-Chin Lily Wang. (Taiwan)

175 Ten Years Retrospective Review of Legal Warnings in Thailand [567]
Pakawadee Sripriyomaya. (Thailand)

176 Hypersensitivity Reactions to Andrographis Paniculata Reported to the Health Product Vigilance Center (HPVC) in Thailand [568]
Wimon Suwankesawong, Surasak Saokaew, Unchalee Permsuwan, Nathorn Chaiyakunapruk. (Thailand)

177 A Review on Quality Surveillance Results of Cosmetics in Taiwan [569]
Meng-Hsuan Chung, Wei-Sheng Huang, Yu-Chang Chang, Yu-Hsuan Chen, Ming-Shin Lee, Hwei-Fang Cheng. (Taiwan)

178 Conditional Approval from CHMP Is Associated with Increased Phase IV Epidemiology Study Commitments [570]
Philip A Spearpoint, Jack O Ziomek, Wenting Zhang, Anjan K Banerjee. (United Kingdom)

179 The Effect of Acquisition with the Outcome of Marketing Authorization Applications of New Active Substances Submitted to the EMA [571]
Cornelia A Van den Bogert, Patrick C Souverein, Michelle Putzeist, Susan Janssen, Gerard H Koëter, Hubert GM Leufkens. (Netherlands)

180 Case Study on a Violation of the Pharmaceutical Affairs Acts Illegal Commission of the Packing Process of Medicinal Products to a Food Factory [572]
Hui-Ling Chen, Yu-Ting Huang, Chyn-Liang Huang, Ming-Shin Lee, Hwei-Fang Cheng. (Taiwan)

**Spotlight Session - Pregnancy SIG**

181 Acid-Suppressive Drug Use during Pregnancy and the Risk of Atopic Dermatitis: A Crossover Study Within the Clinical Practice Research Database [573]
Bianca Mulder, Elko Hak, Catharina CM Schuling-Veninga, Tjalling W de Vries, Susan S Jick. (Netherlands)

182 Association between Antibiotic Use and Birth Defects Among Women Who Had Urinary Tract Infections in the First Trimester of Pregnancy [574]
Elizabeth Ailes, Suzanne Gilboa, Simerpal Gill, Cheryl Broussard, Kari Klungsoyr, Anna Addor, David Tucker, Anke Rißmann, Awi Wiesel, Mary O’Mahony, Anna Pierini, Elisa Calzolari, Miriam Gatt, Marian Bakker, Marie-Claude Latos-Bielenska, Jan P Mejnartowicz, Karin Kallen, Ingeborg Barisic, David Tuck, Kari Klungsoyr, Anna Latos-Bienaska, Jan P Mejnartowicz, Karin Kallen, Ingeborg Barisic, Christine Verellen-Dumoulin, Bérénice Doray, Larraiza Arriola, Diana Wellesley, Amanda Neville, Lolkje TW de Jong-van den Berg, Helen Dolk. (Netherlands)

183 Lamotrigine Use in Pregnancy and Risk of Orofacial Cleft, an Update of EUROCAT Lamotrigine Study [575]
Hao Wang, Maria Loane, Esther Garne, Joan Morris, Vera Nelen, Babak Khoshnood, Anke Rißmann, Anke Rißmann, Awi Wiesel, Mary O’Mahony, Anna Pierini, Elisa Calzolari, Miriam Gatt, Marian Bakker, Marie-Claude Latos-Bielenska, Jan P Mejnartowicz, Karin Kallen, Ingeborg Barisic, Christine Verellen-Dumoulin, Bérénice Doray, Larraiza Arriola, Diana Wellesley, Amanda Neville, Lolkje TW de Jong-van den Berg, Helen Dolk. (Netherlands)
184 Selective Serotonin Reuptake Inhibitor Use in First Trimester Pregnancy and Risk of Congenital Anomalies: A Register-Based Study in 12 European Countries [576]
Anthony Wemakor, Karen Casson, Ester Garne, Mariam Bakker, David Tucker, Babak Khashnood, Vera Nelen, Mary O’Mahoney, Anna Pierini, Kari Klungsoyr, Mariam Gatt, Marie-Claude Addor, Anke Riusmann, Larraitz Arriola, Lolkje de Jong-van Berg, Helen Dolk. (Ghana)

185 Direct-from-Patient Information on Medication Use: PROTECT Pregnancy Study Results [577]
Nancy A Dreyer, Shahrl Mr-Isa, Jonathan L Richardson, Maja Laursen, Priscilla A Zetstra-van der Woude, Lolkje de Jong-van den Berg, Ana Jamry-Dzuria, Simon HL Thomas, Stella CF Blackburn. (United States)

186 Discontinuation of Antipsychotic Medication in Pregnancy: A Cohort Study [578]
Irene Petersen, Rachel L McCrea, David PJ Osborn, Vanessa Pinfold, Ruth Gilbert, Phil J Cowen, Irwin Nazareth. (United Kingdom)

187 Trends in the Use of Anti-Epileptic Drugs during Pregnancy in the Netherlands [579]
Eugene van Puijenbroek, Loes de Vries, Sussie Antonsen, Malene Sørensen. (Denmark)

188 Outcomes of Opioid Use in Pregnancy: A Danish Population-Based Study [580]
Mette Nørgaard, Susjie Anitonsen, Malene S Nielsson, Deirdre J Murphy, Rikke S Nielsen, Sabine M Apelt, Henrik T Nørnsen. (Denmark)

189 Birth Outcomes after Exposure to Mebendazole and Pyrvinium During Pregnancy – A Danish Nationwide Cohort Study [581]
Arendse Torp-Pedersen, Espen Jimenez-Solem, Henrik E Poulsen, Jon T Andersen. (Denmark)

190 NSAID Use during Pregnancy: Maternal Characteristics and Prescription Patterns. A Nationwide Cohort Study [582]
Vanja Cevtanovic, Espen Jimenez-Solem, Henrik Enghusat Poulsen, Jon Trærup Andersen. (Denmark)

191 Combining Adverse Perinatal and Pregnancy Outcomes Using a Latent Trait Model [583]
Xuerong Wen, Kimford J Meador, Joseph C Delaney, Xuefeng Liu, Jeffrey Roth, Rich Segal, Robert Egerman, Abraham Hartzema. (United States)

192 Lithium Prescribing during Pregnancy: A UK Primary Care Database Study [585]
Rachel L McCrea, Irwin Nazareth, David PJ Osborn, Steven Evans, Vanessa Pinfold, Phil J Cowen, Ruth Gilbert, Irene Petersen. (United Kingdom)

193 Parental Exposure to Folic Acid Antagonists During Reproductive Age in a National Sample [586]
Kiraw Demissie, Matthew Cevtanovich, Bijal Balasubramanian, Tefera Gezmu. (United States)

194 First Results of the Nationwide pREGnant Register in the Netherlands [587]
Eugene van Puijenbroek, Saskia Vorstenbosch, Agnes Kant. (Netherlands)

195 Validation of Major Congenital Malformations (MCMs) in Infants of Mothers with Chronic Inflammatory Arthritis (cIA) and Psoriasis (PsO) [588]
Wendy J Carman, Neil A Accortt, Li Zhou, Lauren Sanders, Yasenina T Bartley, Mary S Anthony, Cheryl Enger. (United States)

196 Epidemiology of Pre-Existing Diabetes in Pregnancy from 2000-2006 among Medicaid Patients in 29 US States [589]
Caitlin A Knox, Richard Segal, Almut G Winterstein. (United States)

197 Internet Advertisement Methods Provide Highest Levels of Recruitment to a Pilot Study of Self-Reported Medication Use and Pregnancy Outcomes [590]
Jonathan L Richardson, Simon HL Thomas, Sally Stephens, Anna Jamry, Anna Latos-Bielenska, Priscilla A Zetstra-van der Woude, Lolkje TW de Jong-van den Berg, Maja Laursen, Shahrl Mr-Isa, Valerie Bigouret-Hliva, Nancy A Dreyer, Stella CF Blackburn. (United Kingdom)

Bianca Mulder, Nynke CM Schuilin-Veninga, Leonard P Morsink, Maarten J Bijlasma, Eugene van Puijenbroek, Jan G Aarnoudse, Edloko Hak, Tjalling W de Vries. (Netherlands)

199 Developing a Systematic Approach to Safer Medication Use during Pregnancy: Summary of a Centers for Disease Control and Prevention-Convened Meeting [594]
Cheryl S Brousard, Meghan T Frey, Sonia Hernandez-Diaz, Michael F Greene, Christina D Chambers, Leyla Sahin, Beth A Collins Sharp, Margaret A Honein. (United States)

200 Female Kidney Transplant Patients Taking Mycophenolate Analysis in a Southern Taiwan Hospital [595]
Pili Chih-Min Mao, Mei-Ing Chung, Eric Kin-Lap Lee, Pi-Lai Tseng. (Taiwan)

201 A Comparative Analysis of Signal Detection in Electronic Healthcare Databases vs. Spontaneous Reporting Databases [925]
Alexandra C Pacurararu, Preciosa M Coloma, Gianluca Trifiro, Sabine M Straus, Martijn J Schuemie, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam C Sturkenboom. (Netherlands)

Medications in Pregnancy and Lactation

192 Birth Outcomes after Exposure to Mebendazole and Pyrvinium During Pregnancy – A Danish Nationwide Cohort Study [581]
Arendse Torp-Pedersen, Espen Jimenez-Solem, Henrik E Poulsen, Jon T Andersen. (Denmark)

200 Creating a Pregnancy Register for a UK Population [592]
Rachael Boggon, Tim Williams. (United Kingdom)

201 Evaluation of Medication Use During Pregnancy in the Mini-Sentinel Distributed Database [593]
Susan Andrade, Sengwee Toh, Marilyn Pitts, Monika Houstoun, Katrina Mott, Katie Haffenreffer, Marsha Reichman. (United States)
Spotlight Session-Top 8 Abstracts (C)

1. Combination Vildagliptin Use: Analysis from the Vildagliptin Prescription-Event Monitoring Study [682]
   Nasir Qayum, Deborah Layton, Saad AW Shakir. (United Kingdom)

2. Impact of a Metoprolol Shortage on Post-Myocardial Infarction beta-Blocker Utilization [683]
   Joshua J Gagne, Katsiaryna Bykova, Bo Wang, Nitesh K Choudhary. (United States)

3. The Use of Oral Isotretinoin in France: Assessment of Appropriate Use as a Second Line Treatment [684]
   Aurelie Tricotel, Sara Miranda, Mahmoud Zureik. (France)

5. Survival of Elderly Australian Men Initiating Hormone Therapy for Prostate Cancer [686]
   Sveta Gadanova, Libby Roughhead. (Australia)

   Eric Morgen, Xiaowei Shen, Thomas L Vaughan, David White, Anna Wu, Marliic Gammon, Wong-Ho Chow, Daniel O Stram, Yvonne Romero, Wei Xu, Geoffrey Liu. (Canada)

7. Clinical Factors Associated with Prescription Filling of Mood-Stabilizers in Bipolar Disorder – A Population-Based Cohort Study [688]
   Louise Scheen, Robert Bodén, Lena Brandt, Jari Tiitinen, Morten Andersen, Helle Kieler, Johan Reutferud. (Sweden)

8. Databases in Asia: The Potential for Distributed Network Approach [689]
   Edward Chia-Cheng Lai, Nathorn Louise Scheen, Robert Bodén, Lena Brandt, Jari Tiitinen, Morten Andersen, Helle Kieler, Johan Reutferud. (Sweden)

   Mugdha N Goldhale, John B Buse, Til Strurmer. (United States)

10. Use of Thiadizidinedione and Risk of Urothelial Cancer among Taiwan Diabetes Patients [691]
    Jo-Yen Chao, Tzu-Chieh Lin, Ming-Cheng Wang, Ye-Huei Kao Yang. (Taiwan)

11. Comparing the Risk for Atrial Fibrillation in Patients with Diabetes Initiating Metformin or Sulfonylureas: A Nationwide Population-Based Cohort Study in Taiwan [692]
    Ying Ling Liu, Chi Wen Chiang, Tong Rong Tsai, Wei Chung Tsai. (Taiwan)

12. Statis and Risk of Pulmonary Complications and Mortality after Gastric Bypass Surgery [693]
    Sigrid B Gribsholt, Elisabeth Svensson, Stine Skovbo, Reimar W Thomsen, Bjørn Richelsen, Henrik T Sørensen. (Denmark)

13. Use of N-Methylthiotetrazole (NMTT) - Cephalosporin Antibiotics and the Risk of Hemorrhagic Events [694]
    Li-Ju Chen, Fei-Tuan Hsiao, Li-Juiuan Shu, Wei-Shen Lin. (Taiwan)

14. The Risk of Acute Liver Injury among Users of Antibiotic Medications in the PROTECT Project: The Results of a Nested Case-Control Study Using European Outpatient Healthcare Data [695]
    Ruth Brauer, Ian Douglas, Luis Alberto Garcia Rodriguez, Andrew Bate, Liam Smeeth, Robert Reynolds, Olaf Klungel, Ana Ruijgomez. (United Kingdom)

15. A Structured Database Approach for Addressing Pharmacoepidemiologic Research Needs Concerning Cancer [696]
    Jinghua He, Edra A Bortnichak, Melissia Yong. (United States)

16. Increasing Risks of Stroke in Oral Cancer Patients Treated with Radiotherapy or Chemotherapy: A Nationwide Cohort Study [697]
    Yu-Ting Wu, Chung-Yu Chen, Yaw-Bin Huang, Cheng-Chiu Kuo. (Taiwan)

17. Algorithm to Identify Malignant Lymphoma Patients Extracted from an Electronic Hospital Database and Its Application in Japan [698]
    Sumiko Okubo, Shuko Nojiri, Sepehjn Paul Motson, Yu Yan, Masanori Takezuma, Haru Nakasawa, Hiroya Asou, Rei Maeda. (Japan)

18. The Disproportionate Analysis of Intravenous Iron-Containing Medicines Related Adverse Reactions in Taiwan [699]
    Yu Jie Huang, Wei Ming Ke, Wei I Huang, Wen Wen Chen. (Taiwan)

19. Use of Antihypertensive Drugs and Risk of Stroke in Oral Cancer [700]
    Joshua J Gagne, Katsiaryna Bykov, Bo Wang, Nitesh K Choudhary. (United Kingdom)

20. Cancer Prognosis Following the Usage of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Lung Cancer Patients with Hypertension History [701]
    Pei-Jung Sha, Jong-Rung Tsai, Kun-Pin Hsieh, Yi-Hsin Yang. (Taiwan)

21. Stroke Epidemiology in China over the Past Ten Years, a Study on Subtype Distribution and Case Fatality [702]
    Lei Yan, Jiapeng Lu, Yang Cui, Dena R Ramey, Jing Li, Linxan Jiang. (China)

22. The Effect of Using Statin for Cardiovascular Prevention in Peritoneal Dialysis Patients [703]
    Ping-Hsuan Wu, Yi-Ting Lin, Mei-Chuan Kuo, Yi-Wen Chiu, Hung-Chun Chen. (Taiwan)

23. Statin Use and Risk of New-Onset Diabetes in the Young Population with Hyperlipidemia [704]
    Yi-Ting Lin, Ping-Hsuan Wu, Tsang-Hsien Lin. (Taiwan)

24. Statin Use and the Risk of Urinary Incontinence in Women with Prostate Cancer [705]
    Zhen-Fang Lin, Fe-Lin Wu Lin. (Taiwan)

25. ACE-Inhibitors and the Risk of Urinary Tract Infections: Comparison of a Case-Crossover and Prescription Sequence Symmetry Design [706]
    Koen B Pouwels, Jens HJ Bos, Eelko Hak. (Netherlands)

26. Discontinuation of Angiotensin Converting Enzyme Inhibitors (ACEIs) as a Potential Marker for Adverse Drug Reactions (ADRs) [707]
    Seyed Hamidreza Mahmoud Pour, Catherine E de Keyser, Patrick C Sourvenin, Folkert W Asselbergs, Albert Hofman, Bruno H Stricker, Anthonius de Boer, Anke-Hilse Maitland-van der Zee. (Netherlands)

27. Epidemiology of Psoriasis in Japan: Results from a Descriptive Study Using National Database [708]
    Yukari Kamijima, Nobuhiro Ooba, Tszumichu Sato, Kiyoshi Kubota. (Japan)

28. Risk of Cardiac Valve Disorders with Use of Bisphosphonates [709]
    Preciosa M Coloma, Maria de Ridder, Peter Rijnbeek, Mees Mossevel, Irene Bezemr, Ron MC Herings, Rosa Gini, Serena Pecchioli, Lorenzo Scotti, Johan van der Lee, Gianluca Trifiro, Miriam CJM Steenboom. (Netherlands)
29 Marginal Structural Model (MSM) to Estimate the Effect of Cumulative Osteoporosis Medication (OPM) on Serious Infection (SI) Using Claims Data [710] Fei Xue, Vamshidhar Goli, Paul Petraro, Trevor McMullan, Eric Tchergen Tchegten. (United States)


31 Co-Morbid Medical Conditions in Vascular Dementia: A Case-Control Study [712] Ruby C Castilla-Puentes, Miguel E Habeych. (United States)

32 Effectiveness and Safety of Aspirin in Taiwan Special Population [713] Chung-Yu Chen, Yow-Bin Huang, Wen-Ter Lai, Tzu-Chi Lee. (Taiwan)

33 Analysis of Adverse Drug Reactions of Antiepileptic Drugs by Using Spontaneous Reporting System in Medical Center in Taiwan [714] Shi-Li Wang, Chun-Ching Chiu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

34 Risk of Hip Fractures Associated with Benzodiazepines: Common Methodology But Different Results in a Multi-Site Cohort Study. The PROTECT Project [715] Gema Requena, Consuelo Huerta, Helga Gardarsdottir, Montserrat Miret, Elsa Martín, Patrick C Souverein, Cornelia Schneider, Rocío González-González, Andrew Bate, Yolanda Alvarez, Dolores Montero, Luis A García-Rodríguez, Robert Reynolds, Raymond G Schlenger, Mark CH de Groot, Olaf H Klungel, Francisco J de Abajo. (Spain)

35 No Impact of Adjusting for Lifestyle Factors or General Practice on Risk Estimates for the Association between Antidepressants and Hip/Femur Fracture [716] Patrick C Souverein, Mark CH de Groot, Elisa Martin, Consuelo Huerta, Gianmario Candore, Yolanda Alvarez, Jim Slattery, Raymond G Schlenger, Robert Reynolds, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)


37 Evaluation of “Pre-Treated” Bipolar Disorder Patients Receiving Atypical Antipsychotics in the UK Using an Electronic Health Record Database [718] Mellissa Yong, Jane Liao, Herve Besson, Zhiwen Lui, Pearlsoy Jay. (United States)

38 Deprivation and Cancer Incidence in Southern Europe: A Nation-Wide Ecological Study [719] Maria García-Gil, Josep-Maria Elosua-Ricart, Marta Banque-Navarro, Bonaventura Bolibar, Rafel Ramos, Daniel Prieto-Altambera. (United Kingdom)

39 Antidepressants and Valvular Heart Disease: A Nested Case-Control Study in Taiwan [720] CH Lin, FY Hsiao, FLL Wu, LJ Shen. (Taiwan)

40 Distinguishing an Optimal Risk Modeling Framework for Predicting Adverse Events [721] Zuoyi Zhang, Xiaochun Li, Jon Duke. (United States)

41 Safety of GlaxoSmithKline’s Inactivated Adjuvanted (AS03) A/H1N1pdm09 Pandemic Influenza Vaccine in Solid Organ Transplant Recipients [722] Catherine Cochet, François Haguinet, Germano LC Ferreira, Dave Webb, John Logie, Dominique Rosillon, Vivek Shinde, Gael Dos Santos. (Belgium)


43 Comparative Risk of Post-Operative Mortality between Taiwan Dialysis and Non-Dialysis Patients Receiving First-Time Surgery [724] Tzu Chieh Lin, Hung Chun Chen, Yen Chin Liu, Yea Huei Kao Yang. (Taiwan)

44 Factors Associated with Exposure of Potential Interactions between Chinese Herbal Medicines and Western Medications [725] Hsin-Hui Tsai, Haixiang-Wen Lin, Chu-Ling Tsai, Yow-Wen Hsieh, Shyh-Shyan Jan, Ching-Yeh Tu. (Taiwan)

45 Utilization of Immunosuppressive Drugs in Post-Heart Transplant Recipients in Taiwan [726] Chia-Lin Chou, Chia-Yu Chou, Yin-Yu Huang, Chia-Chen Hsu, Yueh-Ching Chou. (Taiwan)


50 Validating a Multiple Myeloma Algorithm Using a SEER Tumor Registry and Administrative Data [731] Nancy A Brandenburg, Syd Phillips, Karen E Well, Kimberley J Woodcroft, Kandace Amend, Cheryl Enger, Susan A Oliveria. (United States)

51 Risk of Mortality with Venous Thromboembolism in CPRD GOLD: The Impact of Using Linked Data [732] Arlene M Gallagher, Tim Williams, Hubert GM Leufkens, Frank de Vries. (United Kingdom)

52 Identification of Heart Failure by Diagnoses and Cardiac Tests in a U.S. Electronic Health Records Database [733] Hoa V Le, Chi TL Truong, Julie Priest, Julia DiBello, Carlyne Averell. (United States)
53 Validation of Major Adverse Cardiovascular Events (MACE) in US Claims Databases [734]
Kevin Haynes, Melissa S Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Serena Cardillo, Sean Hennessy, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Brian L Strom, Vincent Lo Re. (United States)

54 Concordance of Myocardial Infarction (MI) between Medicare & Atherosclerosis Risk in Communities (ARIC) Study [735]
Montika Bush, Til Stürmer, Sally Stearns, Rosa J Simpson, Jr, Alan Brookhart, Anna Kucharska-Newton. (United States)

55 Comparing the Influence of Month of Birth and Gender in Two Academic Years on Attention Deficit Hyperactivity Disorder Diagnoses (ADHD) Among Children in the Health Improvement Network (THIN) UK Data [736]
Caroline O’Leary, Alison Bourke, David Ansell. (United Kingdom)

56 The Surveillance of Metoclopramide-Induced Extra-Pyramidal Symptoms and Movement Disorders Reported in Samsung Medical Center in Korea [737]
Su Mi Lee, Ji Eun Park, Yong Seok Lee, Hu Kyung Lee, Young Mee Lee, Byung Jae Lee. (Republic of Korea)

57 Osteoporosis in the Community: Findings from a Novel Computerized Registry in a Large Health Organization in Israel [738]
Inbal Goldshtein, Allison Martin Nguyen, Gabriel Chodick, Varda Shalev, Sofia Ish -Shalom, Julie Chandler. (Israel)

58 What Does Natural Language Processing Add to the Structured Data Available in Medical Records? [739]
X Zhou, L Weiss, AM Walker, AN Ananthakrishnan, R Shen, R E Sobel, A Bate, R F Reynolds. (United States)

59 Risk of Hospitalization and HealthCare Cost Associated with Diabetic Complication Severity Index in Taiwan’s National Health Insurance Research Database [740]
Hung-Lin Chen, Fei-Yuan Hsiao. (Taiwan)

60 Validation of Serious Hospitalized Infection Events in US Claims Databases [741]
Kevin Haynes, Melissa Nezamzadeh, Craig W Newcomb, Jason Roy, Whitney Kite, Dena M Carbonari, Serena Cardillo, Sean Hennessy, Cristin P Freeman, Crystal N Holick, Daina B Esposito, Brian L Strom, Lo Re Vincent. (United States)

61 Evaluation of Methods for Identifying Chemotherapy Induced Febrile Neutropenia among Cancer Patients in Denmark [742]
Hairong Xu, Mette Nørgaard, Uffe Heide-Jørgensen, Lars Pedersen, John H Page, Vera Ehrenstein. (United States)

62 How Far Is Estimated Creatinine Clearance (eClcr) and Estimated Glomerular Filtration Rate (eGFR) from Measured Creatinine Clearance (mClcr) in Taiwanese [743]
Yu-Hui Wu, Fe-Lin Lin Wu. (Taiwan)

63 A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System [744]
Keith Altman, Renata Budny. (United States)

64 Socio-Economic Status and Hip Fracture Risk: A Region-Wide Ecological Study [745]
Carlen Reyes, Maria García-Gil, Josep M Elorza-Ricart, Rafael Ramos, Cyrus Cooper, Daniel Prieto-Alhambra. (United Kingdom)

65 Socio-Economic Status and the Risk of Developing Osteoarthritis: A Region-Wide Ecological Study [746]
Carlen Reyes, Maria García-Gil, Josep M Elorza-Ricart, Bonaventura Bollbar, Rafael Ramos, Daniel Prieto-Alhambra. (United Kingdom)

66 Acute Mortality among Psychiatric Patients with Acute Agitation Using a Japanese Hospital Database [747]
Ko Nakajo, Shuko Nojiri, Meghan E Jones, Keji Kido, Masanori Taketsuna, Rei Maeda. (Japan)

67 Under-Recording of Endometriosis in the Health Improvement Network (THIN) Primary Care Database: A Validation Study [748]
Renate Schulze-Rath, Lucia Cea Soriano, Esther Lopez-Garcia, Montse Soriano-Gabarró, Luis A Garcia Rodriguez. (Germany)

68 Performance of an Algorithm for Identifying Primary Hypocalemia in Commercial Health Plan Claims Data [749]
Florence T Wang, Fei Xue, Eva Ng, Cathy W Critchlow, David D Dore. (United States)

69 Predicting the Need for Prolonged Mechanical Ventilation Following the First Hospital Admission Due to Chronic Obstructive Pulmonary Disease with Acute Exacerbation [750]
Kuang-Ming Liao, Wei-Chieh Lin, Chung-Yi Li, Yea-Huei Kao Yang. (Taiwan)

70 Performance of an Algorithm for Identifying Serious Dermatologic Adverse Events in Commercial Health Plan Claims Data [751]
Florence T Wang, Fei Xue, Eva Ng, Cathy W Critchlow, David D Dore. (United States)

71 A Normalization Method for Clinical Laboratory Test Results between Distributed Electronic Healthcare Databases [752]
Dukyong Yoon, Man Young Park, Eun Kyoung Ahn, Martijn J Schuemie, Rae Woong Park, on behalf of the Surveillance of Health Care in Asian Network (SCAN) project. (Republic of Korea)

72 The Predictive Values in Validation Studies: Misleading Statistics? [753]
Hairong Xu, Yanli Li, John H Page. (United States)

73 A Novel Broadly Applicable Risk Score for Predicting Mortality of Patients with Circulatory System Diseases Within Hospitalization Duration [754]
Zhi Qu, Jingchen Song, Siyan Zhan, Xiemin Ma. (China)

74 Applying STROBE in Renal Journals, Is There Any Difference in the Quality of Reporting Observational Studies? [755]
Mahmoud E Elrational, Abdulhassan El Manif. (Saudi Arabia)

75 An Evaluation of Sequential Analysis Methods for Active Drug Safety Surveillance Using Observational Data [756]
Xiaofeng Zhou, Warren Bao, Mike Gaffney, Rongjun Shen, Sara Young, Andrew Bate. (United States)

76 Considerations for Using Electronic Medical Record Data for Pharmacoepidemiology [757]
Scott L DuVall, Corinne H Halls, Olga V Patterson. (United States)

77 Impact of Varying Control Moment Selection in a Case-Crossover (CCO) Study on Antidepressant Drug (AD) Use and Hip/Femur Fracture (FFF) in PROTECT [758]
Mark CH de Groot, Svetlana V Belitser, Patrick C Sourvener, Rolf HH Groenwold, Gianmario Candore, Yolanda Alvarez, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Helga Gardarsdottir. (Netherlands)

78 Study Designs in Pharmacoepidemiologic Studies on Electronic Healthcare Databases: A Systematic Review [759]
Nathalie Gault, Stéphanie Foulon, Sylvie Guillo, Florence Tubach. (France)
90 A Comparison between Chinese and US Electronic Health Records Database Structures [771]
Anokhi J Kapasi, Varinder Singh, Sharmila A Kamani, Bao Nguyen-Khoa, Judith K Jones. (United States)

91 Reducing the Manual Burden of Medical Record Review through Informatics [772]
Scott L DuVall, Tyler B Forbush, Ryan C Cornia, Thomas Ginter, Brad Adams, Miland N Palmer, Olga V Patterson, Jonathan R Nebeker. (United States)

92 Use of Hydroxethyl Starch Solutions in Taiwan [773]
Wei-I Huang, Wei-Ming Ke, Wen-Wen Chen. (Taiwan)

93 Impact of Subgroup Analyses and Adjustment by Stratification on Safety Signal Detection for Individual Case Reports [774]
Suzie Seabroke, Kristina Juhlin, Geraldine Hill, Kristina Star, G Niklas Norén. (Sweden)

94 Structured Assessment for Prospective Identification of Potential Safety Signals in Electronic Health Records [775]
Susanna Cederholm, Alex Asimwe, Andrew Bate, Fatima Bhayat, Gunnar Brobert, Geraldine Hill, Kristina Star, G Niklas Norén. (Sweden)

Spotlight Session - Database SIG

95 Evaluating Survival Outcome for Chemotherapy in Advanced Lung Cancer Patients [776]
PeiYin Lin, MeiFan Lin. (Taiwan)

96 Incidence of Intussusception in Early Childhood in the Netherlands as a Baseline to the Introduction of New Rotavirus Vaccines [778]
Kartini Gadroen, Silvia Pérez-Vilar, Daniel Weibel, Sabine Strauss, Jeanet Kemermer, Nicole van der Maas, Hester de Melker. (Netherlands)

97 Identification of Drug-Induced Liver Injury in Medical Information Databases Using the Japanese Diagnostic Scale [779]
Tadakazu Hanatani, Kimie Sai, Masahito Tohkin, Katsunori Segawa, Michio Kimura, Katsuhito Horii, Junichi Kawakami, Yoshiro Saito. (Japan)

99 Validation of Diagnostic Algorithms to Identify AIDS Status, Hepatitis C Infection, Alcohol Abuse and Illicit Drug Use in HIV Positive Individuals in the Database of the Regie de l'Assurance-Maladie du Quebec [780]
Madeleine Durand, Yishu Wang, Francois Venne, Jason R Guertin, Cécile L Tremblay, Michal Abramovitz. (Canada)

100 Signal Detection for Potential Drug-Drug Interactions Using Inpatient Electronic Health Records with Laboratory Data [781]
Rae Woong Park, Man Young Park, Dukyong Yoon, Eun Kyong Ahn, Martijn Schuemie, Sean Hennessy. (United States)

101 Flumazenil as Trigger Tool for Measuring Adverse Drug Events [782]
Sock Ping Ng, Hau Ling Wu, Alan Ronaldmp Talbot, Su Yu Chien. (Taiwan)

102 Clinical Burden of ANCA Associated Vasculitis [783]
Scott L DuVall, Stephen Agbor, Andrew Wilson, Aaron WC Kamauu, Thomas Ginter, Tyler Forbush, Timira Haselkorn, Pavel Napalkov, Iain D Tart, Curry K Koenig. (United States)
107 Validation of Diagnosis of Age-Related Macular Degeneration in a Computer Database of Primary Care [788]
Zdravko P Vassilev, Luis A García Rodríguez, Montse Soriano-Gabarró, Ana Ruigómez. (United States)

108 Validation of Health Insurance Claims in Identification of Sudden Cardiac Death or Hospitalized Myocardial Infarction (MI) Death through US National Death Index (NDI) Search [789]
Caihua Liang, C Robin Clifford, Alexander M Walker. (United States)

109 A Comparison of Disproportionality Analysis Methods in National Adverse Drug Reaction Databases of China [790]
Jia He, Yongfang Hou, Xiaofei Ye, Guizhi Wu, Gang Cheng, Xiaoxi Du. (China)

110 Signal Detection from Spontaneous Reporting System: An Evaluation of Disproportionality Analysis in China [791]
Jia He, Yongfang Hou, Xiaofei Ye, Guizhi Wu, Gang Cheng, Xiaoxi Du. (China)

111 Feasibility of Alternative Methods for Health Outcomes of Interest Algorithm Validation [792]
Wan-Ju Lee, Todd A Lee, Simon Pickard, Azadeh Shoabiz, Glen T Schumock. (United States)

112 Validation of Clinical Diagnoses, Medication Use, and Health System Utilization in Taiwan’s National Health Insurance Research Database [793]
Chi-Shin Wu, Mei-Shu Lai, Susan Shur-Fen Gau, Sheng-Chang Wang, Hui-Ju Tsai. (Taiwan)

113 What Can Affect the Agreement between Patient and General Practitioner Data on Medicine Use? [794]
Hélène Peyrouzet, Sylvie Blazejewski, Julien Bezin, Jean-Louis Montastruc, Marie-Laure Laroche, Nicholas Moore. (France)

114 Agreement between Patient and General Practitioner Data on Medicine Use [795]
Hélène Peyrouzet, Sylvie Blazejewski, Julien Bezin, Jean-Louis Montastruc, Marie-Laure Laroche, Nicholas Moore. (France)

Methods Potpourri

115 Beyond Crude Cohort Design: Large-Scale Adjustment Approaches for Pharmacoepidemiology [796]
Marc Suchard, Martijn Schuemie, Patrick Ryan. (United States)

116 Refill Variables in Administrative Claims Data – Potential Implications for Defining New Medication User Cohorts [797]
Jane S Der, M Alan Brookhart, Fei Xue. (United States)

117 How to Combine Evidence in a Database Network [798]
Martijn J Schuemie, Rave Harpaz, Patrick B Ryan, William DuMouchel, David Madigan, Marc A Suchard. (United States)

118 Measuring Frailty Using Claims Data for Pharmacoepidemiologic Studies of Mortality in Older Adults: Evidence and Recommendations [799]
Dae Hyun Kim, Sebastian Schneeweiss. (United States)

119 A Critical Review of Pharmacoepidemiological Observational Post-Authorisation Safety Study (PASS) Design Used in the European Union and Its Applicability in Latin America (LA) [800]
Pedro A Lima-Filho, David Brown, Deborah Layton. (United Kingdom)

120 Bayesian Computation on Graphics Processing Units Expands the Reach and Practicability of Bayesian Methods in Pharmacoepidemiology [801]
David C Norris. (United States)

121 Feasibility of Adjusted Parametric Methods to Model Survival Data as a Tool for Signal Strengthening: An Example in Modified Prescription-Event Monitoring (M-PEM) [802]
Deborah Layton, Alan C Kimber. (United Kingdom)

122 Calibration of Statistics from Observational Studies Using Control Drug-Outcome Pairs: Incorporating Uncertainty about Controls [803]
Martijn J Schuemie, Sander Greenland, Patrick B Ryan, Marc A Suchard, William DuMouchel, David Madigan. (United States)

123 Use of a Bayesian Approach to Design and Evaluation of NCE2 [804]
Lien-Cheng Chang, Ming-Kung Yeh, Min-Shung Lin, Chin-Fu Hsiao. (Taiwan)

124 Reporting of Confounding Bias in Observational Intervention Studies: Are We Making Progress? [805]
Koen B Pouwels, Eelko Hak. (Netherlands)

Pharmacoepidemiology in Asia

125 Withrawn By Author

126 Validation of Indonesian Version of Short Formulary-36 Questionnaire in Hypertension Patients [807]
Yuli Rahmawati, Dyah A Perwitasari. (Indonesia)

127 Association between Hospitalizations Due to Cardiovascular and/or Neurologic Diseases and Exposure of High Alert Chinese Medications: Nested Case-Control Study [808]
Hsiang-Wen Lin, Hsin-Hui Tsai, Chu-Ling Tsai, Yow-Wen Hsieh, Sheng-Shing Lin, Wen-Ling Lin, Shyh-Shyan Jan, Ching-Yeh Tu, Kun-Lung Chang. (Taiwan)

128 Assessment of Affect of Geriatric Conditions on Activities of Daily Living in the Elderly [809]
Krishna Undela, Ancy Varghese, Parthasarathi Gurumurthy, Narahari Mg. (India)

129 The Risk of Geriatric Conditions in Patient with Diabetes Mellitus and Hypertension [810]
Parthasarathi Gurumurthy, Ancy Varghese, Krishna Undela, Narahari Mg, Krishna Undela, (India)

130 The Effectiveness and Safety of Febuxostat for Chronic Kidney Disease Patients with Gout and Hyperuricemia [811]
Chien-Huei Huang, Ming-Cheng Wang, Chi-Tai Yen, Ching-Lan Cheng, Pheng-Ying Yeh Liu, Hui-Jen Chang. (Taiwan)

131 Non-Prescription Medicine Purchasing Behavior Among Community Pharmacy Patrons in Malaysia [812]
Abdul Haniff Bin Mohamad Yahaya, Mohamed Azmi Bin Hassali, Asrul Akmal Bin Shafee. (Malaysia)

132 Outcomes of Earlier Use of Inhaled Corticosteroids among Patients Diagnosed with Moderate Chronic Obstructive Pulmonary Diseases [813]
Shan-Chieh Wu, Wei-Erh Cheng, Hsiang-Wen Lin, Yow-Wen Hsieh. (China)

133 Assessment on the Risk of Pneumonia Associated with Inhaled Corticosteroids in COPD Patients in Taiwan [814]
Ya-Chuan Chang, Tsu-Chieh Lin, Jih-Shuin Jeng, Yei-Huei Kao Yang. (Taiwan)

134 The Prescription Analysis of Sedative Hypnotics in Nursing Home of Hospital [815]
Mei Shure Kuo, Hui Ming Pan, Wen Ching Lin. (China)

135 Assessment of Diabetic Care Pay-for-Performance Program [816]
Mei-Chieh Chen, Yae-Huei Kao Yang, Shwu-Jiuan Sheu. (Taiwan)

136 Common Data Model Conversion in AsPEN for SCAN Project [817]
Yinghong Zhang, Edward Chia Cheng Lai, Chanthalee Hardy, Li Lin, Paul Stang, Patrick Ryan, Martijn Schuemie, Soko Setoguchi. (United States)
Naira Romanova, Albert Sahakyan. (Armenia)

138 Framework Proposal for Post-Marketing Surveillance (PMS) from Taiwan NationalADR Reporting Center [819]
Pi-Hui Chao, Wen-Wen Chen, Tsai-Min Tsai, Wei-Ming Ke. (Taiwan)

Spotlight Session-Asian Pharmacoepidemiology Network (AsPEN) SIG

139 The Association between Oral Fluoroquinolones and Incident Seizure Event [820]
Celine SL Chui, Esther W Chan, Ian CK Wong. (Hong Kong)

140 Trastuzumab-Related Cardiototoxicity Among Breast Cancer Patients in Taiwan [821]
Hsu-Chih Chien, Yea-Huei Kao Yang, Jane PF Bai. (Taiwan)

141 Withdrawn By Author

142 Comparative Risk of Oral Ucerations among Antipsychotic Users with Schizophrenia or Bipolar Disorder [823]

143 The Utilization of Pharmacovigilance Databases for the Safety of Health Products: A Systematic Review [824]
Nathorn Chaiyakunapruk, Surasak Saokaw, Undhalee Permuwan, Piyameth Dilokthornsakul, Mingkwan Saokaew, Unchalee Permsuwan, Suwankesawong. (Malaysia)

144 Adverse Drug Reactions Leading to Hospital Admissions: A Prospective Study [825]
Anand Kunchanur, Gurumurthy Parthasarathi. (India)

145 Baseline Characteristics of COPD Clinical Trial Subjects: An Inter-Ethnic Comparison [826]
Christine S Clifton, Sophie L Stocker, Jaeayon Shin, Annette S Gross. (Australia)

146 Pharmacoepidemiology Studies in China: Are There Gaps in Databases, Training Programs or Both? [827]
Hu Li, Natasha Stohlman, Lei Chen, Ken Hornbuckle. (United States)

Cardiovascular Outcome

147 Psoriasis and the Risk of Myocardial Infarction: A Population-Based Cohort Study Using the Clinical Practice Research Datalink [828]
Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S Young, Deborah PM Symmons, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)

148 Psoriasis and the Risk of Stroke: A Population-Based Cohort Study Using the Clinical Practice Research Datalink (CPRD) [829]
Rosa Parisi, Martin K Rutter, Mark Lunt, Helen S Young, Deborah PM Symmons, Christopher EM Griffiths, Darren M Ashcroft. (United Kingdom)

149 Spontaneous Reports of Thromboembolic Events Associated with Cyproterone/ Ethinylestradiol after Media Attention [830]
Florence van Hunsel, Eugene van Puijenbroek, Agnes Kant. (Netherlands)

150 Bisphosphonate and Adverse Cardiovascular Events Meta-Analysis of Randomized Placebo-Controlled Trials [831]
Dae Hyun Kim, James R Rogers, Lisa A Fulchino, Daniel H Solomon, Seoyoung C Kim. (United States)

151 Potential Signals for Cardiovascular-Related Adverse Events with COX Inhibitor Use: Analysis of the WHO Global ICSR Database System (VigiBase) [832]
David Prieto-Merino, Joseph Kim, Stephen JW Evans. (United Kingdom)

152 Temporal Changes in the Prescribing Propensity Following Safety Warnings [833]
Elizabeth M Garry, John B Buse, Virginia Pate, Til Sturmer. (United States)

153 A Comparison of Cardiac Event Rates in Patients with or Without Multiple Myeloma in the US [834]
Kristin D Kieler, Brian Murphy, Jill Kalman, Gagan Sahni, Winifred Werther, Kanya Rajangam, Ajai Chari. (United States)

155 Comparative Safety of NSAIDs on Myocardial Infarction According to the COX-2 Selectivity [836]
Sun-Young Jung, Eunmi Choi, Hyun-Joo Jung, Byung-Joo Park. (Republic of Korea)

156 Risk of Aortic Aneurysm or Aortic Dissection Associated with Fluoroquinolone Therapy [837]
Chien-Chang Lee, Yueh-Sheng Chen, Shih-Hao Lee, Meng-tse Gabriel Lee, Yi-Hsian Lin, Tse-Chih Chou. (Taiwan)

157 Ranibizumab Associated with Increased Risk of Ishaemic Stroke but Not Myocardial Infarct: A Self-Controlled Case Series Analysis [838]
Nicole Pratt, Emmee Ramsay, Anna Kemp, Lisa Kalisch Ellett, Sepehr Shakib, Gillian Caughhey, Philip Ryan, Stephen Graves, Elizabeth Roughhead. (Australia)

158 Methods and Guidelines for Integrity of Multivariable Analysis of Real World (observational) Data [839]
Drew G Levy, David C Norris, Aaron WC Kamau, Andrew Wilson. (United States)

159 Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: REGARDS Study Linked with Medicare Claims [840]
Hiraku Kumamaru, Suzanne E Judd, Jeffrey R Curtis, Rekha Ramachandran, N Chantelle Hardy, J David Rhodes, Monika M Safford, Brett M Kissela, George Howard, Jessica J Jabbert, Thomas G Brott, Soko Setoguchi. (United States)

160 Performance of ICD-10 Codes in a Computerized Hospital Database for Identification of Acute Coronary Syndrome [841]
Julien Bezin, Paul Ferreira, Maelys Touya, Vironique Gilleron, Sahondra Rambelomanana, Pierre-Olivier Girodet, Nicholas Moore, Antoine Pariente. (France)

161 Prevalence of Cardiovascular Risk Factors and Estimated 10 Year Cardiovascular Risk for Patients in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [842]
Claudine G Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)

162 Cardiovascular Risk Management of Patients in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [843]
Claudine G Jennings, Isla S Mackenzie, Rob Flynn, Ian Ford, George Nuki, Thomas M MacDonald. (United Kingdom)

163 Incidence of Heart Failure: A Population-Based Study in General Practice Setting [844]
Ana Ruigomez, Luis A Garcia Rodriguez, Alexander Michel. (Germany)
164 Risk of Death in a Cohort of Newly Diagnosed Heart Failure Patients [845]
Ana Ruigomez, Luis A García Rodriguez, Alexander Michel. (Germany)

165 Cardiac Dysfunction among Soft Tissue Sarcoma Patients in Denmark [846]
Sumitra Shantakumar, Morten Olsen, Mette Norgaard, Lars Pedersen. (Singapore)

166 Risk of QT Prolongation Induced by Atypical Antipsychotics: A Case-Control Study [847]
Nam-Kyong Choi, Joongyub Lee, Bo Ram Yang, Ye-Jee Kim, Mi-Sook Kim, Xue-Mei Jin, Jungmee Kim, Rae Woong Park, Jin-Ho Lee, Byung-Joo Park. (Korea)

167 Cardiac Adverse Events Associated with Macrolide and Fluoroquinolone Antibiotics [848]
Yizhou Ye, Aiding R Caffrey. (United States)

168 Pulse Pressure and Stroke Risk: Development and Validation of a New Stroke Risk Model [849]
Francis Vekeman, Rajeev Ayyagari, Patrick Lefebvre, Siew Hwa Ong, Elizabeth Faust, Alex Trahey, Gerardo Machnicki, Mei Sheng Duh. (Canada)

Cardiovascular Therapeutics

169 Impact of Concomitant Use of Proton Pump Inhibitors and Dual Antiplatelet Therapy on Recurrent Myocardial Infarction: A Population-Based Cross-Over Study [850]
Ye-Jee Kim, Nam-Kyong Choi, Jong-Mi Seong, Joongyub Lee, Mi-Sook Kim, Ju-Young Shin, Sun-Young Jung, Hong-Ji Song, Byung-Joo Park. (Republic of Korea)

170 Long-Term Evaluation of the Effectiveness of Warfarin Interactions Prescription Warning System in a Medical Center [851]
Pili Chih-Min Mao, Mei-Ing Chung, Eric Kin-Lap Lee, Pi-Lai Tseng. (Taiwan)

171 Use of Warfarin and Risk of Stroke and Mortality in Chronic Dialysis Patients with Atrial Fibrillation in Taiwan [852]
Chiu-Ying Chen, Tzu-Chieh Lin, Yea-Huei Kao Yang. (Taiwan)

172 Risk of Peripheral Neuropathy for Dronedarone Compared to Other Antiarrhythmics [853]
Chuntao Wu, Stephanie Tcherny-Lessenot, Wanju Dai, Yunxun Wang, Hayet Kechemri, Laurent Auclert, Jasminda Wu, Patrick Caubel, Juhae Li, Juhaeri. (United States)

173 Risk of New-Onset Diabetes in Users of Lipid Lowering Drugs (LLDs) [854]
Nobuhiro Ooba, Soko Setoguchi, Taugumichi Sato, Kiyoshi Kubota. (Japan)

174 Development of a Collaborative European Post-Authorization Safety Study (PASS) Program-Examining Rivaroxaban Use in Routine Clinical Practice [855]
Luis Garcia Rodriguez, Edeltraut Garbe, Irene Bezemer, Deborah Layton, Kailana Suzart-Woischnik, Gunnar Brobott, Jesse Alderson, Christopher Winchester, Ron Herings, Katharin Jobski, Tania Schink, Saad Shakir, Montse Soriano-Gabarró, Mari-Ann Wallander. (Germany)

175 Comparative Safety of New Oral Anticoagulants in Nonvalvular Atrial Fibrillation – A Single Medical Center Experience [856]
Ying-Hsuan Lai, Chien-Huei Huang, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)

176 Minor Bleedings and Associated Risk Factors Within Patients Initiating Warfarin Therapy: Population-Based Study [857]
Stéphanie Dumas, Payman Shahabi, Étienne Rouleau-Mailoux, Jean-Claude Tardif, Sylvie Perreault, Marie-Pierre Dubé. (Canada)

177 Clinical Outcomes of Pharmacists Providing Medication Education to Inpatients New on Warfarin Therapy [858]
Yu-Chun Hwang, Chuei-Fen Yee, Kuei-Ju Chang, YF Lee, YT Tsai, KL Chu, Cy Chen. (Taiwan)

178 Comparing Individual Angiotensin-Converting Enzyme Inhibitors with Angiotensin Receptor Blockers on the Risk of Pneumonia: A Nationwide Cohort Study [859]
Sheng-Yuan Ruan, Chia-Hsuan Chang, Yen-Chieh Lee, Li-Chiu Wu, Mei-Shu Lai. (Taiwan)

179 Does Use of Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Decrease the Risk of Incident Active Tuberculosis Disease? A Nested Case-Control Study on a National Health Claim Database [860]
Meng-tse Gabriel Lee, Shih-Hao Lee, Yi-Hsian Lin, Chien-Chang Lee. (Taiwan)

180 Does Use of Calcium Channel Blockers Affect the Risk of Incident Active Tuberculosis Disease? A Nested Case Control Study on a National Health Claim Database [861]
Meng-tse Gabriel Lee, Yi-Hsian Lin, Shih-Hao Lee. (Taiwan)

181 Is Statin Use Associated with Reduced Risk of Incident Active Tuberculosis? A Population-Based Nested Case-Control Study [862]
Chien-Chang Lee, Shih-Hao Lee, Yi-Hsian Lin, Meng-tse Gabriel Lee. (United States)

182 Impact of Diuretic Use on Serum Urate Level in the Febuxostat Versus Allopurinol Streamlined Trial (FAST) [863]
Robert W Flynn, Claudine G Jennings, Isla S Mackenzie, George Nuki, Ian Ford, Thomas M MacDonald. (United Kingdom)

183 Is There Less Interaction with Atorvastatin and Rosuvastatin? [864]
Baptiste Demailly, Malak Abou Taim, Marie-Laure Duchenois, François Krabansky, Marie-Paule Roux, Thierry Trenque. (France)

Biologics

184 Early Intervention of Skin Toxicities by Panitumumab and Clinical Outcomes in the Clinical Setting [865]
Hagit Bergman, Tania Walton, Ryan Del Bel, Jack Seki, Wei Xu, Gideon Koren, Neil Shear, Monika Kryzianowska, Doris Howell, Geoffrey Liu. (Canada)

185 Do Pharmaceutical Claims Accurately Reflect Oncology Prescribing Practice: Evidence from an Australian HER2+ Early Breast Cancer Cohort (HER2EBC) [866]
Carole Harris, Benjamin Daniels, Robyn Ward, Sallie-Anne Pearson. (Australia)

186 Analysis of Human Recombinant Somatropins, Erythropoietins and Granulocyte Colony Stimulating Factors in Pharmaceutical Formulations [867]
Jia-Chuan Hsu, Bo-Yin Lai, Der-Yuan Wang, Daniel Yang-Chih Shih. (Taiwan)

187 Hepatotoxicity with Pazopanib for Renal Cell Carcinoma in the Post-Approval Setting [868]
Sumitra Shantakumar, Beth Nordstrom, Luc Djousse, Susan A Hall, Myrthe van-Herk Sukel, Kathy Fraeman, David R Gagnon, Karen Chagin, Jeannine J Nelson. (Singapore)

Spotlight Session-Biologics SIG

188 A Systematic Review of Progressive Multifocal Leukoencephalopathy Case Reports Associated with Monoclonal Antibody Treatment [869]
Alícia Brunnsen, Niklas Schmidt, Edeltraut Garbe. (Germany)

189 Adverse Reactions Associated To Biologics for Psoriasis in Brazil [870]
Luciane Cruz Lopes, Miriam Sanches Silviera, Claudia García Serpa Osorio-De-Castro, Tatiana Chama Borges, Gordon Henry Guyatt. (Brazil)
190 HER2 Positive Early Breast Cancer (HER2EBC): An Australian Patterns of Care Study [871]
Carole Harris, Sallie-Anne Pearson, Ben Daniels, Robyn Ward. (Australia)

191 Bypassing Agents and Risk of Thromboembolic Events in Patients with Hemophilia and Inhibitors [872]
Katsiaryna Bykov, Rhonda L. Bohn, Bruce M Ewenstein, Jerry Avorn, John D Seeger. (United States)

192 Factors Associated with Denosumab Initiation among Postmenopausal Osteoporosis Patients in Medicare [873]
Huifeng Sun, Rui Chen, Nicole C Wright, Robert Matthews, Torun Arora, Ashley N Milford, Fei Xue, Elizabeth Delzell, Jeffrey R Curtis. (United States)

193 Safety Profile of Ophthalmic Biologics: Review of Safety Data [874]
Ana Penedones, Carlos Alves, Francisco Batel Marques. (Portugal)

194 Characteristics of Rheumatoid Arthritis Patients Initiating Abatacept Therapy [875]
Veena Thyagarajan, Teresa A Simon, Nan Liu, Nancy D Lin. (United States)

195 Utilization Pattern of Tumor Necrosis Factor alpha Inhibitors among Patients with Rheumatologic Arthritis in Korea [876]
Joongyub Lee, Nam-Kyong Choi, Bo Ram Yang, Xue-Mei Jin, Byung-Joo Park. (Korea)

Potpourri

196 Drug Safety Evaluation of Linezolid Injection Inducings Thrombocytopenia [877]
Mei-Ying Lu, Chih-I Lee, Yao-Jen Yang, Li-Hsiang Liao. (Taiwan)

197 Challenges of a Post-Authorisation Safety Study (PASS) in an Orphan Oncology Indication [878]
Jane B Porter, Matthew Desmond, Marie O’Donnell, Patrick McNamara, Manfred Lehner, Bingxia Wang, Hnin Hnin Ko. (United States)

198 Assessment of Patient Characteristics of Selective Serotonin Reuptake Inhibitor (SSRI) Plus Add-On Treatment Users in a United States Claims Database [879]
Meghan E Jones, Elise Grace, Dale Marmaduke, James Martinez, Mark Bangs. (United States)

199 Types of Adverse Reactions of Non-Steroidal Anti-Inflammatory Drugs, Multiclassificational Approach [880]
Oleksandr V Matwieiev, Oleksandr Y Ezernitskiy. (Ukraine)

200 Effectiveness of Multidisciplinary Care for Chronic Kidney Disease Stage I to IV: An Experience of CCPC-CKD Program [881]
Yi-Shan Wang, Yuan-Ting Yang, Ping-Fang Chiu, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

201 Pharmacist Role in Diabetes Clinical Care Program Certification (CCPC-DM) [882]
Shui-Mu Lin, Li-Hsuan Kuo, Yi-Shan Wang, Sock-Ping Ng, Su-Yu Chien. (Taiwan)

202 Characterization of Patients with Type 1 and Type 2 Diabetes and Availability of Clinical Measures Within the Humedica Research Database [883]
Anthony P Nunes, Donnie P Funeh, Yan Ding, Robin C Clifford, Jing Yang, Michael C Doherty, Jeanne Loughlin. (United States)

203 The Impact of Clinical Pharmacist on the Medicine Expenditure in the Surgical Intensive Care Unit [884]
Pei-Tau Lin, Ching-Ling Tai. (Taiwan)

204 Cost-Effectiveness Analysis between Rocephin® and Ceftrixone® in Hospitalized Patient with Community-Acquired Pneumonia [885]
Min-Hsin Chao, Shun-Jin Lin. (Taiwan)

205 Teaching Pharmacoeconomics in the GCC Countries: Survey of Pharmacy Schools [886]
Hisham Aljadhey, Mohamed Izham Ibrahim, Nouf Almeshal, Yasser Albogami. (Saudi Arabia)

206 Experience of Joint Post-Authorization Safety Studies (PASS) through an Example [887]
Marie-Laure Kurzinger, Juhaeri Juhaeri, Cristina Chang, Laurent Auclert. (France)

Hisham Aljadhey, Nouf Al-Fadel, Rabih Dabla, Osama Tabbbara, Mansour A Mahmoud. (Saudi Arabia)

208 An Assessment of the Current Medication Safety Practices in the Primary Care Settings in Riyadh, Saudi Arabia [889]
Hisham Aljadhey, Kawan Alenzi, Mansour A Mahmoud, Mohamed Azmi Hassali. (Saudi Arabia)

209 Compounding Training in Singapore: Are Final Year Pharmacy Students Ready in Ensuring Quality and Safety of Compounded Medication? [890]
Yuen-Teng Choo, Cheong Hian Goh, Mui-Ling Tan, Wai-Ping Yau. (Singapore)

210 We’ve Got Your Clinical Data – What’s in It for Clinicians? [891]
Nancy Huang, Ida Hains, Jane London, Clare Delaney, Margaret Williamson, Malcolm B Gilles, Catherine Marshall. (Australia)

211 Analysis of Barriers to Patient Recruitment: A Poster Advertising Campaign for Two Online-Only Clinical Studies [892]
David A Rorie, Rob Flynn, Lewis McConnachie, Tom M MacDonald, Ida Mackenzie, Claudine Jennings. (United Kingdom)

Devices

212 A Novel Approach to Pharmacogenomic and Pharmacoepidemiologic Evidence Synthesis for Predictive Analysis and Regulatory Decision-Making on Medical Device Performance [893]
Yelizaveta Torosyan, Danica Marinac-Dabic. (United States)

213 Impact, in Real Life Conditions, of the Use of a Purifier Spray on Allergy Care in Dust Mite Allergic Subjects [894]
Charles Taieb, Christophe Ripoll. (France)

214 Comparative Safety of Endovascular and Open Surgical Repair of Abdominal Aortic Aneurysms in Low-Risk Patients [895]
Jeffrey J Siracuse, Darren B Schneider, Peter H Connoly, Art Sedrakyan, Andrew J Meltzer. (United States)

215 Cardiac Resynchronization Devices with and Without Defibrillation: A Quantitative Systematic Review and Assessment of National Use [896]
Art Sedrakyan, Jennifer E Moon, Lauren Kunz, Sharon-Lise T Normand, Abby J Isaacs, Bethany Roell, Denica Marinac-Dabic. (United States)

216 Comparative Safety and Effectiveness of Robotic-Assisted Mitral Valve Repair [897]
Subroto Paul, Abby J Isaacs, Jessica J Jalbert, Art Sedrakyan. (United States)

217 The Selection of Prosthetics Aortic Valves for Elderly Medicare Patients from 2006 to 2011 – A Population Based Cross-Sectional Study [898]
Dongyi(Tony) Du, Stephen McKean, Jeffrey Kelman, John Laschinger, Chris Johnson, Rob Warnock, Chris Worrall, Thomas E Mitey, Hector Izurieta. (United States)

218 Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries [899]
Bilal Chughtai, Abby J Isaacs, Art Sedrakyan. (United States)
219  Trend, Utilization, and Outcomes of Male Incontinence Devices [900]
Bilal Chughtai, Abby J Isaacs, Jalin Mao, Art Sedrakyan. (United States)

220  Comparative Effectiveness of Robotic Device Assisted vs. Thoracoscopic Lobectomy [901]
Subroto Paul, Abby J Isaacs, Jessica Jalbert, Art Sedrakyan. (United States)

221  Taiwan Post-Market Surveillance of Medical Devices in Recent 5 Years [902]
Ya-Hui Cheng, Ming-Chan Sung, Pei-Weng Tu, Ming-Kung Yeh, Tsui-Min Tsai, Yi-You Huang. (Taiwan)

Spotlight Session- Device SIG

222  Anti-Coagulation After Hip or Knee Joint Replacement: Assessment of the Benefits and Risks in an Elderly Cohort [903]
Nicole Pratt, Stephen Graves, Kara Cashman, Gillian Caughey, Elizabeth Roughhead. (Australia)

223  12-Year Implantation and Survival Rates of Patients with Implantable Cardioverter-Defibrillator in Routine Clinical Practice Compared with the Background Population, and the Prognostic Impact of Age, Sex, and Comorbidity: A Danish Nationwide Population-Ba [904]
Morten Schmidt, Susanne B Pedersen, Dorit K Farkas, Søren P Hjortshøj, Hans E Bøtzer, Jens C Nielsen, Henrik T Sørensen. (Denmark)

224  Comparative Effectiveness of Peripheral Vascular Stents and Surgical Bypass for Critical Limb Ischemia in the Vascular Study Group of Greater New York [905]
Andrew J Meltzer, Abby J Isaacs, Abraham Hartzema. (United States)

225  How Do Routine Care Carotid Artery Stenting Patients Fare Compared to Those Enrolled in Trials? [906]
Jessica J Jalbert, Louis L. Nguyen, Marie D Gerhard-Herman, Michael R Jaff, John D Seeger, Hiraku Kumamaru, Lauren A Williams, Jun Liu, Chih-Ying Chen, Soko Setoguchi. (United States)

226  Use of Optional ICD-9-CM Articulating Surface Codes for Total Hip Arthroplasty in US Claims Data [907]
Jonathan Schelfhout, Chao Chen, Abraham Hartzema. (United States)

227  Hospital Volume and Outcomes for Total Hip Arthroplasty [908]
Chao Chen, Ele Ewuroke, Jonathan Schelfhout, Abraham Hartzema. (United States)

228  Evaluation of Implant Stabilization and Mobility in Total Knee Arthroplasty [909]
Art Sedrakyan, Elizabeth W Paxton, Steven E Graves, Guy Cafri, Abby J Isaacs, Barbara Bordini, Otto Robertsson, Alejandro Allepuz, Ove Furnace, Denica Marinac-Dabic. (United States)

229  Creation and Use of a “Lag Time” Variable for Comparative Effectiveness Research Using Claims Data [910]
Sarah R Hoffman, Nilaa Loyo-Berrios, Megan Gatski, Manuel Bayona, Veronica Price. (United States)

Late Breaking

230  Identifying Important Sensitivity Analyses Empirically for Pre-Specification in CER Protocols [911]
Cynthia J Girman, Douglas Faries, Patrick Ryan, Matt Rotelli, Mark Belger, Bruce Binkowitz, Robert O’Neill. (United States)

231  Withdrawn By Author

232  Risk of Spontaneous Abortion in Young Women Exposed to Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in the United Kingdom: An Observational Cohort Study [913]
Laurence Baril, Dominique Rousillon, Corinne Willame, Maria-Genalin Angelo, Julia Zima, Judith H van den Bosch, Tjerd van Staa, Rachel Boggan, Eveline Bunge, Sonia Hernandez-Diaz, Christina Chambers. (Belgium)

233  Withdrawn By Author

234  Risk of Microscopic Colitis during Use of PPIs, NSAIDs, beta-Blockers and Other Drugs [915]
Gwen MC Masclee, Preci M Coloma, Ernest J Kuipers, Miriam CJM Sturkenboom. (Netherlands)

235  A Descriptive Analysis to Compare the Occurrence of Myocardial Infarction (MI) in Testosterone-Treated and Untreated Hypogonadal Males and PDE5-Inhibitor Users [916]
Hu Li, Karin Benoit, James Michael, Stephen Motsko.

236  Risk of Sudden Sensorineural Hearing Loss in Adults Using Phosphodiesterase Type 5 Inhibitors [917]
Wei Liu, Patrick J Antonelli, Philipp Dahm, Tobias Gerhard, Joseph AC Delaney, Richard Segal, Stephen Crystal, Almut G Winterstein. (United States)

Mondira Bhattacharya, Tobias Sayre, Jeff Frimpter, Scott Snyder. (United States)

238  Educational Intervention to Improve the Practice of Pharmacovigilance among Traditional Medicine Practitioners [919]
Ibrahim Oreagba, Iwalewa Ogunleye. (Nigeria)

239  Natural Language Processing of Clinical Notes in Electronic Health Records to Improve Capture of Hypoglycemia [920]
Anthony P Nunes, Shengsheng Yu, Karen Kurtyka, Cynthia Senerchia, Jeffrey Hill, Kimberly G Brodovicz, Larry Radican, Samuel S Engel, Sean R Calvo, David D Dore. (United States)

240  Incidence Rate of Microscopic Colitis in the Netherlands [921]
Gwen MC Maslce, Preci M Coloma, Ernest J Kuipers, Miriam CJM Sturkenboom. (Netherlands)

241  The Positive Impact of Pharmacist on Appropriateness of Ambulatory Prescriptions in Medical Center [922]
Wen Chuan Lin, Hau Chuan Lee, Wen Liang Lin, Shu Hua Tai, Feng Ying Yeh, Hui Hui-Jen Chang.

242  Risk of Diabetes among Patients Exposed to Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer [923]
Huei-Ting Tsai, Nancy L Keating, Marianne Ullickas Yood, Stephen K Van Den Eeden, Reina Haque, Andrea E Cassidy-Bushrow, Matthew R Smith, Arnold L Potosky. (United States)

243  Study of Ursodeoxycholic Acid Influence on Efficacy and Safety of Statin Therapy in Patients with Liver, Gall Bladder and/or Biliary Tract Diseases (the RAKURS Study) [924]
Sergey Martsevich, Nataly Kutishenko, Lyubov Drodzova, Olga Lerman. (Russian Federation)
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>10:30 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>10:45 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>11:00 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>11:15 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>11:30 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>11:45 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Saturay, October 25, 2014**

**All About Statins**

7 10:30 am 201AF Oral
8 10:45 am 201AF Oral
9 11:00 am 201AF Oral
10 11:15 am 201AF Oral
11 11:30 am 201AF Oral
12 11:45 am 201AF Oral

**Biologics Bouillabaisse**

7 10:30 am 201AF Oral
8 10:45 am 201AF Oral
9 11:00 am 201AF Oral
10 11:15 am 201AF Oral
11 11:30 am 201AF Oral
12 11:45 am 201AF Oral

**Continuing the Discussion on Antipsychotic Safety**

13 10:30 am 201DE Oral
14 10:45 am 201DE Oral
15 11:00 am 201DE Oral
16 11:15 am 201DE Oral
17 11:30 am 201DE Oral
18 11:45 am 201DE Oral

**Improving Strength and Balance**

19 10:30 am 4th Floor VIP Oral
20 10:45 am 4th Floor VIP Oral
21 11:00 am 4th Floor VIP Oral
22 11:15 am 4th Floor VIP Oral
23 11:30 am 4th Floor VIP Oral
24 11:45 am 4th Floor VIP Oral

**The Good, the Bad, and the Ugly of Anti-Infectives**

25 10:30 am 103 Oral
26 10:45 am 103 Oral
27 11:00 am 103 Oral
28 11:15 am 103 Oral
29 11:30 am 103 Oral
30 11:45 am 103 Oral

**Women's Health**

31 10:30 am 102 Oral
32 10:45 am 102 Oral
33 11:00 am 102 Oral
34 11:15 am 102 Oral
35 11:30 am 102 Oral
36 11:45 am 102 Oral

**Antibiotics and Other Exposures in Pregnancy**

37 1:30 pm 102 Oral
38 1:45 pm 102 Oral
39 2:00 pm 102 Oral
40 2:15 pm 102 Oral
41 2:30 pm 102 Oral
42 2:45 pm 102 Oral

**Cancer Care Continuum**

43 1:30 pm 201DE Oral
44 1:45 pm 201DE Oral
45 2:00 pm 201DE Oral
46 2:15 pm 201DE Oral
47 2:30 pm 201DE Oral
48 2:45 pm 201DE Oral

**CER and Safety in CV TX/Care**

49 1:30 pm 201BC Oral
50 1:45 pm 201BC Oral
51 2:00 pm 201BC Oral
52 2:15 pm 201BC Oral
53 2:30 pm 201BC Oral
54 2:45 pm 201BC Oral

**Pseudorandom Exposures**

55 1:30 pm 4th Floor VIP Oral
56 1:45 pm 4th Floor VIP Oral
57 2:00 pm 4th Floor VIP Oral
58 2:15 pm 4th Floor VIP Oral
59 2:30 pm 4th Floor VIP Oral
60 2:45 pm 4th Floor VIP Oral

**Understanding Antidepressant Use and Safety**

61 1:30 pm 103 Oral
62 1:45 pm 103 Oral
63 2:00 pm 103 Oral
64 2:15 pm 103 Oral
65 2:30 pm 103 Oral
66 2:45 pm 103 Oral

**Watch Closely**

67 1:30 pm 201AF Oral
68 1:45 pm 201AF Oral
69 2:00 pm 201AF Oral
70 2:15 pm 201AF Oral
71 2:30 pm 201AF Oral
72 2:45 pm 201AF Oral

**A Guide to Guidelines. A Symposium Sponsored by the ISPE Public Policy Committee**

73 5:00 - 6:30 pm 201DE Sympos.

**Academic Detailing: Putting Pharmacoepidemiology into Practice**

74 5:00 - 6:30 pm 103 Sympos.

**Biospecimens from Asia in Pharmacoepidemiology Research: Opportunities and Challenges in a Global Environment**

75 5:00 - 6:30 pm 4th Floor VIP Sympos.

**Challenges in Risk Minimization Evaluation: CIOMS Working Group IX Consensus and Recent Field Experience**

76 5:00 - 6:30 pm 102 Sympos.

**Gender Differences in Pharmacoepidemiology**

77 5:00 - 6:30 pm 201BC Sympos.

**Impact of Methodological Choices on Findings from Pharmacoepidemiological Studies: Final Results of the IMI-PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) Project**

78 5:00 - 6:30 pm Plenary Hall, 3rd Fl. Sympos.

**The New ISPE Vaccine Special Interest Group (VAXSIG): Helping to Advance the Global Vaccine Agenda**

79 5:00 - 6:30 pm 201AF Sympos.
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room Format</th>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>1</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>130</td>
<td>51</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>81</td>
<td>2</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>131</td>
<td>52</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>82</td>
<td>3</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>132</td>
<td>53</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>83</td>
<td>4</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>133</td>
<td>54</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>84</td>
<td>5</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>134</td>
<td>55</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>85</td>
<td>6</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>135</td>
<td>56</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>86</td>
<td>7</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>136</td>
<td>57</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>87</td>
<td>8</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td>137</td>
<td>58</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>138</td>
<td>59</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>139</td>
<td>60</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>140</td>
<td>61</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>141</td>
<td>62</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>142</td>
<td>63</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>143</td>
<td>64</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>144</td>
<td>65</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>145</td>
<td>66</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>146</td>
<td>67</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>147</td>
<td>68</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>148</td>
<td>69</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>149</td>
<td>70</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>150</td>
<td>71</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>151</td>
<td>72</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>152</td>
<td>73</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>153</td>
<td>74</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>154</td>
<td>75</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>155</td>
<td>76</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>156</td>
<td>77</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>157</td>
<td>78</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>158</td>
<td>79</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>159</td>
<td>80</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>160</td>
<td>81</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>161</td>
<td>82</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>162</td>
<td>83</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>163</td>
<td>84</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>164</td>
<td>85</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>165</td>
<td>86</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>166</td>
<td>87</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>167</td>
<td>88</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>168</td>
<td>89</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>169</td>
<td>90</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>170</td>
<td>91</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>171</td>
<td>92</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>172</td>
<td>93</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>173</td>
<td>94</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>174</td>
<td>95</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>175</td>
<td>96</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>176</td>
<td>97</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>177</td>
<td>98</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>178</td>
<td>99</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>179</td>
<td>100</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>180</td>
<td>101</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>181</td>
<td>102</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>182</td>
<td>103</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>183</td>
<td>104</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>184</td>
<td>105</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>185</td>
<td>106</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>186</td>
<td>107</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
</tr>
<tr>
<td>Abstract #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>-------------------</td>
<td>------</td>
<td>--------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>187</td>
<td>108</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>188</td>
<td>109</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>189</td>
<td>110</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>111</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>191</td>
<td>112</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>192</td>
<td>113</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>193</td>
<td>114</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>194</td>
<td>115</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>195</td>
<td>116</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>117</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>118</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>119</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>120</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>121</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>201</td>
<td>122</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>202</td>
<td>123</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>203</td>
<td>124</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>204</td>
<td>125</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>205</td>
<td>126</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>206</td>
<td>127</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>207</td>
<td>128</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>208</td>
<td>129</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>130</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>131</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>211</td>
<td>132</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>212</td>
<td>133</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>134</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>214</td>
<td>135</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>136</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>216</td>
<td>137</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>217</td>
<td>138</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>218</td>
<td>139</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>219</td>
<td>140</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>141</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>221</td>
<td>142</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>222</td>
<td>143</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>223</td>
<td>144</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>224</td>
<td>145</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>146</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>147</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>227</td>
<td>148</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>228</td>
<td>149</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>229</td>
<td>150</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>230</td>
<td>151</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>231</td>
<td>152</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>232</td>
<td>153</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>233</td>
<td>154</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>234</td>
<td>155</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>235</td>
<td>156</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>236</td>
<td>157</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>237</td>
<td>158</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>238</td>
<td>159</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>239</td>
<td>160</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>161</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>241</td>
<td>162</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SATURDAY, OCTOBER 25

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>294</td>
<td>215</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>295</td>
<td>216</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>296</td>
<td>217</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>297</td>
<td>218</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>298</td>
<td>219</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>299</td>
<td>220</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Vaccines

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>300</td>
<td>221</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>301</td>
<td>222</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>302</td>
<td>223</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>303</td>
<td>224</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>304</td>
<td>225</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Spotlight Session- Vaccine SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>305</td>
<td>226</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>306</td>
<td>227</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>307</td>
<td>228</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>308</td>
<td>229</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>309</td>
<td>230</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>310</td>
<td>231</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>311</td>
<td>232</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>312</td>
<td>233</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### SUNDAY, OCTOBER 26

#### Antidepressants During Pregnancy and Diverse Outcomes

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>313</td>
<td></td>
<td>8:00 am</td>
<td>103</td>
<td>Oral</td>
</tr>
<tr>
<td>314</td>
<td></td>
<td>8:15 am</td>
<td>103</td>
<td>Oral</td>
</tr>
<tr>
<td>315</td>
<td></td>
<td>8:30 am</td>
<td>103</td>
<td>Oral</td>
</tr>
<tr>
<td>316</td>
<td></td>
<td>8:45 am</td>
<td>103</td>
<td>Oral</td>
</tr>
<tr>
<td>317</td>
<td></td>
<td>9:00 am</td>
<td>103</td>
<td>Oral</td>
</tr>
<tr>
<td>318</td>
<td></td>
<td>9:15 am</td>
<td>103</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Diabetes and Cancers: The Double Whammy

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>319</td>
<td></td>
<td>8:00 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>320</td>
<td></td>
<td>8:15 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>321</td>
<td></td>
<td>8:30 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>322</td>
<td></td>
<td>8:45 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>323</td>
<td></td>
<td>9:00 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
<tr>
<td>324</td>
<td></td>
<td>9:15 am</td>
<td>201BC</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### Equity, Elderly & Ecclecticism

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>325</td>
<td></td>
<td>8:00 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
<tr>
<td>326</td>
<td></td>
<td>8:15 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
<tr>
<td>327</td>
<td></td>
<td>8:30 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
<tr>
<td>328</td>
<td></td>
<td>8:45 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
<tr>
<td>329</td>
<td></td>
<td>9:00 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
<tr>
<td>330</td>
<td></td>
<td>9:15 am</td>
<td>201AF</td>
<td>Oral</td>
</tr>
</tbody>
</table>

#### How Thin is Your Blood?

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>331</td>
<td></td>
<td>8:00 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
<tr>
<td>332</td>
<td></td>
<td>8:15 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
<tr>
<td>333</td>
<td></td>
<td>8:30 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
<tr>
<td>334</td>
<td></td>
<td>8:45 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
<tr>
<td>335</td>
<td></td>
<td>9:00 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
<tr>
<td>336</td>
<td></td>
<td>9:15 am</td>
<td>201DE</td>
<td>Oral</td>
</tr>
</tbody>
</table>

### Abstract # 305

- **Title:** Sticks and Stones May Break My Bones
- **Room:** 102
- **Format:** Oral
- **Time:** 8:00 am
- **Summary:**

### Abstract # 306

- **Title:** Well Adjusted by Design
- **Room:** 4th Floor VIP
- **Format:** Oral
- **Time:** 8:00 am
- **Summary:**

### Abstract # 307

- **Title:** Diverse Topics in Pediatric Populations
- **Room:** 103
- **Format:** Oral
- **Time:** 8:00 am
- **Summary:**

### Abstract # 308

- **Title:** Don’t Go Breaking My Heart
- **Room:** 201BC
- **Format:** Oral
- **Time:** 8:00 am
- **Summary:**

### Abstract # 309

- **Title:** How Sick We Are
- **Room:** 102
- **Format:** Oral
- **Time:** 10:00 am
- **Summary:**

### Abstract # 310

- **Title:** Not All Diabetes Are Alike: Issues of Diagnosis
- **Room:** 201DE
- **Format:** Oral
- **Time:** 10:00 am
- **Summary:**

### Abstract # 311

- **Title:** PS or What???
- **Room:** 4th Floor VIP
- **Format:** Oral
- **Time:** 10:00 am
- **Summary:**

### Abstract # 312

- **Title:** To Use or Not to Use Psychotropic Medications
- **Room:** 201AF
- **Format:** Oral
- **Time:** 10:00 am
- **Summary:**

---

*Note: The above summary is a representation of the abstracts and their details as presented in the document.*
## SUNDAY, OCTOBER 26 CONTINUED

### Plenary Session: Edlavitch Award

- **385**: 1:00 - 2:30 pm, Plenary Hall, Plenary

### Adherence to Drug Treatment: A Practical Look at Complex Measurement Issues

- **386**: 4:30 - 6:00 pm, 201AF, Oral

### Databases in China: Are We Ready Yet?

- **387**: 4:30 - 6:00 pm, 201AF, Symposium

### Evaluating the Drug Regulatory System: Lessons from the Escher Project

- **388**: 4:30 - 6:00 pm, Symposium

### Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods: International Assessment and Exchange

- **389**: 4:30 - 6:00 pm, Plenary Hall, Symposium

### Leveraging Electronic Health Data for Medical Device Epidemiology: Approaches to Post-Market Surveillance of Joint Replacement Surgery

- **390**: 4:30 - 6:00 pm, 103, Symposium

### Primary Data Collection in Pharmacoepidemiology: Design, Practical, and Methodologic Considerations

- **391**: 4:30 - 6:00 pm, 102, Symposium

### Tracking of Adverse Drug Reactions in Social Media: Current Status of Requirements, Best Practices, Methods and Tools

- **392**: 4:30 - 6:00 pm, 4th Floor VIP, Symposium

## POSTER SESSION B

### Top 8 Abstracts (Day 2) Spotlight Session

- **393**: 1: 8:00 am – 6:00 pm, Poster
- **394**: 2: 8:00 am – 6:00 pm, Poster
- **395**: 3: 8:00 am – 6:00 pm, Poster
- **396**: 4: 8:00 am – 6:00 pm, Poster
- **397**: 5: 8:00 am – 6:00 pm, Poster
- **398**: 6: 8:00 am – 6:00 pm, Poster
- **399**: 7: 8:00 am – 6:00 pm, Poster
- **400**: 8: 8:00 am – 6:00 pm, Poster

### Adherence

- **401**: 9: 8:00 am – 6:00 pm, Poster
- **402**: 10: 8:00 am – 6:00 pm, Poster
- **403**: 11: 8:00 am – 6:00 pm, Poster
- **404**: 12: 8:00 am – 6:00 pm, Poster
- **405**: 13: 8:00 am – 6:00 pm, Poster
- **406**: 14: 8:00 am – 6:00 pm, Poster
- **407**: 15: 8:00 am – 6:00 pm, Poster
- **408**: 16: 8:00 am – 6:00 pm, Poster
- **409**: 17: 8:00 am – 6:00 pm, Poster
- **410**: 18: 8:00 am – 6:00 pm, Poster
- **411**: 19: 8:00 am – 6:00 pm, Poster
- **412**: 20: 8:00 am – 6:00 pm, Poster
- **413**: 21: 8:00 am – 6:00 pm, Poster
- **414**: 22: 8:00 am – 6:00 pm, Poster
- **415**: 23: 8:00 am – 6:00 pm, Poster

### Spotlight Session Adherence SIG

- **416**: 24: 8:00 am – 6:00 pm, Poster
- **417**: 25: 8:00 am – 6:00 pm, Poster

### Benefit Risk Assessment, Communication and Evaluation

- **424**: 32: 8:00 am – 6:00 pm, Poster
- **425**: 33: 8:00 am – 6:00 pm, Poster
- **426**: 34: 8:00 am – 6:00 pm, Poster
- **427**: 35: 8:00 am – 6:00 pm, Poster
- **428**: 36: 8:00 am – 6:00 pm, Poster
- **429**: 37: 8:00 am – 6:00 pm, Poster
- **430**: 38: 8:00 am – 6:00 pm, Poster
- **431**: 39: 8:00 am – 6:00 pm, Poster
- **432**: 40: 8:00 am – 6:00 pm, Poster
- **433**: 41: 8:00 am – 6:00 pm, Poster
- **434**: 42: 8:00 am – 6:00 pm, Poster
- **435**: 43: 8:00 am – 6:00 pm, Poster
- **436**: 44: 8:00 am – 6:00 pm, Poster
- **437**: 45: 8:00 am – 6:00 pm, Poster
- **438**: 46: 8:00 am – 6:00 pm, Poster
- **439**: 47: 8:00 am – 6:00 pm, Poster
- **440**: 48: 8:00 am – 6:00 pm, Poster
- **441**: 49: 8:00 am – 6:00 pm, Poster
- **442**: 50: 8:00 am – 6:00 pm, Poster
- **443**: 51: 8:00 am – 6:00 pm, Poster
- **444**: 52: 8:00 am – 6:00 pm, Poster
- **445**: 53: 8:00 am – 6:00 pm, Poster
- **446**: 54: 8:00 am – 6:00 pm, Poster
- **447**: 55: 8:00 am – 6:00 pm, Poster
- **448**: 56: 8:00 am – 6:00 pm, Poster
- **449**: 57: 8:00 am – 6:00 pm, Poster

### Spotlight Session- Benefit Risk Assessment, Communication and Evaluation (BRACE) SIG

- **450**: 58: 8:00 am – 6:00 pm, Poster
- **451**: 59: 8:00 am – 6:00 pm, Poster
- **452**: 60: 8:00 am – 6:00 pm, Poster
- **453**: 61: 8:00 am – 6:00 pm, Poster
- **454**: 62: 8:00 am – 6:00 pm, Poster
- **455**: 63: 8:00 am – 6:00 pm, Poster
- **456**: 64: 8:00 am – 6:00 pm, Poster
- **457**: 65: 8:00 am – 6:00 pm, Poster

### Comparative Effectiveness Research

- **458**: 66: 8:00 am – 6:00 pm, Poster
- **459**: 67: 8:00 am – 6:00 pm, Poster
- **460**: 68: 8:00 am – 6:00 pm, Poster
- **461**: 69: 8:00 am – 6:00 pm, Poster
- **462**: 70: 8:00 am – 6:00 pm, Poster
- **463**: 71: 8:00 am – 6:00 pm, Poster
- **464**: 72: 8:00 am – 6:00 pm, Poster
- **465**: 73: 8:00 am – 6:00 pm, Poster
- **466**: 74: 8:00 am – 6:00 pm, Poster
- **467**: 75: 8:00 am – 6:00 pm, Poster
- **468**: 76: 8:00 am – 6:00 pm, Poster
- **469**: 77: 8:00 am – 6:00 pm, Poster
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>470</td>
<td>78</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>471</td>
<td>79</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>472</td>
<td>80</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>473</td>
<td>81</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>474</td>
<td>82</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>475</td>
<td>83</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>476</td>
<td>84</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>477</td>
<td>85</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>478</td>
<td>86</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>479</td>
<td>87</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>480</td>
<td>88</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>481</td>
<td>89</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>482</td>
<td>90</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>483</td>
<td>91</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>484</td>
<td>92</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>485</td>
<td>93</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>486</td>
<td>94</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>487</td>
<td>95</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>488</td>
<td>96</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>489</td>
<td>97</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>490</td>
<td>98</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>491</td>
<td>99</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>492</td>
<td>100</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>493</td>
<td>101</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>494</td>
<td>102</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>495</td>
<td>103</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

Spotlight Session - Comparative Effectiveness Research (CER) SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>496</td>
<td>104</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>497</td>
<td>105</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>498</td>
<td>106</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>499</td>
<td>107</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>500</td>
<td>108</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>501</td>
<td>109</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>502</td>
<td>110</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>503</td>
<td>111</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

Classical Pharmacoepidemiology

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>504</td>
<td>112</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>505</td>
<td>113</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>506</td>
<td>114</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>507</td>
<td>115</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>508</td>
<td>116</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>509</td>
<td>117</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>510</td>
<td>118</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>511</td>
<td>119</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>512</td>
<td>120</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>513</td>
<td>121</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>514</td>
<td>122</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>515</td>
<td>123</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>516</td>
<td>124</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>517</td>
<td>125</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>518</td>
<td>126</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>519</td>
<td>127</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>520</td>
<td>128</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>521</td>
<td>129</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>522</td>
<td>130</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

Pharmacovigilance

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>523</td>
<td>131</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>524</td>
<td>132</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>525</td>
<td>133</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>526</td>
<td>134</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>527</td>
<td>135</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>528</td>
<td>136</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>529</td>
<td>137</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

Risk Management / Risk Minimization/Communication

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>561</td>
<td>169</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>562</td>
<td>170</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>563</td>
<td>171</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>564</td>
<td>172</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>565</td>
<td>173</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>566</td>
<td>174</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>567</td>
<td>175</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>568</td>
<td>176</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>569</td>
<td>177</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>570</td>
<td>178</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>571</td>
<td>179</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>572</td>
<td>180</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

Spotlight Session - Pregnancy SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>573</td>
<td>181</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>574</td>
<td>182</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>575</td>
<td>183</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>
## 30th ICPE Abstract Index

### Sunday, October 26

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>576</td>
<td>184</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>577</td>
<td>185</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>578</td>
<td>186</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>579</td>
<td>187</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>580</td>
<td>188</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Medications in Pregnancy and Lactation

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>581</td>
<td>189</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>582</td>
<td>190</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>583</td>
<td>191</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>585</td>
<td>193</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>586</td>
<td>194</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>587</td>
<td>195</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>588</td>
<td>196</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>589</td>
<td>197</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>590</td>
<td>198</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>591</td>
<td>199</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>592</td>
<td>200</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>593</td>
<td>201</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>594</td>
<td>202</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>595</td>
<td>203</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>925</td>
<td>204</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Monday, October 27

#### Kids Up and Down and All Around

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>596</td>
<td>8:30 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>597</td>
<td>8:45 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>598</td>
<td>9:00 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>599</td>
<td>9:15 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>600</td>
<td>9:30 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>9:45 am</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

#### On or Off Course

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>602</td>
<td>8:30 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>603</td>
<td>8:45 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>604</td>
<td>9:00 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>605</td>
<td>9:15 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>606</td>
<td>9:30 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>607</td>
<td>9:45 am</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

#### Steroids With a Twist!

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>608</td>
<td>8:30 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>609</td>
<td>8:45 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>610</td>
<td>9:00 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>611</td>
<td>9:15 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>612</td>
<td>9:30 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>613</td>
<td>9:45 am</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

#### Strings Making Sense (SMS) Harvesting Data

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>614</td>
<td>8:30 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>615</td>
<td>8:45 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>616</td>
<td>9:00 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>617</td>
<td>9:15 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>618</td>
<td>9:30 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>619</td>
<td>9:45 am</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Translating Policy into Practice

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>620</td>
<td>8:30 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>621</td>
<td>8:45 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>622</td>
<td>9:00 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>623</td>
<td>9:15 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>624</td>
<td>9:30 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>625</td>
<td>9:45 am</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Diabetes: Is It Safe Enough?

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>626</td>
<td>8:30 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>8:45 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>628</td>
<td>9:00 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>629</td>
<td>9:15 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>630</td>
<td>9:30 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>631</td>
<td>9:45 am</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Comparative and Clinical Effectiveness Studies Based on Taiwan National Health Insurance Research Database

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>632</td>
<td>10:30 am - Noon</td>
<td>201BC</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### Confirmation of Medical Events (ME) Identified from Existing Electronic Databases in Pharmacoepidemiology (PE) Studies

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>633</td>
<td>10:30 am - Noon</td>
<td>402</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### Drugs and Devices: Challenges and Opportunities for the Evaluation of Combination Medical Products

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>634</td>
<td>10:30 am - Noon</td>
<td>201DE</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### HOT, HOT, HOT and Getting HOTTER! – Climate Change and Pharmacoepidemiology

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>635</td>
<td>10:30 am - Noon</td>
<td>102</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### How Do We Overcome Challenges of Diverse Views in Multi-Disciplinary Collaboration on CER?

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>636</td>
<td>10:30 am - Noon</td>
<td>4th Floor VIP</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### Improving the Science of Regulatory Decision-Making – Advances in 2013/2014

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>637</td>
<td>10:30 am - Noon</td>
<td>201AF</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### International Collaboration on Pharmacogenomics in Epidemiology Research

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>638</td>
<td>10:30 am - Noon</td>
<td>103</td>
<td>Symposium</td>
<td></td>
</tr>
</tbody>
</table>

### From Epilepsy to Dementia

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>639</td>
<td>1:30 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>640</td>
<td>1:45 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>641</td>
<td>2:00 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>642</td>
<td>2:15 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>643</td>
<td>2:30 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>644</td>
<td>2:45 pm</td>
<td>201BC</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Gain on Pain

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>645</td>
<td>1:30 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>646</td>
<td>1:45 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>647</td>
<td>2:00 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>648</td>
<td>2:15 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>649</td>
<td>2:30 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>650</td>
<td>2:45 pm</td>
<td>201AF</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### Probably a Good Link

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>651</td>
<td>1:30 pm</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>652</td>
<td>1:45 pm</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>653</td>
<td>2:00 pm</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>654</td>
<td>2:15 pm</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>655</td>
<td>2:30 pm</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>656</td>
<td>2:45 PM</td>
<td>201DE</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>
# 30th ICPE Abstract Index

## Monday, October 27 Continued

### Abstract

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>657</td>
<td>9</td>
<td>1:30 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
</tr>
<tr>
<td>658</td>
<td>1:45 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>659</td>
<td>2:00 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>660</td>
<td>2:15 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>661</td>
<td>2:30 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>662</td>
<td>2:45 PM</td>
<td>4th Floor VIP</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### World War V: Vaccines and Viruses

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>663</td>
<td>1:30 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>664</td>
<td>1:45 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>665</td>
<td>2:00 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>666</td>
<td>2:15 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>667</td>
<td>2:30 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>668</td>
<td>2:45 PM</td>
<td>102</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

### For Better or for Worse

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>669</td>
<td>1:30 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>670</td>
<td>1:45 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>671</td>
<td>2:00 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>672</td>
<td>2:15 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>673</td>
<td>2:30 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>674</td>
<td>2:45 PM</td>
<td>103</td>
<td>Oral</td>
<td></td>
</tr>
</tbody>
</table>

**Common Data Model vs. Common Protocol – Can We Identify Gold Standards for Multi-Database Drug Effect Studies?**

### Comparisons in Pharmacoepidemiology: New Challenges and Limitations of Current Approaches

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>675</td>
<td>4:30 - 6:00 pm</td>
<td>201DE</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

### How to Bridge the Gap between Requirements of Regulatory and Health Technology Assessment Authorities for Post Authorization Studies? Examples from Europe and Asia

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>677</td>
<td>4:30 - 6:00 pm</td>
<td>103</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

**Multi-National Pharmacoepidemiological Studies in Asia – Methodological Challenges and Potential Cross-Continental Collaboration**

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>678</td>
<td>4:30 - 6:00 pm</td>
<td>201BC</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

### Special Issues in Pharmacovigilance in Emerging Countries

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>679</td>
<td>4:30 - 6:00 pm</td>
<td>402</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

### The Patient’s Voice in the Heart of BRACE (Benefit-Risk Assessment, Communication and Evaluation)

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>680</td>
<td>4:30 - 6:00 pm</td>
<td>201AF</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

### Using Pharmaceutical Data for Evaluating Medicines Policy and Informing Quality Use of Medicines

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>681</td>
<td>4:30 - 6:00 pm</td>
<td>102</td>
<td>Symposia</td>
<td></td>
</tr>
</tbody>
</table>

---

### POSTER SESSION C

#### Top 8 Abstracts (Day 3) Spotlight Session

<table>
<thead>
<tr>
<th>#</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Rooms</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>682</td>
<td>1</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>683</td>
<td>2</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>684</td>
<td>3</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>685</td>
<td>4</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>686</td>
<td>5</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>687</td>
<td>6</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>688</td>
<td>7</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>689</td>
<td>8</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>
## 30th ICPE Abstract Index

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>746</td>
<td>65</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>747</td>
<td>66</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>748</td>
<td>67</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>749</td>
<td>68</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>750</td>
<td>69</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>751</td>
<td>70</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>752</td>
<td>71</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>753</td>
<td>72</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>754</td>
<td>73</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>755</td>
<td>74</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>756</td>
<td>75</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>757</td>
<td>76</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>758</td>
<td>77</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>759</td>
<td>78</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>760</td>
<td>79</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>761</td>
<td>80</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>762</td>
<td>81</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>763</td>
<td>82</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>764</td>
<td>83</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>765</td>
<td>84</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>766</td>
<td>85</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>767</td>
<td>86</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>768</td>
<td>87</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>769</td>
<td>88</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>770</td>
<td>89</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>771</td>
<td>90</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>772</td>
<td>91</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>773</td>
<td>92</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>774</td>
<td>93</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>775</td>
<td>94</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Spotlight Session - Database SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>776</td>
<td>95</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>778</td>
<td>97</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>779</td>
<td>98</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>780</td>
<td>99</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>781</td>
<td>100</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>782</td>
<td>101</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>783</td>
<td>102</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Measurement/Validation Studies

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>784</td>
<td>103</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>785</td>
<td>104</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>786</td>
<td>105</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>787</td>
<td>106</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>788</td>
<td>107</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>789</td>
<td>108</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>790</td>
<td>109</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>791</td>
<td>110</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>792</td>
<td>111</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>793</td>
<td>112</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>794</td>
<td>113</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>795</td>
<td>114</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Methods Potpourri

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>796</td>
<td>115</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>797</td>
<td>116</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Pharacoepidemiology in Asia

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>798</td>
<td>117</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>799</td>
<td>118</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>800</td>
<td>119</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>801</td>
<td>120</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>802</td>
<td>121</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>803</td>
<td>122</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>804</td>
<td>123</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>805</td>
<td>124</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Spotlight Session - Asian Pharmacoepidemiology Network (AsPEN) SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>806</td>
<td>125</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>807</td>
<td>126</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>808</td>
<td>127</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>809</td>
<td>128</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>810</td>
<td>129</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>811</td>
<td>130</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>812</td>
<td>131</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>813</td>
<td>132</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>814</td>
<td>133</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>815</td>
<td>134</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>816</td>
<td>135</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>817</td>
<td>136</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>818</td>
<td>137</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

### Cardiovascular Outcome

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>819</td>
<td>138</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>820</td>
<td>139</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>821</td>
<td>140</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>822</td>
<td>141</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>823</td>
<td>142</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>824</td>
<td>143</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>825</td>
<td>144</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>826</td>
<td>145</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>827</td>
<td>146</td>
<td>8:00 am – 6:00 pm</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

- **Abstract Withdrawn by Author**
## 30th ICPE Abstract Index

### Monday, October 27

### Cardiovascular Therapeutics

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>850</td>
<td>169</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>851</td>
<td>170</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>852</td>
<td>171</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>853</td>
<td>172</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>854</td>
<td>173</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>855</td>
<td>174</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>856</td>
<td>175</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>857</td>
<td>176</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>858</td>
<td>177</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>859</td>
<td>178</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>860</td>
<td>179</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>861</td>
<td>180</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>862</td>
<td>181</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>863</td>
<td>182</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>864</td>
<td>183</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Biologics

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>865</td>
<td>184</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>866</td>
<td>185</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>867</td>
<td>186</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>868</td>
<td>187</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Spotlight Session-Biologics SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>869</td>
<td>188</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>870</td>
<td>189</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>871</td>
<td>190</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>872</td>
<td>191</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>873</td>
<td>192</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>874</td>
<td>193</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>875</td>
<td>194</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>876</td>
<td>195</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Potpourri

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>877</td>
<td>196</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>878</td>
<td>197</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>879</td>
<td>198</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>880</td>
<td>199</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>881</td>
<td>200</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>882</td>
<td>201</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>883</td>
<td>202</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>884</td>
<td>203</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>885</td>
<td>204</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>886</td>
<td>205</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>887</td>
<td>206</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>888</td>
<td>207</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>889</td>
<td>208</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>890</td>
<td>209</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>891</td>
<td>210</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>892</td>
<td>211</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Devices

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>893</td>
<td>212</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>894</td>
<td>213</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>895</td>
<td>214</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>896</td>
<td>215</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>897</td>
<td>216</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>898</td>
<td>217</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>899</td>
<td>218</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>900</td>
<td>219</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>901</td>
<td>220</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>902</td>
<td>221</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Spotlight Session- Device SIG

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>903</td>
<td>222</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>904</td>
<td>223</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>905</td>
<td>224</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>906</td>
<td>225</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>907</td>
<td>226</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>908</td>
<td>227</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>909</td>
<td>228</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>910</td>
<td>229</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

### Late Breaking

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>911</td>
<td>230</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>912</td>
<td>231</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>913</td>
<td>232</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>914</td>
<td>233</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>915</td>
<td>234</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>916</td>
<td>235</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>917</td>
<td>236</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>918</td>
<td>237</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>919</td>
<td>238</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>920</td>
<td>239</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>921</td>
<td>240</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>922</td>
<td>241</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>923</td>
<td>242</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
<tr>
<td>924</td>
<td>243</td>
<td>8:00 am – 6:00 pm</td>
<td></td>
<td>Poster</td>
</tr>
</tbody>
</table>

*Abstract Withdrawn by Author*
ADVERTISERS INDEX

- Amgen ................................................................. 42
- Analysis Group ..................................................... 20
- Anolinx .............................................................. 35
- Bayer HealthCare ............................................... 44
- Boehringer Ingelheim Int. GmbH ......................... 15
- CRPD, Clinical Practice Research Datalink ........... 21
- Degge Group and DGI, LLC .............................. 41
- IMS Health ......................................................... 33
- Kantar Health ..................................................... 11
- Medical Data Vision Co., Ltd ............................ 48
- Merck & Co., Inc., Whitehouse Station, NJ, USA .... 18
- Optum ............................................................... 46
- Pfizer ................................................................. 30
- Quintiles ............................................................ 12
- RTI Health Solutions ........................................... 28
- Takeda ............................................................... 34
- Truven Health Analytics ..................................... 27
- UBC ................................................................. 17
- Wiley Publications .............................................. inside back cover
Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods, and opinion in the discipline of pharmacoepidemiology.

Free online access for ISPE members via the society website

Congratulations to
The Ronald D. Mann Best Article of 2013 Awards Winners

Best paper:
Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control

Honorable mention:
Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years
Shahed Iqbal, John P. Barile, William W. Thompson and Frank DeStefano Volume 22, Issue 12, December 2013, Pages: 1263–1270

Honorable mention:
Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study

Honorable mention:
Use of case–time–control design in pharmacovigilance applications: exploration with high-risk medications and unplanned hospital admissions in the Western Australian elderly

For more information on these top papers and other journal features, please visit www.pdsjournal.org
Join the conversation
#ICPetaipei

30th ICPE
International Conference on
Pharmacoepidemiology & Therapeutic Risk Management

OCT 24-27, 2014
Taipei International Convention Center
Taipei, Taiwan

Jointly Sponsored by:

International Society for Pharmacoepidemiology
Institute of Clinical Pharmacy & Pharmaceutical Sciences, National Cheng Kung University
National Taiwan University

www.abstracts2view.com/ispe
- Online only Abstract Supplement
- Free WiFi is provided for you to access this tool

Access ICPE Abstracts on your mobile device

#ICPetaipei